ESCMID Global

Final Programme

35th Congress of the European Society of Clinical Microbiology and Infectious Diseases

Vienna, Austria

11–15 April 2025

2025

ESCMID Global 2025 - Programme

Friday, 11 April 2025

EW001 08:30 – 10:30 **Hall 2**

Educational Session

CLN IPC

Surgical site infections: principles and practice in the era of multidrug resistance

Chairs *Gabriel Birgand (Nantes, France)*
Efthymia Giannitsioti (Athens, Greece)

W0001	08:30	**Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?** *Camilla Rodrigues (Mumbai, India)*
W0002	08:50	**Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance** *Prasannakumar Palanikumar (Vellore, India)*
W0003	09:10	**Screening for MDR GNR colonisation: is there evidence for prophylaxis** *Elisabeth Presterl (Vienna, Austria)*
W0004	09:30	**Perioperative prophylaxis in special populations in the era of MDR** *Divyashree Shanthamurthy (Mumbai, India)*

EW002 08:30 – 10:30 **Hall 3**

Educational Session

ANT

Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts

Chairs *Shampa Das (Liverpool, United Kingdom)*
João Paulo Telles (Sao Paulo, Brazil)

W0005	08:30	**Pharmacokinetics 101: navigating the basics for optimal dosing** *Linda Aulin (Leiden, The Netherlands)*
W0006	08:50	**The ABCs of population pharmacokinetic models** *Erwin Dreesen (Leuven, Belgium)*
W0007	09:10	**Looking into the crystal ball: exploring the fabulous world of PK-PD simulations** *Vincent Aranzana-Climent (Poitiers, France)*
W0008	09:30	**Decoding population pharmacokinetic papers: interpreting, comparing and discussing results** *Iris K. Minichmayr (Vienna, Austria)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW003 08:30 – 10:30 **Hall 5**

Educational Session

DX

Challenges in identification and relevance of slow-growing pathogens

Chairs *Kerrie Davies (Leeds, United Kingdom)*
Yann Dumont (Nancy, France)

W0009	08:30	**Sampling and culturing anaerobes** *Hugo Cruz (Porto, Portugal)*
W0010	08:50	**I have an anaerobe: what is it and does it matter?** *Kathleen Boiten (Groningen, The Netherlands)*
W0011	09:10	**Actinomyces in clinical samples: when is it worth the trouble?** *Eija Inkeri Könönen (Turku, Finland)*
W0012	09:30	**Nocardiosis: when to test and how to manage results?** *David Lebeaux (Paris, France)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)

EW004 08:30 – 10:30 **Hall 6**

Educational Session

CLN DX IPC

A hard nut to crack in HIV

Chairs *Yoav Keynan (Winnipeg, Canada)*
Justyna Kowalska (Warsaw, Poland)

W0013	08:30	**Viral reservoir: what a physician should know** *Ivailo Alexiev (Sofia, Bulgaria)*
W0014	08:50	**Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians** *Jose Arribas (Madrid, Spain)*
W0015	09:10	**Chronic vascular and pulmonary disease and HIV: what can we do about it?** *Susanne Dam Poulsen (Copenhagen, Denmark)*
W0016	09:30	**Opportunistic infections: most common and most deadly** *Milena Stevanovikj (Sopje, North Macedonia)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group

EW005 08:30 – 10:30 **Hall 8**

Educational Session

DX

Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?

Chairs *Miriam José Álvarez-Martínez (Barcelona, Spain)*
Caroline Rönnberg (Stockholm, Sweden)

W0017	08:30	**Artificial intelligence for the diagnosis of parasitic infections** *Bobbi Pritt (Rochester, United States)*
W0018	08:50	**Histopathology of parasitic infections** *Richard Bradbury (Townsville, Australia)*
W0019	09:10	**Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections** *Sitara Sr Ajjampur (Vellore, India)*
W0020	09:30	**Paleoparasitology: what diagnostic tools?** *Ayman El-Badry (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW006 08:30 – 10:30 **Hall 9**

Educational Session

PRO PHEI

Vaccine hesitancy: from issues to solutions through developing communication skills

Chairs *Monia Chemais (Soignies, Belgium)*
Petar Velikov (Sofia, Bulgaria)

W0021	08:30	**Vaccine hesitancy and its consequences** *Noni Macdonald (Halifax, Canada)*
W0022	08:50	**Why are patients and parents hesitant about vaccination?** *Eve Dube (Quebec City, Canada)*
W0023	09:10	**Addressing vaccine hesitancy in a country: the Danish HPV vaccination crisis** *Bolette Søborg (Copenhagen S, Denmark)*
W0024	09:30	**Using social media to deal with vaccine hesitancy** *Muge Cevik (St Andrews, United Kingdom)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SP1 08:30 – 10:30 **Hall 0**

Special Session

CLN

Antimicrobial stewardship in different scenarios

Chairs *Murat Akova (Ankara, Türkiye)*
Maddalena Giannella (Bologna, Italy)
Angela Huttner (Geneva, Switzerland)
Benedikt Huttner (Geneva, Switzerland)
José Ramon Pano-Pardo (Zaragoza, Spain)
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
Holger Rohde (Hamburg, Germany)
Oana Sandulescu (Bucharest, Romania)
Jeroen Schouten (Nijmegen, The Netherlands)
Valentijn Schweitzer (Utrecht, The Netherlands)
Thomas Tängdén (Uppsala, Sweden)
Suzanne Van Asten (Nijmegen, The Netherlands)
Bart Vlaminckx (Utrecht, The Netherlands)
Dafna Yahav (Ramat-Gan, Israel)

Co-organised with: ESCMID Education Subcommittee

ME007 **11:00 – 12:00** **Hall 2**

Meet-the-Expert

AMR DX

How to interpret resistance patterns from antibiograms

M0025	11:00	*Tommaso Giani (Florence, Italy)*
M0026	11:12	*Diaz Lorena (Santiago, Chile)*

ME008 **11:00 – 12:00** **Hall 3**

Meet-the-Expert

CLN

Children are not just small adults: interactive paediatric cases

M0027	11:00	*Julie Toubiana (Paris, France)*
M0028	11:12	*Sanjay Patel (Winchester, United Kingdom)*

ME009 **11:00 – 12:00** **Hall 5**

Meet-the-Expert

IPC

How to practise WHO guidelines for the prevention of bloodstream infections and other intravascular catheter infections

M0029	11:00	*Kushlani Jayatilleke (Battaramulla, Sri Lanka)*
M0030	11:12	*Walter Zingg (Zurich, Switzerland)*

ME010 **11:00 – 12:00** **Hall 6**

Meet-the-Expert

PHEI

Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience

M0031	11:00	*Ecaterina Noroc (Chisinau, Moldova, Republic of)*
M0032	11:12	*Fakhriddin Nizamov (Almaty, Kazakhstan)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)

ME011 **11:00 – 12:00** **Hall 8**

Meet-the-Expert

CLN

Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare

M0033	11:00	*Jaime Esteban (Madrid, Spain)*
M0034	11:12	*Philippe Morand (Paris, France)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)

ME012 **11:00 – 12:00** **Hall 9**

Meet-the-Expert

PHEI

How to understand infectious disease risks in changing climates

M0035	11:00	*Kimberly Fornace (Singapore, Singapore)*
M0036	11:12	*Rachel Lowe (Barcelona, Spain)*

SP2 **11:00 – 12:00** **Hall 0**

Special Session

PRO

Principles of systematic reviews (with and without meta-analysis)

Chairs *Miranda Langendam (Amsterdam, The Netherlands)*
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel)
Luigia Scudeller (Pavia, Italy)

Co-organised with: ESCMID Education Subcommittee

ME013 **13:30 – 14:30** **Hall 2**

Meet-the-Expert

CLN TRN

Orthopaedic implant infections: new approaches for improved outcomes

M0037	13:30	*Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)*
M0038	13:42	*Trisha Peel (Melbourne, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME014 **13:30 – 14:30** **Hall 3**

Meet-the-Expert

CLN

Timing of antimicrobials in sepsis and septic shock: the sooner the better?

M0039	13:30	*Laura Evans (Seattle, United States)*
M0040	13:42	*Evangelos Giamarellos-Bourboulis (Athens, Greece)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

ME015 **13:30 – 14:30** **Hall 5**

Meet-the-Expert

CLN

PrEP in Europe: current gaps and solutions

M0041	13:30	*Teymur Noori (Stockholm, Sweden)*
M0042	13:42	*Milosz Parczewski (Szczecin, Poland)*

Co-organised with: European AIDS Clinical Society (EACS)

ME016 **13:30 – 14:30** **Hall 6**

Meet-the-Expert

CLN

Short regimens for treating drug-susceptible and drug-resistant tuberculosis: insights from guidelines

M0043	13:30	*Daria Podlekareva (Copenhagen, Denmark)*
M0044	13:42	*Raquel Duarte (Porto, Portugal)*

Co-organised with: European Respiratory Society (ERS)

ME017 **13:30 – 14:30** **Hall 8**

Meet-the-Expert

PRO PHEI

How to navigate risk communication in public health

M0045	13:30	*Christina Rolfheim-Bye (Oslo, Norway)*
M0046	13:42	*Marius Gilbert (Brussels, Belgium)*

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

ME018 **13:30 – 14:30** **Hall 9**

Meet-the-Expert

VAX

Do we need antiviral stewardship in immunocompromised hosts? Role of cell-mediated immunity

M0047 **13:30** *Michelle Yong (Melbourne, Australia)*
M0048 **13:42** *Genovefa Papanicolaou (New York, United States)*

SP3 **13:30 – 14:30** **Hall 0**

Special Session

IPC

Top five mistakes in infection prevention and control

Chairs *Maeve Doyle (Waterford, Ireland)*
Barbara Juliane Holzknecht (Copenhagen, Denmark)
David Ong (Zoetermeer, The Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)

Co-organised with: ESCMID Education Subcommittee

ME019 **14:45 – 15:45** **Hall 2**

Meet-the-Expert

CLN DX

Healthcare-associated CNS infections

M0049 **14:45** *Diederik Van De Beek (Amsterdam, The Netherlands)*
M0050 **14:57** *Alexandra Mailles (Paris, France)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME020 **14:45 – 15:45** **Hall 3**

Meet-the-Expert

TRN

Translation of gut microbiome data to clinical practice: a guide for clinicians

M0051 **14:45** *Aycan Gundogdu (Kayseri, Türkiye)*
M0052 **14:57** *Niranjan Nagarajan (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME021 **14:45 – 15:45** **Hall 5**

Meet-the-Expert

PRO

How to make sense out of guidelines and scientific evidence

M0054 **14:45** *Blin Nagavci (Gjakove, Kosovo)*
M0053 **14:57** *Luigia Scudeller (Pavia, Italy)*

Co-organised with: ESCMID Guidelines Subcommittee

ME022 **14:45 – 15:45** **Hall 6**

Meet-the-Expert

CLN

Multidisciplinary management of bone and joint infections: is there a recipe for success?

M0055 **14:45** *Natividad Benito (Barcelona, Spain)*
M0056 **14:57** *Tiziana Ascione (Naples, Italy)*

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

ME023 **14:45 – 15:45** **Hall 8**

Meet-the-Expert

PHEI

How to manage and prevent travellers' diarrhoea

M0057 **14:45** *Tinja Laaveri (Helsinki, Finland)*
M0058 **14:57** *David Tribble (Bethesda, United States)*

ME024 **14:45 – 15:45** **Hall 9**

Meet-the-Expert

CLN DX IPC

How to diagnose and treat infectious complications in critically ill patients receiving ECMO support

M0059 **14:45** *Jordi Riera (Barcelona, Spain)*
M0060 **14:57** *Giacomo Grasselli (Besana In Brianza, Italy)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

SP4 **14:45 – 15:45** **Hall 0**

Special Session

PRO

Science slam: How to communicate science with clarity

Chairs *Mary Horgan (Dublin, Ireland)*
Jaroslav Hrabak (Plzen, Czechia)
Nina Khanna (Basel, Switzerland)
Preeti Malani (Ann Arbor, United States)
Emily G. Mcdonald (Montreal, Canada)
Joshua Nosanchuk (Bronx, United States)
Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

EW025 **16:15 – 18:15** **Hall 2**

Educational Session

AMR DX

AMR surveillance: current challenges and new perspectives

Chairs *Anna Both (Paris, France)*
Tomislav Mestrovic (Varazdin, Croatia)

W0061 **16:15** **The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden** *Authia Gray (Washington, United States)*
W0062 **16:35** **Networks for surveillance of AMR in animal pathogens** *Lucie Collineau (Lyon, France)*
W0063 **16:55** **Transition to genomic-based methodology for surveillance and outbreak detection to effectively combact AMR** *Camilla Wiuff Coia (Copenhagen, Denmark)*
W0064 **17:15** **Implementing and running hospital-wide genomic surveillance of pathogens** *Alexander Mellmann (Münster, Germany)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW026 **16:15 – 18:15** **Hall 3**

Educational Session

AMR

New insights into antifungal agents and resistance

Chairs *Anuradha Chowdhary (New Delhi, India)*
Jon Salmanton-Garcia (Cologne, Germany)

W0065	16:15	**Emerging resistance in *Candida tropicalis*** *Sharon Chen (Sydney, Australia)*
W0066	16:35	**Mechanisms of resistance in *Candida glabrata*** *David Perlin (Nutley, United States)*
W0067	16:55	**Surveillance of resistance in *Aspergillus* species** *Maiken Cavling Arendrup (Copenhagen, Denmark)*
W0068	17:15	**Environmental surveillance for antifungal resistance** *Eveline Snelders (Wageningen, The Netherlands)*

EW027 **16:15 – 18:15** **Hall 5**

Educational Session

ANT CLN TRN

Going viral! Phage therapy clinical rounds

Chairs *Gregory German (Maple, Canada)*
Ameneh Khatami (Sydney, Australia)

INT22	16:15	**Introduction** *Gregory German (Maple, Canada), Ameneh Khatami (Sydney, Australia)*
W0069	16:15	**Clinical cases and lessons from the STAMP protocol** *Holly Sinclair (Syndney, Australia)*
W0070	16:35	**Difficult cases treated with phages** *Ghady Haidar (Pittsburgh, United States)*
W0071	16:55	**Challenging osteoarticular cases treated with phages** *Tristan Ferry (Lyon, France)*
W0072	17:15	**Treating urinary tract infections with phages: dream or reality?** *Saima Aslam (San Diego, United States)*
INT23	17:35	**Conclusion** *Gregory German (Maple, Canada), Ameneh Khatami (Sydney, Australia)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW028 **16:15 – 18:15** **Hall 6**

Educational Session

CLN VAX

Addressing infection challenges in immunocompromised patients: a case-based exploration

Chairs *Maddalena Giannella (Bologna, Italy)*
Asma Nasim (Karachi, Pakistan)

W0073	16:15	**Challenges in managing gastrointestinal infections in patients with primary immunodeficiency** *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*
W0074	16:35	**Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies** *Gemma Reynolds (Heidelberg, Australia)*
W0075	16:55	**Mycobacterial infections in patients with HIV infection** *Graeme Ayton Meintjes (Observatory, South Africa)*
W0076	17:15	**Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation** *Dimitrios P. Kontoyiannis (Houston, Tx, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EW029 **16:15 – 18:15** **Hall 8**

Educational Session

TRN

Impact of diabetes on infectious diseases: what should we know?

Chairs *Mark G. J. De Boer (Leiden, The Netherlands)*
Suzanne Van Asten (Nijmegen, The Netherlands)

W0077	16:15	**The impact of diabetes and host-pathogen interaction and gut microbiome** *Reinout Van Crevel (Nijmegen, The Netherlands)*
W0078	16:35	**Diabetes and invasive fungal infections** *Jochem Buil (Nijmegen, The Netherlands)*
W0079	16:55	**Viral infections and diabetes: is there a connection?** *Malin Flodström-Tullberg (Stockholm, Sweden)*
W0080	17:15	**Pathogenesis of diabetic wound infection** *Marco Moretti (Jette (brussel), Belgium)*

EW030 **16:15 – 18:15** **Hall 9**

Educational Session

DX IPC

Primer on infection prevention and control: the crucial support by clinical microbiology

Chairs *Nico Tom Mutters (Bonn, Germany)*
Margreet C. Vos (Rotterdam, The Netherlands)

W0081	16:15	**Microbial fundamentals: building blocks of infection prevention and control** *Laurence Armand-Lefevre (Paris, France)*
W0082	16:35	**Optimising environmental sampling in infection control: rational use of the microbiology laboratory** *John E. Coia (Esbjerg, Denmark)*
W0083	16:55	**The crucial role of molecular typing in infection control** *Stefanie Kampmeier (Würzburg, Germany)*
W0084	17:15	**How can we link diagnostic and antibiotic stewardship?** *Constantinos Tsioutis (Nicosia, Cyprus)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SP5 **16:15 – 18:15** **Hall 0**

Special Session

CLN

Multidisciplinary approach to early sepsis management

Chairs *Markus Bald (Lüdenscheid, Germany)*
Aleksandra Davidovic (Luedenscheid, Germany)
Charalambos Dokos (Lüdenscheid, Germany)

Co-organised with: ESCMID Education Subcommittee

Saturday, 12 April 2025

OS002 **08:30 – 10:30** **Hall 11**

2-hour Oral Session

DX

Translating metagenomics into clinical practice

Chairs *Benjamin Peter Howden (Parkville (Victoria), Australia)*
Paula Mölling (Örebro, Sweden)

O0011	08:30	**Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study** *H.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen*
O0012	08:42	**Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash.** *J. Alexander* (Orlando, United States), A. Charles*
O0013	08:54	**Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care** *R. Hammond* (London, United Kingdom), A. Kopec, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer*
O0014	09:06	**Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy** *T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle*

O0015 09:18 **Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes** *E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser*

O0016 09:30 **Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study** *L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia*

O0017 09:42 **Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU** *B. Ran* (Taiyuan, China), Y. Liu, X. Wu, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang, X. Lin, X. Li, Q. Zhan, C. Wang*

O0018 09:54 **Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence** *C. Peng* (Shiyan, China), S. Qi, C. Jiachang, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun, P. Chunyan*

O0019 10:06 **A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS)** *M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy*

O0020 10:18 **Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study** *M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona*

OS001 **Hall 5**

08:30 – 10:30

2-hour Oral Session

AMR PHEI TRN

One Health means resistance everywhere

Chairs *Alessandra Carattoli (Rome, Italy)*
Prasannakumar Palanikumar (Vellore, India)

O0001 08:30 **Decoding the role of *bla*$_{CPE}$-carrying plasmids on wings: A holistic view using the One Health approach** *S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres*

O0002 08:42 **A novel isolation room model leveraging culture-independent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs** *V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng*

O0003 08:54 **Deciphering the pathogenic potentials and epidemiological identities of *Staphylococcus pseudintermedius* colonizing companion dogs in Sao Paulo** *I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales*

O0004 09:06 **Recent progress towards integrated surveillance of antimicrobial resistance in France** *L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin*

O0005 09:18 **Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: insights into horizontal gene transfer and AMR dissemination** *B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczkó, G. Kardos*

O0006 09:30 **Emergence of mobile colistin resistance in *Klebsiella* at human-animal-environment interface in Bangladesh** *S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana*

O0007 09:42 **Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective** *I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja*

O0008 09:54 **Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples** *E. Ouranou* (Heraklion, Greece), M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos, A. Psaroulaki, D. Chochlakis*

O0009 10:06 **One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison** *G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaite, D. Belay, J. Guitian, M. Dione, E. Emes*

O0010 10:18 **Clinically important sequence types and resistance genes in *Enterobacteriaceae* from coastal environments and gulls** *V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas*

SY034 **Hall 10**

08:30 – 10:30

2-hour Symposium

IPC

Endoscopy: infection risks and mitigation

Chairs *Elisabeth Presterl (Vienna, Austria)*
Gordon Ramage (Glasgow, United Kingdom)

S0097 08:30 **Should we be concerned about infection from contaminated endoscopes?** *Claire Aumeran (Clermont-Ferrand, France)*

S0098 09:00 **Prevention of multidrug-resistant infections from contaminated duodenoscopes** *Margreet C. Vos (Rotterdam, The Netherlands)*

S0099 09:30 **Understanding the causes of medical device contamination: it is all biofilm!** *Roberto Rusconi (Milan, Italy)*

S0100 10:00 **Does the European medical Device Regulation bring us safer duodenoscopes?** *Markus Hell (Salzburg, Austria)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

SY035 **Hall 12**

08:30 – 10:30

2-hour Symposium

PHEI

Barriers to TB/HIV elimination in low- and high-incidence settings

Chairs *Graeme Ayton Meintjes (Observatory, South Africa)*
Daria Podlekareva (Copenhagen, Denmark)

S0101 08:30 **HIV and TB epidemic: the storm hasn't subsided yet** *Tetiana Koval (Poltava, Ukraine)*

S0102 09:00 **Approaches for latent and active TB screening in people living with HIV** *Raimonda Matulionyte (Vilnius, Lithuania)*

S0103 09:30 **Integration of HIV and TB care to improve patient outcome in resource-limited settings** *Akaki Abutidze (Tbilisi, Georgia)*

S0104 10:00 **How researchers can influence policy and practice in HIV/TB care** *Jens D. Lundgren (Copenhagen, Denmark)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group

---

SY036 **Hall 15**

08:30 – 10:30

2-hour Symposium

ANT

ESCMID Global 2025 - Programme

The quality of antibiotics used in the communities of LMICs

Chairs *Thi Thuy Nga Do (Ha Noi, Vietnam)*
Christina Obiero (Kilifi, Kenya)

S0105	08:30	**The quality of antibiotics and their potential impact on patient outcome and AMR** *Paul Newton (Oxford, United Kingdom)*
S0106	09:00	**Community antibiotic access and use in Sub-Sahara Africa** *Samuel Afari-Asiedu (Kintampo, Ghana)*
S0107	09:30	**Encountered challenges and reflections on conducting multi-country medicine quality studies** *Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)*
S0108	10:00	**Confusion in appearance of common used antibiotics in LMICs** *Heiman Wertheim (Nijmegen, The Netherlands)*

SY037 **08:30 – 10:30** **Hall 16**

2-hour Symposium

CLN DX

Unveiling the challenges: nosocomial infections in ECMO-supported patients

Chairs *Antonios Katsounas (Bochum, Germany)*
Jordi Riera (Barcelona, Spain)

S0109	08:30	**Source of infection and pathogens** *Christian Eckmann (Hannover, Germany)*
S0110	09:00	**Prophylaxis and empiric treatment** *Giacomo Grasselli (Besana In Brianza, Italy)*
S0111	09:30	**Diagnostic criteria and definitions** *Graeme Maclaren (Singapore, Singapore)*
S0112	10:00	**Microbial films** *Marta Hernández-Meneses (Barcelona, Spain)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

SY031 **08:30 – 10:30** **Hall 6**

2-hour Symposium

CLN VAX

To screen or not to screen prior to transplant?

Chairs *Laura Alicia Barcan (Buenos Aires, Argentina)*
Oscar Len (Barcelona, Spain)

S0085	08:30	**HHV-8 Screening** *Alessandra Mularoni (Palermo, Italy)*
S0086	09:00	**TB screening and prevention in endemic regions** *Rubina Naqvi (Karachi, Pakistan)*
S0087	09:30	**Screening for and prevention of chagas in immunocompromised hosts** *Marcelo Victor Radisic (Buenos Aires, Argentina)*
S0088	10:00	**Screening of lung donors for Mollicutes** *Michael G Ison (Derwood (MD), United States)*

SY032 **08:30 – 10:30** **Hall 7**

2-hour Symposium

TRN

New insights into *Candida* pathogenesis

Chairs *Aleksandra Barac (Belgrade, Serbia)*
Joshua Nosanchuk (Bronx, United States)

S0089	08:30	**Insights into the evolution of *Candida* under antifungal pressure** *Attila Gacser (Szeged, Hungary)*
S0090	09:00	**How do *Candida* extracellular vesicles modify virulence during disease?** *Leonardo Nimrichter (Rio De Janeiro, Brazil)*
S0091	09:30	**The commensal to pathogen transition: kind to killer** *Ilse D. Jacobsen (Jena, Germany)*
S0092	10:00	**Fungal-bacterial interactions: who wins?** *Rebecca Hall (Canterbury, United Kingdom)*

SY033 **08:30 – 10:30** **Hall 8**

2-hour Symposium

TRN

Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.

Chairs *Christian Stephan Lentz (Tromsø, Norway)*
Annelies Zinkernagel (Zurich, Switzerland)

S0093	08:30	**Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections** *Christoph Ernst (Cologne, Germany)*
S0094	09:00	**Single-cell imaging and heterogeneity in antimicrobial resistance** *Stefano Pagliara (Exeter, United Kingdom)*
S0095	09:30	**Single-cell RNAseq and heterogeneity in bacterial transcription** *Anna Kuchina (Seattle, United States)*
S0096	10:00	**Dissecting the function of individual bacteria in their spatial context** *Knut Drescher (Basel, Switzerland)*

EW041 **08:30 – 10:30** **Hall 13**

Educational Session

CLN DX VAX

RSV infections: diagnosis, surveillance and treatment in the advent of vaccines

Chairs *Monika Redlberger-Fritz (Vienna, Austria)*
Makeda Semret (Montreal, Canada)

W0126	08:30	**Costs of RSV infection, compared to other respiratory viruses** *Barbara Rath (Besançon, France)*
W0127	08:50	**Virology and host interactions of RSV** *Peter Openshaw (London, United Kingdom)*
W0128	09:10	**RSV surveillance in the EU/EEA in the vaccine era** *Eeva Broberg (Solna, Sweden)*
W0129	09:30	**RSV fusion inhibitors and monoclonals: current status and future developments** *Louis Bont (Utrecht, The Netherlands)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

EW042 **08:30 – 10:30** **Hall 14**

Educational Session

CLN

Traumatic wound infections: diagnosis and treatment options

Chairs *Amparo Fernández-Rodríguez (Madrid, Spain)*
Veroniek Saegeman (Sint-Niklaas, Belgium)

W0130	08:30	**Multidrug-resistant infections after trauma in warzone** *Shehan Hettiaratchy (Hampton, United Kingdom)*
W0131	08:50	**Fungal infections during natural disasters** *Anuradha Chowdhary (New Delhi, India)*
W0132	09:10	**Bacteriophage therapy for multidrug-resistant wound infections in trauma** *Tristan Ferry (Lyon, France)*
W0133	09:30	**Infection of burn wounds** *Nur Benzonana (Istanbul, Türkiye)*

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clinica), International Society of Antimicrobial Chemotherapy (ISAC)

EW039 **08:30 – 10:30** **Hall 2**

Educational Session

CLN DX

Are urinary tract infections still the same?

Chairs *Suzanne Geerlings (Amsterdam, The Netherlands)*
Agnes Maria Sonnevend (Pécs, Hungary)

W0118	08:30	**Update on paediatric UTI** *Michael Buettcher (Luzern, Switzerland)*
W0119	08:50	**Diagnosis and treatment of UTI in the era of antimicrobial resistance** *Jennifer Kranz (Aachen, Germany)*
W0120	09:10	**Can UTI be prevented?** *Chris Harding (Newcastle Upon Tyne, United Kingdom)*

EW040 — **08:30 – 10:30** — **Hall 3**

Educational Session

ANT CLN

OPAT: from aged wine to new vintage

Chairs — *Birgit Koch (Rotterdam, The Netherlands)*, *Sonia Luque (Barcelona, Spain)*

W0122	08:30	**OPAT: principles, practice and checklists** *Charlotte Quintens (Leuven, Belgium)*
W0123	08:50	**COPAT: complex outpatient parenteral antimicrobial therapy** *Ronald Andrew Seaton (Glasgow, United Kingdom)*
W0124	09:10	**Antimicrobial stability and other challenges for OPAT practice?** *Mark Gilchrist (London, United Kingdom)*
W0125	09:30	**New OPAT safety and efficacy data to guide practice** *Matthew Rawlins (Murdoch, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)

EW038 — **08:30 – 11:30** — **Hall 4**

Educational Session

AMR DX

EUCAST educational workshop

Chairs — *Marlene Amara (Le Chesnay Cedex, France)*, *Alasdair P. Macgowan (Bristol, United Kingdom)*

W0113	08:30	**EUCAST update** *Sören G. Gatermann (Bochum, Germany)*
W0114	08:50	**Setting clinical breakpoints, assessing evidence** *Anouk Edwina Muller (The Hague, The Netherlands)*
W0115	09:10	**Benzylpenicillin susceptibility testing of *S. pneumoniae* by disk diffusion** *Gunnar Kahlmeter (Tävelsås, Sweden)*
W0116	09:30	**What to do when there are no breakpoints** *Barbara Juliane Holzknecht (Copenhagen, Denmark)*
W0117	09:50	**Detection of resistance mechanisms** *Christian Giske (Stockholm, Sweden)*

Co-organised with: EUCAST Steering Committee

EF003 — **08:30 – 09:30** — **Arena 1**

ePoster Flash Session

CLN VAX

01a. On the frontiers of vaccine driven prevention

Chair — *Maria Ganczak (Zielona Gora, Poland)*

E0021	08:30	**Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine** *J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll*
E0022	08:36	**A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine** *P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li*
E0023	08:42	**A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design** *M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen*
E0024	08:48	**Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years** *M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, J. Goswami, F. Priddy, R. Das*
E0025	08:54	**Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms** *S. Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. Mcconnell*
E0026	09:00	**Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics** *T. Russell* (London, United Kingdom), J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr, E.C. Wall, A.J. Kucharski*
E0027	09:06	**Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study** *L. Mcgeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall*
E0028	09:12	**Immunogenicity and safety of second COVID-19 booster and influenza vaccination coadministration** *I. Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone*
E0029	09:18	**The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania** *S. Cristea* (Sibiu, Romania), C. Grigore*

EF004 — **08:30 – 09:30** — **Arena 3**

ePoster Flash Session

ANT

Pharmacology from bench to the bedside

Chair — *Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)*

E0030	08:30	***Enterococcus faecalis* impairs *Escherichia coli* response to antibiotics in a dual-species intracellular infection model** *G. Wang* (Brussels, Belgium), F. Van Bambeke*
E0031	08:36	**In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing *Enterobacterales* clinical isolates** *M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Sauco Carballo, J. Rodriguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha*
E0032	08:42	***In vivo* activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant *Pseudomonas aeruginosa* following subcutaneous administration** *S. Paukner* (Vienna, Austria), W.W. Wicha*
E0033	08:48	**Synergistic Potency Unveiled: []-Lactam and []-Lactamase Inhibitor Combination against *Mycobacterium abscessus* with Dual Action of []-Lactamase Inhibition and Multi-Target Receptor Inactivation** *R.A. Bonomo* (Nutley, United States), E. Shin, K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry*
E0034	08:54	**Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with *Mycobacterium abscessus* infection** *W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane*
E0035	09:00	**Pharmacokinetic/pharmacodynamic modelling of**

immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models *R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg*

E0036 09:06 **Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study** *P. Le Turnier* (Cayenne, French Guiana), C. Deschanvres, S. Jamard, A. Lorleac'h, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard*

E0037 09:12 **No time to waste: hospital-wide assessment of IV-vial and line residuals and impact on target attainment.** *D. Vanneste* (Leuven, Belgium), M. Gijsen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet*

E0038 09:18 **Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection** *D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer*

SY043 09:30 – 10:30 **Hall 1**

1-hour Symposium

IPC

Year in infection control

Chairs *Nico Tom Mutters (Bonn, Germany)*
Ermira Tartari (Msida, Malta)

S0134 09:30 *Andrew James Stewardson (Melbourne, Victoria, Australia)*

S0135 10:00 *Kalisvar Marimuthu (Singapore, Singapore)*

EF005 09:30 – 10:30 **Arena 2**

ePoster Flash Session

CLN DX

It's all in the blood

Chair *Colin R. Mackenzie (Neuss, Germany)*

E0039 09:30 **Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivity** *L. Hardy* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet*

E0040 09:36 **Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital network** *C. Hall* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main*

E0042 09:48 **Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of results** *C. Magri* (Rome, Italy), C. Magri, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti*

E0043 09:54 **Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient Management** *S. Buyukberber* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan*

E0044 10:00 **Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of Turkiye** *Ö. Türkmen Recen* (Izmir, Türkiye), M. Kıplapınar, H. Özdemir, S. Kurutepe, H. Gazi*

E0045 10:06 **Performance of direct pathogen and []-lactamase detection workflow using MALDI-TOF MS from positive blood culture specimens** *K. Kosai* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara*

E0046 10:12 **Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infections** *L. Van Balen* (Maastricht, The Netherlands), R. Koeck*

E0047 10:18 **Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in Europe** *C. Pina-Vaz* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva*

EF006 09:30 – 10:30 **Arena 4**

ePoster Flash Session

AMR ANT CLN

Emerging developments in antifungal pharmacology

Chair *Roger Brüggemann (Nijmegen, The Netherlands)*

E0048 09:30 **NATURE-US: the natural history of antifungal failure in invasive candidiasis** *L. Ostrosky-Zeichner* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo*

E0049 09:36 **The antidepressant vortioxetine enhances resistance toward multiple azoles** *S. Rizzo* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli*

E0050 09:42 **Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration** *D. Amit* (Chicago, United States), A. Desai, L. Kovanda*

E0051 09:48 **Identification of efflux inhibitors for *Candida albicans* through a drug repurposing strategy** *D. Marques* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues*

E0052 09:54 **Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of *Candida auris* fungemia** *J. Hou* (Chicago, Il, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega*

E0053 10:00 **Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis** *A. Soriano* (Barcelona, Spain), G.R. Thompson, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely*

E0054 10:06 **Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by *Candida auris*: a multicentre, open-label study (CARES)** *M. Miceli* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson III, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breedt, N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M. Middle, M. Hoenigl*

E0055 10:12 **High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis** *S. Wurster* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis*

E0056 10:18 **Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits** *V. Petraitis* (New York, United States), R. Petraitiene, E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pockevicius, M. Zimmerman, A.H. Groll, T.J. Walsh*

OS010 11:00 – 12:00 **Hall 10**

1-hour Case Session

CLN

Antimicrobial drugs in action

Chairs *Katy Jeannot (Besançon, France)*
Timothy R. Walsh (Oxford, United Kingdom)

O0072 11:00 ***In vivo* cefiderocol resistance due to *cirA* modification during treatment** *P. Pini* (Reggio Emilia, Italy), R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M.*

Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh, E. Carretto

O0073 **11:11** **Long-term outcomes in dalbavancin-treated patients with vascular graft infection.** *A. Specklin* (Reims, France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien*

O0074 **11:22** **Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant *E.coli* on peritonitis in a pediatric liver transplant recipient** *R. Morales Junior* (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio*

O0075 **11:33** **Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by *Cutibacterium acnes* – a case series** *M. Karolyi* (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fischoeder, M. Ortler, C. Wenisch*

O0076 **11:44** **Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant *K. pneumoniae* shunt-related ventriculitis: two case reports.** *G. Giuliano* (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello*

OS009 **11:00 – 12:00** **Hall 8**

1-hour Case Session

CLN

Osteoarticular uninvited guests

Chairs *Tiziana Ascione (Naples, Italy)*
Jaime Esteban (Madrid, Spain)

O0067 **11:00** **Antibiotic-refractory oligoarthritis in an adolescent caused by *Borrelia bavariensis* in Croatia** *N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović*

O0068 **11:11** **Progression of vertebral echinococcosis despite radiotherapy treatment** *M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D. Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-Molina*

O0069 **11:22** **Two cases of septic osteoarthritis of *Cutibacterium acnes* detected by 16S rRNA gene sequencing in immunocompetent adolescents** *H. Okuno* (Osaka, Japan), K. Shiota, K. Amo*

O0070 **11:33** **A UK case of Melioidosis with osteomyelitis two years after geographical exposure** *C. Darlow* (Liverpool, United Kingdom), L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis*

O0071 **11:44** **When Infection Masquerades as Malignancy: A Case of Disseminated *Mycobacterium fortuitum* complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-[] Immunodeficiency Syndrome** *N. Hiranburana* (Bangkok, Thailand), S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul*

OS011 **11:00 – 12:00** **Hall 13**

1-hour Oral Session

ANT TRN

Around the lab in 80 ways: a journey through innovative therapeutics

Chairs *Zuzanna Drulis-Kawa (Wroclaw, Poland)*
Helena Zemlickova (Prague, Czechia)

O0077 **11:00** **In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in a disease model** *C. Tkaczyk* (Gaithersburg, United States), N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret*

O0078 **11:12** **Hijacking intrinsic resistance in Mycobacterium abscessus** *G. Phelps* (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee*

O0079 **11:24** **Tripartite bacteriophage-based strategy to combat human clinical pathogens** *P. Kalatzis* (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén*

O0080 **11:36** **Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy** *Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu*

O0081 **11:48** **Identification of compounds capable of removing established bacterial biofilms** *T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar*

OS012 **11:00 – 12:00** **Hall 15**

1-hour Oral Session

PHEI

Climate impact and One Health approaches against infectious diseases

Chairs *Juliette Severin (Rotterdam, The Netherlands)*
Chadia Wannous (Paris, France)

O0082 **11:00** **Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective** *C. Royo-Cebrecos* (Andorra, Andorra), N. Duran Torralbo, M. Clusas Antolin, L. Trapero, D. Vilanova Gonzalez*

O0083 **11:12** **Effects of climate change on Aedes aegypti abundance and dengue transmission** *L. Geng* (Singapore, Singapore)*

O0084 **11:24** **Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia** *M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshtkar-Jahromi*

O0085 **11:36** **Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning** *E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear*

O0086 **11:48** **Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater** *M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni*

OS013 **11:00 – 12:00** **Hall 16**

1-hour Oral Session

CLN DX

Viral challenges in organ transplantation

Chairs *Ghady Haidar (Pittsburgh, United States)*
Cristiana Oprea (Bucharest, Romania)

O0087 **11:00** **Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients** *I. Rodríguez-Goncer* (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Góncer*

O0088 **11:12** **Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients** *A. Mughrabi* (Rochester, Minnesota, United States), B. Bisono-Garcia, S. Chesdachai, N. Ranganath, R. Razonable*

O0089 **11:24** **Real-world administration of maribavir beyond the eight weeks established in the clinical trial** *D.*

Martínez-Simón (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len*

O0090 **11:36** **Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients** *M. Solis* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer*

OS007 **Hall 6**

11:00 – 12:00

1-hour Oral Session

ANT CLN VAX

New developements in prophylaxis and treatment of COVID-19

Chairs *Gülsen Özkaya Sahin (Lund, Sweden)*
Snjezana Zidovec Lepej (Zagreb, Croatia)

O0057 **11:00** **Ensitrelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP** *F. Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara*

O0058 **11:12** **Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial** *R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri*

O0059 **11:24** **COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach.** *T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R. Méndez, E. Calbo, M. Ballestero-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano, C. Garcia-Vidal*

O0060 **11:36** ***Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis*** *C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola*

O0061 **11:48** **Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial** *C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader*

OS008 **Hall 7**

11:00 – 12:00

1-hour Oral Session

CLN TRN

Advancing malaria research: from molecular insights to clinical challenges

Chairs *Kamruddin Ahmed (Kota Kinabalu, Malaysia)*
Giri Shan Rajahram (Kota Kinabalu, Malaysia)

O0062 **11:00** **Influence of second blood meals on *Plasmodium vivax* development and infectivity in mosquitoes** *S. Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. Sattabongkot, C. Kumpitak*

O0064 **11:12** **Severe imported *Plasmodium falciparum* malaria with hyperparasitaemia: evaluation of predictors for critical disease** *T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth*

O0065 **11:24** **The current status of *Plasmodium falciparum* chloroquine resistance transporter gene (K76T) and *Plasmodium falciparum* multi-drug resistance gene 1 (N86Y) in Cameroon** *M. Fru* (Buea, Cameroon)*

O0066 **11:36** **SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed.** *E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes*

LB001 **Hall 9**

11:00 – 12:00

1-hour Oral Session

VAX

Advances in vaccine effectiveness for respiratory infections

Chairs *Joel Mossong (Luxembourg, Luxembourg)*
Jean Paul Stahl (Corenc, France)

L0001 **11:00** **Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants** *F. Priddy* (Cambridge, United States), A. Figueroa, D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt*

L0002 **11:12** **JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE** *H.R. Volkman* (New York, United States), L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. Mclaughlin, K. Bollaerts*

L0003 **11:24** **Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults ≥65 years of age in the United States** *A. Miles* (New York, United States), J.T. Vietri, S. Rosenstock, H. Li, J. Vojicic, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani*

L0004 **11:36** **Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure** *D. Jenkin* (Oxford, United Kingdom), E. Sheehan, R. Huq, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhadef, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy*

L0005 **11:48** **Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals** *J. Atwell* (New York, United States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner*

SY047 **Hall 11**

11:00 – 12:00

1-hour Symposium

IPC

How long should contact isolation precautions be continued?

Chairs *Cansu Cimen (Oldenburg, Germany)*
Kyriaki Tryfinopoulou (Heraklion, Greece)

S0141 **11:00** **Contact isolation in patients with MDR organisms: Why, when, where?** *Gabriel Birgand (Nantes, France)*

S0142 **11:30** **Is discontinuation of contact precautions associated with an increase in infections?** *Daniel Diekema (Harpswell, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS

SY045 **Hall 2**

11:00 – 12:00

1-hour Symposium

CLN

What happens following TB infection?

Chairs *Catherine Ong (Singapore, Singapore)*
Sean Wasserman (London, United Kingdom)

S0137 **11:00** **Post-TB disease: burden and treatment**

		strategies *Deborah Chong (London, United Kingdom)*
S0138	**11:30**	**TB sequelae and fungal infection** *Helmut Salzer (Linz, Austria)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet

---

SY046 **11:00 – 12:00** **Hall 5**

1-hour Symposium

TRN VAX

New frontiers in bacterial pathogenesis

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Abdou Hachani (Melbourne, Australia)

S0139	**11:00**	**Bacterial infections and cellular immunity** *Charlotte Odendall (London, United Kingdom)*
S0140	**11:30**	**Immuno-metabolism in bacterial diseases** *Tania Wong (New York, United States)*

YIA **11:00 – 12:00** **Hall 3**

Awards

PRO

Young Investigator Award Session

Chairs *Emmanuelle Cambau (Paris, France)*
Jan A.J.W. Kluytmans (Utrecht, The Netherlands)

A001	**11:00**	**Deciphering the pathogenic traits and epidemiological identities of *Staphylococcus pseudintermedius*: an emerging and underestimated zoonotic pathogen** *Ikechukwu Benjamin Moses (Abakaliki, Nigeria)*
A002	**11:12**	**Drugs for Vector-borne Infections: Facts and Fibrillations** *Xin Hui Chan (Oxford, United Kingdom)*
A003	**11:24**	**Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet?** *Matthaios Papadimitriou Olivgeris (Sion, Switzerland)*
A004	**11:36**	**Finding a place for observational studies in infectious diseases research** *Anthony Bai (Kingston, Canada)*
A005	**11:48**	**Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis** *Simon Feys (Leuven, Belgium)*

EF014 **11:00 – 12:00** **Arena 2**

ePoster Flash Session

IPC PHEI

Infection control and prevention around the world

Chair *Divyashree Shanthamurthy (Mumbai, India)*

E0092	**11:00**	**WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets** *G. Satta* (Geneva, Switzerland), P. Bischoff, S. Tomczyk, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi*
E0093	**11:06**	**Healthcare-associated infections in african intensive care units: A multicentre prospective cohort study** *M. Gaye* (Paris, France), N. Madani, J. Ben Khlil, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Naija, M. Kahloul, R. Herch, R. Toumi, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly*
E0094	**11:12**	**Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022.** *E. Liddy* (Dublin, Ireland), A. Vellinga, D. Amin*
E0095	**11:18**	**Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network** *I. Kopsidas* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou*
E0096	**11:24**	**Characterisation of plasmids disseminating antibiotic resistance in *Klebsiella pneumoniae* isolates from Pretoria, South Africa** *T. Govender* (Pretoria, South Africa), M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Moultrie, M. Moodley, J. Featherston, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock*
E0097	**11:30**	**Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin** *K. Sintondji* (Abomey-Calavi, Benin), V. Dougnon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou*
E0098	**11:36**	**Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units.** *M. Salomão* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao*
E0100	**11:48**	**Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study** *D. Nagy* (Oxford, United Kingdom), V. Pennetta, G. Rodger, K. Hopkins, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown, N. Stoesser, S. Lipworth*

EF015 **11:00 – 12:00** **Arena 3**

ePoster Flash Session

ANT CLN DX

Advances in the diagnosis and treatment of skin, bone, and joint infections

Chair *Norma Jung (Köln, Germany)*

E0101	**11:00**	**Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic** *F. Petri* (Milan, Italy), F. Borgonovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari*
E0102	**11:06**	**Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection** *B.J.H. Frank* (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter*
E0103	**11:12**	**Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis** *F. Olearo* (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker*
E0104	**11:18**	**Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study** *A. Tili* (Modena, Italy), G. Franceschi, M. Pellegrino, L. Benassi, A. Soffritti, M. Del Monte, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina, A. Bedini*

E0105 11:24 **Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study** *A. Diarra* (Tourcoing, France), M. Degrendel, P. Patoz, P.Y. Tortai, V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, O. Robineau, E. Senneville*

E0106 11:30 **Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infections.** *F. Braojos Sanchez* (Madrid, Spain), R. Escudero-Sánchez, S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tasias Pitarch, M. Salaver Lleti, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote Rivas, B. De La Torre Escuredo, J. Cobo*

E0107 11:36 **Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial** *M. Dudareva* (Oxford, United Kingdom), M. Kumin, C. Scarborough, W. Vach, J. Ferguson, M. Scarborough, M. Mcnally*

E0108 11:42 **Clinical and Antibacterial Diversity of *Staphylococcal* Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective.** *F. Zeeshan* (Karachi, Pakistan), A. Naeem, F. Uddin*

E0109 11:48 **Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study.** *F. Romani* (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, B. Fontana, G. Franceschi, M. Sarti, C. Mussini*

EF016 **Arena 4**

11:00 – 12:00

ePoster Flash Session

AMR CLN PHEI

Rising threats: antimicrobial resistance in STIs

Chair *Marcos Rust (Feldkirch, Austria)*

E0110 11:00 **Important rise of antibiotic resistance of *Mycoplasma genitalium*, a sexually transmitted pathogen, in a French University hospital** *F. Doucet Populaire* (Clamart, France), W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos*

E0111 11:06 **Molecular characterization of antimicrobial resistance and genotyping of *Mycoplasma genitalium* positive samples of the Lisbon area, Portugal** *M. Barros* (Lisbon, Portugal), F. Pereira, L. Rodrigues*

E0112 11:12 **Antimicrobial Resistance in Mycoplasma genitalium: Surveillance and Management in São Paulo, Brazil** *V. Passarelli* (São Paulo, Brazil), F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa*

E0113 11:18 **Impact of genotypic substitutions on treatment failure for *Mycoplasma genitalium* infection** *N.B. Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti*

E0114 11:24 **Macrolide-resistant *Mycoplasma genitalium*: an emerging threat to public health?** *J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas*

E0115 11:30 **Comparison of carbapenem MIC in wild-type, MDR and XDR *Neisseria gonorrhoeae* isolates** *J. Brousseau* (Paris, France), A. Braille, M. Mainardis, F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot*

E0117 11:42 **Surveillance of *Neisseria gonorrhoeae* antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024** *M. Giovanni* (Singapore, Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan*

E0118 11:48 **Molecular surveillance results of *N. gonorrhoeae* in Korea** *K.H. Roh* (Goyang, Korea, Republic of), C. Liu, Y.H. Suh, H. Lee, K. Lee*

KN044 **Hall 1**

11:00 – 12:00

Keynote Lecture

AMR PHEI

Asia: an AMR hot zone

Chairs *Giulia De Angelis (Rome, Italy)*
Robert Leo Skov (Copenhagen, Denmark)

K0136 11:00 *David L. Paterson (Singapore, Singapore)*

ME048 **Hall 12**

11:00 – 12:00

Meet-the-Expert

DX

Cut a long story short: choosing NGS platforms

M0143 11:00 *Etienne Ruppe (Paris, France)*
M0144 11:12 *Stefan Green (Chicago, United States)*

ME049 **Hall 14**

11:00 – 12:00

Meet-the-Expert

PRO

How to perform clinical trials in mycoses?

M0145 11:00 *Monica Slavin (Melbourne, Australia)*
M0146 11:12 *Nkechi Azie (Barrington, United States)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

FO050 **Arena 1**

11:00 – 12:00

Open Forum

PHEI

HIV: a global ethical conundrum

Chair *Seif Al-Abri (Muscat, Oman)*

F0147 11:00 **HIV, from key population to general population: a Pandora's Box** *Syed Faisal Mahmood (Karachi, Pakistan)*

F0148 11:10 **Ethical considerations in preventing mother-to-child HIV transmission** *Glory Alexander (Bangalore, India)*

F0149 11:20 **HIV drug trials in Africa: ethical concerns** *Shah Reena (Nairobi, Kenya)*

F0150 11:30 **HIV-related stigma and discrimination in the healthcare setting** *Teymur Noori (Stockholm, Sweden)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

OS017 **Hall 5**

13:30 – 14:30

1-hour Case Session

CLN

Bad bacteria

Chairs *Maristela P. Freire (Sao Paulo, Brazil)*
Siegbert Rieg (Freiburg, Germany)

O0119 13:30 **Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug** *R. Gupta (bagga)* (London, Canada), A. Cabrera, A. Kanyua, F. Almutawa, J. Delport, K. Kavanoor Sridhar*

O0120 13:41 **Whipple's disease: one of medicine's great imitators** *S. Kesavan* (Nottingham, United Kingdom),*

F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson

O0121 13:52 **Phage Therapy as a Rescue Treatment for Recurrent Pseudomonas aeruginosa Bentall Infection** *V. Eiferman* (Paris, France), P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu*

O0122 14:03 **A clinical case of *Legionella longbeachae* pneumonia featuring unique epidemiological features in a major italian hospital** *S. Guerriero* (Rome, Italy), M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti*

O0123 14:14 ***Francisella tularensis* – First autochthonous case in the UK** *G. Vanstone* (Truro, United Kingdom), A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou*

OS018 **13:30 – 14:30** **Hall 11**

1-hour Oral Session

ANT IPC

Battling the spore: *C. difficile* epidemiology and management

Chairs *Nicolas Benech (Lyon, France)*
Fidelma Fitzpatrick (Dublin, Ireland)

O0124 13:30 **Molecular epidemiology and antimicrobial resistome of Clostridioides difficile from private and public healthcare settings in three provinces in South Africa** *H. Shirinda* (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers*

O0125 13:42 **Screening for *Clostridioides difficile* colonization at admission and during hospitalization** *N. Khanafer* (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems*

O0126 13:54 **Revolutionizing CDI treatment: Are shorter antibiotic regimens the future** *M. Duricek* (Prague, Czechia), J. Benes, K. Halmova*

O0127 14:06 **Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of *Clostridioides difficile* infection** *E. Rubio-Martín* (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tasias, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M. Montero, D. Echeverría-Esnal, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo*

O0128 14:18 **Gut phageome profiling in *Clostridioides difficile* infection and faecal microbiota transplantation** *C. Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine*

OS019 **13:30 – 14:30** **Hall 12**

1-hour Oral Session

TRN

Microbiome dynamics and health: from pathogenesis to therapeutic potential

Chairs *Mauricio Farfan (Santiago, Chile)*
Eija Inkeri Könönen (Turku, Finland)

O0129 13:30 **Multi-omics integrated analysis revealed the key role of Fusobacterium periodonticum in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis.** *J. Xinmiao* (Beijing, China), X. Chu, Q. Yang*

O0130 13:42 **Exploring the respiratory microbiome in COPD patients: The role of *Haemophilus* spp. in disease pathogenesis** *P. Camps-Massa* (Barcelona, Spain), L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Dominguez, S. Santos, S. Martí*

O0131 13:54 **Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes** *I. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley*

O0132 14:06 **Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: insights into the impacts of Westernization on human health** *M. Thorp* (Gent, Belgium), C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke*

O0133 14:18 **Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria?** *K. Villageois-Tran* (Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé*

OS020 **13:30 – 14:30** **Hall 15**

1-hour Oral Session

ANT

How to evaluate AMS programmes

Chairs *Esther Calbo (Terrassa, Spain)*
Sabiha Essack (Durban, South Africa)

O0134 13:30 **Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data** *V. Nguyen* (Oxford, United Kingdom), J.V. Robotham, S. Yu, S. Wordsworth, K. Pouwels*

O0135 13:42 **Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study** *B. Moshy* (London, United Kingdom), R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan*

O0136 13:54 **Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital** *V. Huang* (Glendale, United States), T. Pham, A. Vogler, H. Chhen, C. Vandenberg*

O0137 14:06 **Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting** *A. Hopkins* (Livingston, United States), A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime*

O0138 14:18 **Timing of Novel []-Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings** *J. Min* (Rahway, United States), Y. Wang, M. Vendetti, Y. Emre, R.K. Shields*

SY051 **13:30 – 14:30** **Hall 1**

1-hour Symposium

CLN

Year in infectious diseases

Chairs *Nur Benzonana (Istanbul, Türkiye)*
Evelina Tacconelli (Verona, Italy)

S0151 13:30 *Yoav Keynan (Winnipeg, Canada)*
S0152 14:00 *Elisa Cordero Matia (Seville, Spain)*

SY053 **13:30 – 14:30** **Hall 16**

1-hour Symposium

PRO

Developing guidelines with AI tools: are they ready for prime time?

Chairs *Miranda Langendam (Amsterdam, The Netherlands)*
Blin Nagavci (Gjakove, Kosovo)

S0155 **13:30** **The PROs and CONs of using AI tools for developing guidelines** *Holger Schuenemann (Milano, Italy)*

S0156 **14:00** **AI in action: validated tools for speeding up your systematic reviews and how to use them** *Sara Fernandez (Oslo, Norway)*

Co-organised with: ESCMID Guidelines Subcommittee

SY052 **Hall 2**

13:30 – 14:30

1-hour Symposium

IPC PHEI

Exploring children's role in infection spread

Chairs *Angelika Berger (Vienna, Austria)*
Sanjay Patel (Winchester, United Kingdom)

S0153 **13:30** **Are children really super-spreaders of respiratory viruses?** *Emmanuel André (Leuven, Belgium)*

S0154 **14:00** **Should schools be closed at the start of the next pandemic?** *Vittoria Colizza (Paris, France)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

EF021 **Arena 1**

13:30 – 14:30

ePoster Flash Session

AMR CLN DX

Infections in haemato-oncological hosts: from bacterial to viral

Chair *Genovefa Papanicolaou (New York, United States)*

E0139 **13:30** **Vancomycin-resistant *Enterococcus faecium* bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study** *J. Fung* (Vancouver, Canada), K. Aldhaheri, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga*

E0140 **13:36** **Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.** *I. Grafia Perez* (Barcelona, Spain), I. Grafia, A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco-Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde*

E0141 **13:42** **Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy** *C. Charalampidis* (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsirigotis, K. Thomas*

E0143 **13:48** **The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy** *B. Teh* (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin*

E0144 **13:54** **Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity** *P. Bono* (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri*

E0145 **14:00** **Safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)** *E. Dubberke* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M. Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen*

E0146 **14:06** **Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients** *S. De Aragón De La Cruz* (Basel, Switzerland), C.S. Walti, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck, N. Khanna, K. Leuzinger*

E0147 **14:12** **Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients.** *J. Boan Perez* (Madrid, Spain), J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoaín, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado*

EF022 **Arena 2**

13:30 – 14:30

ePoster Flash Session

DX

Syndromic testing is still coming of age

Chair *Tommaso Giani (Florence, Italy)*

E0148 **13:30** **Bacterial infections of the central nervous system: addressing the diagnostic gap in non- community-acquired meningitis** *G. Menchinelli* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti*

E0149 **13:36** **Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform** *M. Rey* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona*

E0150 **13:42** **Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital** *S. Subedi* (Brisbane, Australia), P. Harris, D. Paterson*

E0151 **13:48** **Performance evaluation of the NxTAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital.** *S. Gibaud* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec*

E0152 **13:54** **Correct discrimination of Monkeypox virus clades by fast syndromic testing** *S. Reister* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen*

E0153 **14:00** **Managing a *Mycoplasma pneumoniae* Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies** *L. Brusca* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-Borrás, G. Santillana-Cernuda, M. Ballestero-Tellez, A. Boronat, J. Perez*

E0154 **14:06** **Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – interim analysis** *R. Riccardi* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella*

E0155 **14:12** **Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia** *S. Chantharasut* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaipisuttikul*

E0156 **14:18** **BacteREVEAL: Analytical performance and contribution of BioFire® BCID2 and Vitek® REVEAL™ in intensive care patients with Gram-negative bloodstream infections** *C. Roger* (Nimes, France), L. Oudiane, M. Benyahia, F. Salipante, A. Dubois, L. Muller, J.P. Lavigne, A. Pantel*

EF023 **13:30 – 14:30** **Arena 3**

ePoster Flash Session

DX

Effective microbiology for the management of sepsis

Chair *Maurizio Sanguinetti (Rome, Italy)*

E0157 **13:30** **Molecular epidemiology of Klebsiella bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study** *D. Nagy* (Oxford, United Kingdom), V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown, N. Stoesser, S. Lipworth*

E0158 **13:36** **Investigating seasonality of antibiotic resistance associated with *E. coli* and *Klebsiella pneumoniae* bloodstream infections** *S. Lipworth* (Oxford, United Kingdom), L. Gorman, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner, A. Dowsey, K. Pouwels*

E0159 **13:42** **Sensitivity of a host-protein test for microbiologically confirmed bacterial infections** *R. Navon* (Tirat Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide*

E0160 **13:48** **Comparative genomics of *Klebsiella pneumoniae* from gut colonisation and bloodstream infections reveal novel genetic associations** *M. Hetland* (Stavanger, Norway), K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr*

E0161 **13:54** **Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study** *C. Tol* (Izmir, Türkiye), G. Şanlıdağ İşbilen, B. Akkul, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi*

E0162 **14:00** **Contribution of *Escherichia coli* microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study** *N. Maldonado* (Seville, Spain), I. López-Hernández, L.E. López-Cortes, P.M. Martínez Pérez-Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-Kindelán, J.M. Reguera Iglesias, C. Armiñanzas-Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-Hernández, J. Rodríguez-Baño*

E0163 **14:06** **Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP.** *C. Treille* (Saclay, France), X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland, K. Perez-Toralla, H. Boutal*

E0164 **14:12** **Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australia.** *K. Laupland* (Herston, Australia), A. Stewart, F. Edwards, P. Harris, S. Coulter*

E0165 **14:18** **Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery** *S. Soueges* (Lyon, France), A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-Schiava, U. Huvelle, A. Millon, F. Valour*

EF024 **13:30 – 14:30** **Arena 4**

ePoster Flash Session

AMR TRN

A never-ending evolution of antimicrobial resistance

Chair *Antonio Oliver (Palma De Mallorca, Spain)*

E0166 **13:30** **Gfa, a novel integron-born fosfomycin resistance mechanism** *N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, J.A. Escudero*

E0167 **13:36** **Regulons of RamA, RarA and SoxS mediated tigecycline resistance and oxidative stress among *in vitro* tigecycline resistant evolution trajectory of *Klebsiella pneumoniae*.** *X. Wang* (Beijing, China), J. Kuai, Y. Zhao*

E0168 **13:42** **Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing Escherichia col** *C. Tellapragada* (Stockholm, Sweden), P. Jonsson, C. Giske*

E0170 **13:48** ***Enterococcus faecalis* penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration** *O. Funk* (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano*

E0171 **13:54** **Uncommon genomic rearrangements drive vancomycin resistance in *vanB*-positive *Enterococcus faecium*** *K. Xanthopoulou* (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins*

E0172 **14:00** **Heteroresistance in *Enterococcus faecalis*: prevalence and mechanistic insights across clinically relevant antibiotics** *S. Heidarian* (Uppsala, Sweden), S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I. Andersson*

E0173 **14:06** **Side effects of rifampicin resistance: transcriptome modulation by *rpoB* mutations in *Staphylococcus aureus*** *M. Roch* (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenko, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley*

E0174 **14:12** **Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance** *T. Echelmeyer* (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenscher, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufler, E. Eger*

ME055 **13:30 – 14:30** **Hall 14**

Meet-the-Expert

CLN

Long acting injectables to treat and prevent infections: an example from HIV field

M0159 **13:30** *Monica Gandhi (Salt Lake City, United States)*

M0160 **13:42** *Pedro Cahn (Buenos Aires, Argentina)*

ME054 **13:30 – 14:30** **Hall 3**

Meet-the-Expert

AMR TRN

How antimicrobial tolerance impacts polymicrobial biofilm-associated infections

M0157 **13:30** *Hans Steenackers (Leuven, Belgium)*

M0158 **13:42** *Brian Conlon (Chapel Hill, United States)*

OS026 **14:45 – 15:45** **Hall 11**

1-hour Oral Session

AMR ANT CLN

Carbapenem resistance Gram-negatives, what's new in treatment?

Chairs *Matteo Bassetti (Genoa, Italy)*
Maria Milagro Montero (Barcelona, Spain)

O0180 **14:45** **Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?** *Y. Verma* (Hisar, India), K. Narang, D. Bandlish, C. Sharma*

O0181 14:57 **Sulbactam-durlobactam as an effective alternative option against NDM-producing *Escherichia coli* including cefiderocol and aztreonam-avibactam-resistant isolates in Swizterland** *C. Le Terrier* (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel*

O0182 15:09 **Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by *in vitro* Antibiotic Combination Testing** *T. Lim* (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa*

O0183 15:21 **Management of infections caused by ST308 New Dehli metallo-*β*-lactamase-producing *Pseudomonas aeruginosa* with *in vitro*-guided combination antibiotic therapy** *J. Teo* (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa*

O0184 15:33 ***In vitro* activity of cefepime/enmetazobactam against clinical isolates of *Enterobacterales* in Portugal: A multicentre retrospective study** *H. Cruz* (Porto, Portugal), C. Chaves, L. Carneiro*

OS027 **14:45 – 15:45** **Hall 12**

AMR TRN

1-hour Oral Session

Staphylococcus aureus: colonisation, virulence, and persistence

Chairs *Jennifer Karin Bender (Wernigerode, Germany)*
Stefano Giulieri (Melbourne, Australia)

O0185 14:45 **The nasal microbiome redefines and predicts *Staphylococcus aureus* nasal colonisation status** *D. Aggarwal* (London, United Kingdom), K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. Mcmahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison*

O0186 14:57 **Development of a *Staphylococcus aureus* human nasal colonisation model** *A. Hachani* (Melbourne, Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan*

O0187 15:09 **Selection-free, virulence gene promoter-controlled CRISPR interference system for *in vivo* pathogenesis study of *Staphylococcus aureus* - A proof of concept** *R. Miah* (Tromsø, Norway), M. Johannessen, M. Kjos, C. Lentz*

O0188 15:21 **Placebo-controlled study of competitive exclusion using *Lactococcus lactis* to reduce transmission of LA-MRSA from pigs to humans** *B. Duim* (Utrecht, The Netherlands), A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar*

O0189 15:33 **Rifampicin-induced *Staphylococcus aureus* persister formation is driven by CodY and oxidative stress level** *N. Pordone* (Lyon, France), J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven*

OS028 **14:45 – 15:45** **Hall 15**

DX

1-hour Oral Session

Unlocking the potential of the human microbiome for clinical diagnostics

Chairs *John W. A. Rossen (Groningen, The Netherlands)*
Maria Vehreschild (Frankfurt Am Main, Germany)

O0190 14:45 **Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions** *O. Nalbantoglu* (Kayseri, Türkiye), B.H. Ermis, A. Gundogdu*

O0191 14:57 **Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis** *E. Rubio García* (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual*

O0192 15:09 **Donor for fecal microbiota transplantation: a challenging research.** *B.S. Orena* (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani*

O0193 15:21 **Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy** *N. Boutouchent* (Rouen, France), S. Kennedy*

O0194 15:33 **Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology** *A. Gundogdu* (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture*

OS025 **14:45 – 15:45** **Hall 5**

DX IPC

1-hour Oral Session

Bacterial battles: a paediatric perspective on infections and interventions

Chairs *Angelika Berger (Vienna, Austria)*
Julie Toubiana (Paris, France)

O0175 14:45 **Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections** *D. Dona* (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito*

O0176 14:57 **Correlation between antibiotic consumption and digestive colonization with multidrug-resistant *Enterobacterales* in a paediatric haematology department** *S. Frigui Ep Oueslati* (Tunis, Tunisia), N. Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour*

O0177 15:09 **Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study** *S. Whelan* (Dublin, Ireland), M. Eogan, N. Mccallion, A. Walsh, F. Moriarty, M. Elsammak, R. Drew*

O0178 15:21 **Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center** *E. Vaugon* (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard*

O0179 15:33 **Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre** *M. De Luca* (Rome, Italy), S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti, R. Iacobelli*

SY059 **14:45 – 15:45** **Hall 13**

IPC

1-hour Symposium

Value-based syndromic diagnostics in medical microbiology: Pro / Con debate

Chairs *Hege Vangstein Aamot (Lørenskog, Norway)*
Eric Claas (Leiden, The Netherlands)

S0166 14:45 **Pro: clinical benefit and potential for improved patient outcomes** *Kirstine K. Søgaard (Aalborg, Denmark)*

S0167 15:15 **Con: limitations, costs, and possible overuse of syndromic panels** *Gilbert Greub (Lausanne, Switzerland)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

SY060 **14:45 – 15:45** **Hall 14**

1-hour Symposium

IPC

We need to talk about toilets...

Chairs *Stephanie J. Dancer (Glasgow, United Kingdom)*
Juliette Severin (Rotterdam, The Netherlands)

S0168 **14:45** **Infection risks from sanitation engineering** *Davey Jones (Bangor, United Kingdom)*

S0169 **15:15** **Ventilation in toilets: how can we improve it?** *Michael Gormley (Edinburgh, United Kingdom)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

SY057 **14:45 – 15:45** **Hall 2**

1-hour Symposium

ANT CLN

Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

Chairs *Marc J.M. Bonten (Utrecht, The Netherlands)*
Karin Thursky (Carlton, Australia)

S0162 **14:45** **Pro: maximising outcomes with evidence-based use** *Evangelos Giamarellos-Bourboulis (Athens, Greece)*

S0163 **15:15** **Con: the risks of routine (over)use** *Aurélien Dinh (Garches, France)*

SY058 **14:45 – 15:45** **Hall 4**

1-hour Symposium

VAX

Top papers in transplant ID

Chairs *Nicolas Mueller (Zurich, Switzerland)*
Alessandra Mularoni (Palermo, Italy)

S0164 **14:45** **Top 10 papers in infections in SOT** *Patricia Munoz (Madrid, Spain)*

S0165 **15:15** **Top 10 paper in infections in HCT and cellular therapy** *Joshua Hill (Seattle, United States)*

EF029 **14:45 – 15:45** **Arena 2**

ePoster Flash Session

VAX

Vaccination uptake-challenges and opportunities

Chair *Joanne M. Langley (Halifax, Canada)*

E0196 **14:45** **Psychological Predictors of *Influenza* Vaccination Intent Among Healthcare Workers in Bulgaria** *P. Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenova, D. Ivanov, A. Zasheva, A. Hori*

E0197 **14:51** **Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort study** *Q. Hofsink* (Amsterdam, The Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof, S. Hahné, J. Heijmans, I.S. Nijhof*

E0199 **14:57** **Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programme** *A.C.M. Breschel* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersend*

E0200 **15:03** **Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024** *M. Hakim* (Hayat Abad Peshawar Kp Pakistan, Pakistan)*

E0201 **15:09** **Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIV** *D. Yaman* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin*

E0202 **15:15** **Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018–2022** *A. Palmborg* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar*

E0203 **15:21** **Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkey** *C. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal*

EF030 **14:45 – 15:45** **Arena 3**

ePoster Flash Session

CLN DX PHEI

Viruses crossing the blood-brain barrier

Chair *Rick Dersch (Freiburg, Germany)*

E0204 **14:45** **Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study** *L. Duerlund* (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen*

E0205 **14:51** **Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study** *S. Lant* (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tulius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon*

E0206 **14:57** **Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology** *C. Marin* (Bucharest, Romania), A. Paun, E. Nedu, S. Tetradov, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu*

E0207 **15:03** **Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model** *Z. Ou* (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng*

E0208 **15:09** **Intrathecal immunoglobulin synthesis in tick-borne encephalitis** *S. Grygorczuk* (Bialystok, Poland), P. Czupryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska*

E0209 **15:15** **B and T cell responses to Tick-borne Encephalitis Virus** *N. Mayola Danes* (Stockholm, Sweden), N. Mayola Danés, R. Varnaitė, K. Blom, H.G. Ljunggren, S. Gredmark-Russ*

E0210 **15:21** **Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights** *D. Sharma* (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh*

E0212 **15:33** ***Toxoplasma gondii* IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era** *T. Ou* (New Taipei City, Taiwan), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung*

EF031 **14:45 – 15:45** **Arena 4**

ePoster Flash Session

ANT CLN

AMS around the world: know your data!

Chair *Eoghan De Barra (Dublin, Ireland)*

E0213 **14:45** **Duration of antibiotic treatment for respiratory tract**

infections in primary care. *C. Llor* (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis*

E0214 14:51 **Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys** *V. Nguyen* (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland*

E0215 14:57 **Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys** *V. Nguyen* (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland*

E0216 15:03 **Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription** *R. Koizumi* (Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari*

E0217 15:09 **Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey.** *C. Palos* (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa*

E0218 15:15 **Evaluating the impact on 28-day mortality of different empiric AWaRe antibiotic treatment strategies for hospital-acquired infections across different hospital settings.** *C. Lim* (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper*

E0219 15:21 **Update on WHO's Global antibiotic use surveillance system (GLASS-AMU)** *B. Huttner* (Geneva, Switzerland), M. Escher, A. Muller, V. Ivanoska, D. Tong*

E0220 15:27 **Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPS** *A. Versporten* (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe*

E0221 15:33 **Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital** *N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa*

KN056 **Hall 1**

14:45 – 15:45

Keynote Lecture

PHEI

Defending against dengue: global epidemiology and strategies for prevention and control

Chairs *Anu Kantele (Helsinki, Finland)*
Carlos Seas (Lima, Peru)

K0161 14:45 *Fernanda Boulos (São Paulo, Brazil)*

ME062 **Hall 16**

14:45 – 15:45

Meet-the-Expert

ANT CLN

Untangling the web: antimicrobial dose adjustments in renal impairment

M0172 14:45 *Claire Roger (Nimes, France)*
M0173 14:57 *Isabel Spriet (Leuven, Belgium)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

ME061 **Hall 3**

14:45 – 15:45

Meet-the-Expert

PHEI TRN

How to use large language models and machine learning for improving One Health

M0170 14:45 *Javier Fernández (Oviedo, Spain)*
M0171 14:57 *Nicolas Radomski (Teramo, Italy)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)

FO063 **Arena 1**

14:45 – 15:45

Open Forum

PRO

Science communication in a noisy world: podcasting and social media in ID/CM

Chair *Emily G. Mcdonald (Montreal, Canada)*

F0174 14:45 **The ID:IOTS guide to creating a successful CM/ID podcast"** *Callum Mutch (Edinburgh, United Kingdom)*

F0175 14:55 **Using social media for CM/ID education** *Scott Jake (Oakland, United States)*

F0176 15:05 **Podcasting and social media for antimicrobial stewardship and pharmacy** *Erin Mccreary (Pittsburgh, United States)*

Co-organised with: CMI Communications Board of Editors

LB006 **Hall 13**

16:15 – 18:15

2-hour Oral Session

CLN IPC

The Trial Run: recent trials on *S. aureus* bacteraemia management

Chairs *Julia Anna Bielicki (London, United Kingdom)*
Vance Fowler (Durham, United States)

L0031 16:39 **Introduction**, *Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)*

L0032 16:51 **Description of SNAP trial**, *Joshua Saul Davis (Newcastle, Australia), Steven Tong (Melbourne, Australia)*

L0033 17:03 **Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible *Staphylococcus aureus* bacteraemia: a randomised controlled trial of the *S. aureus* network adaptive platform (SNAP)** *S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group*

L0034 17:15 **Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus network adaptive platform (SNAP)** *J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group*

L0035 17:27 **Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trial** *X. Lescure* (Paris, France), C. Burdet, N. Saïdani, A. Lemaignien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin, F. Vandenesch, X. Duval, S. Tubiana*

L0037 17:39 **Trial Discussion** *Vance Fowler (Durham, United States)*

L0036 17:51 **Trial Discussion.** *Julia Anna Bielicki (London, United Kingdom)*

L0038 18:03 **Open Discussion and Q&A**

OS032 **Hall 14**

16:15 – 18:15

2-hour Oral Session

CLN DX PHEI

Unraveling respiratory viruses, 2025

Chairs *Eeva Broberg (Solna, Sweden)*
Florian Krammer (New York, United States)

O0222 16:15 **Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France** *P. Loubet* (Nimes, France), S. Guitton, R. Simon, L.*

Lefrancois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay

O0223 **16:27** **Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids** *F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert*

O0224 **16:39** **Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection.** *B. Huckestein* (Memphis, United States), P. Thomas*

O0225 **16:51** **Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France** *S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand-Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Deroche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti*

O0226 **17:03** **Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort** *C. Geurts Van Kessel* (Rotterdam, The Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel*

O0227 **17:15** **Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems** *J.Y.J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye*

O0228 **17:27** **Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study** *S. Bratkovic* (Copenhagen, Denmark), M.J. Fonseca, S. Bratković, N. Vestergaard Dich, M. Pedersen, M. Kany, T. Pliakas, R. Reeves, A. Marijam, Y. Çolak, M. Helleberg*

O0229 **17:39** **The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study** *E. Carter* (Liverpool, United Kingdom), H. Hill, C. Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J. Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P. Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn, D. Ferreira, A. Collins*

O0230 **17:51** **Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers** *M. Knoll* (Hinxton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison*

SY067 **16:15 – 18:15** **Hall 11**

2-hour Symposium

PHEI

STIs: an ongoing crisis

Chairs *Dagmar Heuer (Berlin, Germany)*
Tomislav Mestrovic (Varazdin, Croatia)

S0189 **16:15** **STI treatment options are running out due to AMR** *Magnus Unemo (Örebro, Sweden)*

S0190 **16:45** **Genomic surveillance of *Neisseria gonorrhoeae* strains** *Petra Wolffs (Maastricht, The Netherlands)*

S0191 **17:15** **Evolutionary insights into syphilis and *Treponema pallidum*** *Mathew Beale (Hinxton, United Kingdom)*

S0192 **17:45** **Challenges in chlamydial STI infections** *Cecile Bebear (Bordeaux, France)*

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie

---

SY068 **16:15 – 18:15** **Hall 12**

2-hour Symposium

CLN DX VAX

Tick-borne encephalitis: contemporary diagnosis and management

Chairs *Joanna Maria Zajkowska (Białystok, Poland)*
Dace Zavadska (Riga, Latvia)

S0193 **16:15** **Tick-borne encephalitis: immune response and clinical experience** *Sara Gredmark Russ (Stockholm, Sweden)*

S0194 **16:45** **TBE immune responses and vaccine effectiveness** *Karin Stiasny (Vienna, Austria)*

S0195 **17:15** **NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection** *Gerhard Dobler (Munich, Germany)*

S0196 **17:45** **Treatment for TBE: where do we stand?** *Daniel Ruzek (Brno, Czechia)*

SY069 **16:15 – 18:15** **Hall 16**

2-hour Symposium

TRN

Controlled human infection models

Chairs *Frederick Hayden (Charlottesville, United States)*
Nikolai Siemens (Greifswald, Germany)

S0197 **16:15** **Updates on the dengue human infection model** *Kirsten Lyke (Baltimore, United States)*

S0198 **16:45** **CHIM in endemic countries** *Melissa Kapulu (Kilifi, Kenya)*

S0199 **17:15** **Controlled human infection models of parasitic infections** *Meta Roestenberg (Leiden, The Netherlands)*

S0200 **17:45** **Controlled human infection models of non-typhoidal *Salmonella*** *Malick Gibani (London, United Kingdom)*

Co-organised with: British Infection Association (BIA)

SY064 **16:15 – 18:15** **Hall 2**

2-hour Symposium

AMR ANT

PK/PD to avoid emergence of resistance?

Chairs *Anne-Grete Märtson (Leiden, The Netherlands)*
Joseph Meletiadis (Athens, Greece)

S0177 **16:15** **PK/PD and antibacterial therapy** *Dolors Soy-Muner (Barcelona, Spain)*

S0178 **16:45** **PK/PD and antifungal therapy** *Roger Brüggemann (Nijmegen, The Netherlands)*

S0179 **17:15** **PK/PD and antiviral therapy** *Joe Standing (London, United Kingdom)*

S0180 **17:45** **PK/PD considerations in anthelminthic treatment** *Jennifer Keiser (Allschwil, Switzerland)*

SY065 **16:15 – 18:15** **Hall 4**

2-hour Symposium

AMR

Gram-positives, are they still going?

Chairs *Erik Bathoorn (Groningen, The Netherlands)*
Stefania Stefani (Catania, Italy)

S0181	16:15	**The vanco chronicles: enterococci's global journey** *Guido Werner (Wernigerode, Germany)*
S0182	16:45	**Pitfall in susceptibility testing of Gram-positives** *Helena Zemlickova (Prague, Czechia)*
S0183	17:15	**Drivers for daptomycin and linezolid resistance in Gram-positives** *Glen Carter (Melbourne, Australia)*
S0184	17:45	**What is new in treatment against MDR Gram-positives?** *Alex Soriano (Barcelona, Spain)*

SY066 — **16:15 – 18:15** — **Hall 5**

CLN DX

2-hour Symposium

Biomarker testing to manage respiratory infections in primary care in low resource settings

Chairs — *Sonia Lewycka (Hanoi, Vietnam)*, *Heiman Wertheim (Nijmegen, The Netherlands)*

S0185	16:15	**The Vietnamese experience with CRP testing in the community setting** *Thi Thuy Nga Do (Ha Noi, Vietnam)*
S0186	16:45	**The Nigerian experience with CRP testing in the community setting** *Augustine Onwunduba (Awka, Nigeria)*
S0187	17:15	**CRP testing in diagnosing tuberculosis in Zambia and South Africa** *Helen Ayles (Lusaka, Zambia)*
S0188	17:45	**The health economics of CRP testing in LMICs** *Yoel Lubell (Bangkok, Thailand)*

EW071 — **16:15 – 18:15** — **Hall 15**

PRO

Educational Session

The rare art of writing scientific articles: from conception to submission

Chairs — *Marlieke De Kraker (Geneva, Switzerland)*, *Mical Paul (Haifa, Israel)*

W0205	16:15	**Expressing yourself correctly: writing tips** *Angela Huttner (Geneva, Switzerland)*
W0206	16:35	**Constructing your manuscript for an original article** *Jesús Rodríguez-Baño (Seville, Spain)*
W0207	16:55	**The use of artificial intelligence tools for writing articles: what to do and not to do** *Erlangga Yusuf (Rotterdam, The Netherlands)*
W0208	17:15	**Selecting the best journal for my manuscript** *Andre Kalil (Omaha, United States)*

Co-organised with: CMI Board of Editors

EW070 — **16:15 – 18:15** — **Hall 3**

AMR CLN DX

Educational Session

Malaria: when the drugs don't work management of treatment failure in non-endemic countries

Chairs — *Laura Nabarro (London, United Kingdom)*, *Caroline Rönnberg (Stockholm, Sweden)*

W0201	16:15	**Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure** *Emmanuel Bottieau (Antwerp, Belgium)*
W0202	16:35	**Malaria resistance mutations in the non-endemic setting: role of genomic surveillance** *Anna Rosanas Urgell (Antwerp, Belgium)*
W0203	16:55	**How to manage *Plasmodium Knowlesi* infection** *Giri Shan Rajahram (Kota Kinabalu, Malaysia)*
W0204	17:15	**Epidemiology and control of *Plasmodium Knowlesi*** *Kimberly Fornace (Singapore, Singapore)*

Co-organised with: British Infection Association (BIA)

EF033 — **16:15 – 17:15** — **Arena 2**

AMR ANT CLN

ePoster Flash Session

Current treatment options for invasive fungal infections

Chair — *Andreas H. Groll (Münster, Germany)*

E0232	16:15	**The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates** *Z.D. Pana* (Nicosia, Cyprus), A. Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely, A.H. Groll*
E0233	16:21	**Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers** *C. Palamin Buonafine* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo*
E0234	16:27	**Rezafungin showed high *in vitro* activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024** *J. Guinea* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz*
E0235	16:33	**Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight** *R. Wrishko* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch*
E0236	16:39	**Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis** *H. Kang* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooge, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson*
E0237	16:45	**Activity of manogepix against a worldwide collection of mould isolates from 2023** *M. Winkler* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira*
E0239	16:51	***Candida auris* displays an inoculum effect with multiple antifungal drug classes** *R. Ben-Ami* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi*
E0240	16:57	***In vitro* olorofim activity against *Aspergillus* spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (*ASPE*IN II and III)** *J. Guinea* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz*

EF034 — **16:15 – 17:15** — **Arena 4**

AMR IPC

ePoster Flash Session

Surgical site infections: epidemiology, risk factors, and prevention strategies

Chair — *Trisha Peel (Melbourne, Australia)*

E0241	16:15	**Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France** *P. Astagneau* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-Trannoy, J. Auraix, K. Lebascle*
E0242	16:21	**Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients** *S. Largiadèr* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. Harbarth, R. Sommerstein*
E0245	16:27	***Cutibacterium* species in Neurosurgical Infections: Not Such a "Cute" Pathogen After All** *J. Donnelly* (Dublin, Ireland), B. Dinesh, S. O'donnell*
E0246	16:33	**The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome** *K. Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y. Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands*

E0247 16:39 **Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis** *A. Abialevich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich*

E0249 16:45 **Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses** *M.C. Hufano* (Taguig, Philippines), R.R. Gabunada, C.M. Villavicencio, Z. Alano*

EF035 **17:15 – 18:15** **Arena 1**

DX PHEI

ePoster Flash Session

Genomics in pathogen surveillance

Chair *Vítor Borges (Lisbon, Portugal)*

E0250 17:15 **Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden** *L. Cipolla* (Buenos Aires, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto*

E0251 17:21 **Understanding the population structure of *Moraxella catarrhalis* using core-genome multilocus sequence typing** *I. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann*

E0252 17:27 **Impact of the COVID-19 pandemic on the *Streptococcus pyogenes* clones causing adult invasive infections** *M. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections*

E0254 17:39 **Genomic description of outbreak of VIM-1 carrying *Enterobacter* in Switzerland suggests plasmid transmission between sequence types** *H. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli*

E0256 17:51 **Phylogenetic mixing and undetected circulation of multiple *Candida auris* lineages following recognition of imported cases in Italy** *V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna*

E0257 17:57 **Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater** *T.T. Severs* (Groningen, The Netherlands), A.K. Bari, M.J. Cardoso, M. Savin, B. Sinha, J.W.A. Rossen, B.B. Xavier*

E0258 18:03 **Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technology** *S. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli*

EF036 **17:15 – 18:15** **Arena 3**

CLN

ePoster Flash Session

Heads up! CNS infections

Chair *Jacob Bodilsen (Aalborg, Denmark)*

E0259 17:15 **Central Nervous System Involvement by *Mycobacterium avium Complex* in Advanced HIV: A Rare and Underdiagnosed Challenge** *E. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta*

E0260 17:21 **Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports & Review of Literature** *M. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia*

E0261 17:27 **Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review** *D. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina*

E0262 17:33 **Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections** *F. Prataviera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini*

E0263 17:39 **Multidrug-Resistant Klebsiella pneumoniae Meningitis in the Absence of Intracranial Devices: A Case Report** *M. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano*

E0264 17:45 **Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with Morganella morganii, Acinetobacter baumannii, and Vancomycin-resistant Enterococcus faecium** *Y. Çakir Kiymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldı*

E0265 17:51 **Invasive pulmonary *Arthrographis kalrae* infection with cerebral abscesses in an immunocompromised child** *B. Winkel* (Utrecht, The Netherlands), J. Jans, M. Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen*

E0266 17:57 **Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient** *A. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt*

E0267 18:03 **A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult** *N.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra*

Sunday, 13 April 2025

OS038 **08:30 – 10:30** **Hall 14**

AMR DX

2-hour Oral Session

Making fast for making better: AMR rapid diagnostics

Chairs *Giulia De Angelis (Rome, Italy)*
Onur Karatuna (Växjö, Sweden)

O0278 08:30 **Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections** *J. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch*

O0279 08:42 **Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria** *C. Moguet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas*

O0280 08:54 **The NitroSpeed Taniborbactam NP test; easy detection of []-lactamase sensitivity to taniborbactam** *O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. Nordmann*

O0281 09:06 **Rapid detection of []-lactamase-mediated resistance to aminopenicillins from urines.** *P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poirel, R. Dessein*

O0282 09:18 **Rapid detection of antibiotic resistance in direct urine samples** *M. Bot* (Arnhem, The Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer*

O0283 09:30 **Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs** *E. Iseri* (Stockholm, Sweden), R. Santini, A. Nakama, O. Ekelund, A. Van Belkum, W. Van Der Wijngaart, V. Özenci*

O0284 09:42 **Screening for ceftriaxone-resistant *Neisseria gonorrhoeae* with the Urogenital and Resistance kit (AusDiagnostic)** *A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot*

O0285 09:54 **Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures** *D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti*

O0286 10:06 **Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy** *K. Chaudhary* (New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar*

OS037 **Hall 5**

08:30 – 10:30

2-hour Oral Session

DX IPC

Whole genome sequencing: tracking transmission and reservoirs in outbreaks

Chairs *Eric Claas (Leiden, The Netherlands)*
Paul G. Higgins (Cologne, Germany)

O0268 08:30 **From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting** *N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer*

O0269 08:42 **Why do routine genome-oriented surveillance for Pseudomonas aeruginosa?** *A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert*

O0270 08:54 **TreeTime estimation depicts transmission dynamics of clinical and environmental *Pseudomonas aeruginosa* from common reservoirs in healthcare environment through whole genome sequencing (WGS)** *Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson*

O0271 09:06 **Understanding *Serratia* transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis** *K. Jaakkola* (Lyon, France), A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Haÿs, J.P. Rasigade, C. Dananché*

O0272 09:18 **Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing** *C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin*

O0273 09:30 **Genome-oriented analysis of the first outbreaks involving the novel Serratia sarumanii at a neonatal unit** *A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert*

O0274 09:42 **Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTIPE Study** *J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Mookerjee, M. Krutikov*

O0275 09:54 **Outbreak of Carbapenem-Resistant *Acinetobacter seifertii* in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance.** *D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochevis, R. Paiva, K. Tragnago, A. Barth, A. Martins*

O0276 10:06 **Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant *Klebsiella pneumoniae* in the ICU environment** *X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu*

O0277 10:18 **Survey of Infection Prevention staff perception of WGS integration into routine IPC practice** *D. Ling* (Melbourne, Australia), B. Baral, V. Madigan*

SY073 **Hall 12**

08:30 – 10:30

2-hour Symposium

AMR ANT

Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship

Chairs *Bhanu Sinha (Groningen, The Netherlands)*
Annelies Verbon (Bosch En Duin, The Netherlands)

S0213 08:30 **A broad spectrum of possibilities: spectrum scores as a unifying metric** *Céline Pulcini (Nancy, France)*

S0214 09:00 **Proxy indicators to estimate appropriateness of antibiotic prescriptions** *Diane Ashiru-Oredope (London, United Kingdom)*

S0215 09:30 **How to bridge the gap between surveillance and antimicrobial stewardship** *Mark G. J. De Boer (Leiden, The Netherlands)*

S0216 10:00 **Health economics, surveillance and antimicrobial stewardship** *Zhu Nina Jiayue (London, United Kingdom)*

Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)

SY074 **Hall 13**

08:30 – 10:30

2-hour Symposium

CLN IPC

***Difficile* to treat: advanced management strategies in difficult to treat CDI**

Chairs *Frédéric Barbut (Paris, France)*
Kerrie Davies (Leeds, United Kingdom)

S0217 08:30 **Severe CDI: when standard protocols fail** *Hynek Bartos (Prague, Czechia)*

S0218 09:00 **Therapies for complicated CDI** *Emma Bishop (Clayton Vic, Australia)*

S0219 09:30 **Recurrent CDI: Breaking the cycle** *Andrea Marino (Catania, Italy)*

S0220 10:00 **Live biotherapeutic products for *Clostridioides difficile* infection** *Simon Goldenberg (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)

SY075 **Hall 15**

08:30 – 10:30

2-hour Symposium

PHEI

Diphtheria: from re-emergence to vaccine strategies

Chairs *Helena Seth-Smith (Zurich, Switzerland)*
Julie Toubiana (Paris, France)

S0221 08:30 **Diphtheria: from clinical picture to medical management** *Regina Oladokun (Oyo, Nigeria)*

S0222 09:00 **The epidemiology of diphtheria worldwide over the last half-century: more than one comeback** *Andreas Hoefer (Solna, Sweden)*

S0223 09:30 **There's more than one toxigenic *Corynebacterium*: the current genomics landscape of diphtheria-associated strains** *Sylvain Brisse (Paris, France)*

S0224 10:00 **Diphtheria vaccination: a reappraisal** *Gayatri Amirthalingam (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)

SY076 **Hall 16**

08:30 – 10:30

2-hour Symposium

AMR

AMR Surveillance in low resource countries: insights into clinical and policy translation

Chairs *Sabiha Essack (Durban, South Africa)*
H. Rogier Van Doorn (Hanoi, Vietnam)

S0225 08:30 **New indicators in national monitoring and evaluation of AMR supported by improved data utilisation** *Direk Limmathurotsakul (Bangkok, Thailand)*

S0226 09:00 **Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections** *Stephen*

Mshana (Mwanza, Tanzania, United republic of)

S0227 09:30 **A clinically-oriented AMR surveillance network: case-based surveillance and implementation** *Paul Turner (Siem Reap, Cambodia)*

S0228 10:00 **National prescribing guidelines based on AMR surveillance data** *Vilada Chansamouth (Vientiane, Lao People's democratic republic)*

Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

SY072 08:30 – 10:30 **Hall 3**

2-hour Symposium

PHEI VAX

Tackling the emergence of dengue and other *Aedes*-borne diseases in Europe

Chairs *Fernanda Boulos (São Paulo, Brazil)*
Martin P. Grobusch (Amsterdam, The Netherlands)

S0209 08:30 **How dengue, chikungunya and zika virus disease became emerging threats to Europe** *Celine Gossner (Solna, Sweden)*

S0210 09:00 **Surveillance of dengue in urbanised tropical regions** *Vincent Junxiong Pang (Singapore, Singapore)*

S0211 09:30 **Mosquito surveillance and control: opportunities and challenges** *David Roiz (Montpellier, France)*

S0212 10:00 **Tracking autochthonous arboviral infection** *Luisa Barzon (Padua, Italy)*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

EW079 08:30 – 10:30 **Hall 11**

Educational Session

CLN DX

New guidelines for management of brain infections

Chairs *Jacob Bodilsen (Aalborg, Denmark)*
Kartika Maharani (Jakarta, Indonesia)

W0237 08:30 **Tuberculous meningitis: what can we learn from the first global guidelines?** *Joseph Donovan (Ho Chi Minh City, Vietnam)*

W0238 08:50 **WHO guidelines on bacterial meningitis: change of clinical practice?** *Matthijs Brouwer (Amsterdam, The Netherlands)*

W0239 09:10 **ESCMID encephalitis guidelines 2024: what's new?** *Tom Solomon (Liverpool, United Kingdom)*

W0240 09:30 **WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation** *Nelesh Govender (Johannesburg, South Africa)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

EW077 08:30 – 10:30 **Hall 2**

Educational Session

CLN DX

New tools in acute bacterial infections and sepsis: from machine learning to precision medicine

Chairs *Benjamin Mcfadden (Perth, Australia)*
Rita Murri (Rome, Italy)

W0229 08:30 **Differentiating acute infection, sepsis and sepsis mimics in the ED?** *Lisa Mellhammar (Lund, Sweden)*

W0230 08:50 **Machine learning for early recognition of sepsis** *Karsten Borgwardt (Martinsried, Germany)*

W0231 09:10 **How to avoid common mistakes in randomised clinical study design** *Yin Mo (Singapore, Singapore)*

W0232 09:30 **Improved clinical trials in community-acquired pneumonia using precision medicine** *Lennie Derde (Utrecht, The Netherlands)*

Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro

---

EW078 08:30 – 10:30 **Hall 4**

Educational Session

DX

Implementing metagenomics in my lab and mistakes to avoid

Chairs *Hege Vangstein Aamot (Lørenskog, Norway)*
Claudio Neidhöfer (Bonn, Germany)

W0233 08:30 **Is metagenomics right for my lab?** *Paula Mölling (Örebro, Sweden)*

W0234 08:50 **Understanding the experimental and certification aspects of metagenomics** *Mads Albertsen (Aalborg, Denmark)*

W0235 09:10 **Navigating tools, techniques, and procurement** *Basil Britto Xavier (Groningen, The Netherlands)*

W0236 09:30 **Setting realistic goals and outcomes for metagenomics integration** *Claire Bertelli (Lausanne, Switzerland)*

Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

---

EF039 08:30 – 09:30 **Arena 1**

ePoster Flash Session

CLN PHEI TRN

Novel approaches to antiviral therapy

Chair *Pinyo Rattanaumpawan (Bangkok, Thailand)*

E0288 08:30 **Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection** *J. Pitts* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello*

E0289 08:36 **EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study** *J. Devincenzo* (Watertown, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus*

E0290 08:42 **A Combined *In Silico* and *In Vitro* Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A Virus** *C.L. Pierri* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi*

E0291 08:48 **Bemnifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus *in vitro*** *D. Grandgirard* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib*

E0292 08:54 **Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses** *S. Ellis* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer*

E0293 09:00 **The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants** *A. Gaggar* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi*

E0294 09:06 **Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time** *L. Sudarsono* (Leiden, The Netherlands), X. Liu,*

J.G.C. Van Hasselt, A.G. Märtson

E0295 09:12 **Efficacy of molnupiravir and baloxavir against influenza A H1N1 infection *in vitro* and *in vivo*** *D. Liu* (Hong Kong, Hong Kong), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung*

E0296 09:18 **Human defensin derived peptide showing broad antiviral activity against human adenoviruses** *X. Wang* (Hongkong, China), H. Zhao*

EF040 08:30 – 09:30 **Arena 3**

ePoster Flash Session

CLN TRN

New frontiers in parasitic disease and migrant health research

Chair *Miriam José Álvarez-Martínez (Barcelona, Spain)*

E0299 08:36 **Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?** *M.D. Hernández Rabadán* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García*

E0300 08:42 ***Schistosoma haematobium* infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment** *A.M. Mertelsmann* (Zurich, Switzerland), J.K. Maganga, M.H. Lee, M. Ward, A.Y. Tan, S.F. Bowers, L. Mhango, D. De Jong, P.L.A.M. Corstjens, G.J. Van Dam, S. Kapiga, K. Dupnik, H.D. Mazigo, J.A. Downs, J.M. Changalucha*

E0301 08:48 **Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?** *G. Lam* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P. Mawa, J. Friedman, A. Bustinduy*

E0302 08:54 **Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024** *G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller*

E0303 09:00 **NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut** *B. Song* (Kowloon, Hong Kong), J. Zeb, N. Buchon, O. Sparagano, P. Butaye*

E0304 09:06 **Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in *Onchocerca volvulus*** *A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil*

E0305 09:12 **Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis** *G. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro*

EF041 09:30 – 10:30 **Arena 2**

ePoster Flash Session

AMR CLN DX

Contemporary diagnostic approaches for fungal infections

Chair *Ilse D. Jacobsen (Jena, Germany)*

E0306 09:30 **Evaluation of persistence of C. auris colonization in a cohort of patients discharged from a C. auris endemic area** *M. Bavastro* (Genoa, Italy), L. Mezzogori, M. Bonaffini, L. Magnasco, F. Centorrino, V. Di Pilato, E. Willison, F. Portunato, D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska, M. Bassetti*

E0307 09:36 **A pilot study of digital retinal photography (DRP) and tele-ophthalmology of patients with candidemia.** *C. Clancy* (Pittsburgh, United States), C. Hadi, E. Waxman, J.A. Viehman, A. Eller, M. O'donnell, F. Silveira, P. Samantha, B. Smith, S. Padival, V. Nauriyal, M.H.T. Nguyen*

E0308 09:42 **Epidemiology and diagnosis of Pneumocystis pneumonia : a 11 years-surveillance in France** *A. Alanio* (Paris, France), K. Boukris-Sitbon, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier, O. Lortholary*

E0309 09:48 **Chronic pulmonary aspergillosis coexisting with pulmonary cystic echinococcosis: a global systematic review** *A. Adhikari* (Chame, Nepal), F. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan, N.V. Rhijn, D. Denning*

E0310 09:54 **Implementation and performance of a universal Mucorales PCR assay for diagnosis of mucormycosis** *A. Haas* (Salt Lake City, United States), K. Hanson*

E0311 10:00 **Blood cultures (BCs) contain populations of genetically diverse Candida strains that may differ in antifungal resistance and tolerance** *C. Clancy* (Pittsburgh, United States), S. Cheng, H. Badrane, B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H. Nguyen*

E0312 10:06 **Clinical validation of a urinary antigen test as an aid to diagnose invasive aspergillosis in hematology patients** *Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, T. Mercier, E. Boon, G. Gysembert, E. Houben, K. Lagrou, J. Maertens*

E0313 10:12 **Genomic epidemiology of Greek *Candida auris* clinical isolates** *M. Siopi* (Athens, Greece), B. Spruijtenburg, I. Anagnostakis, C. Antholaki, A. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P. Giannopoulou, K. Gartzonika, M. Damala, I. Daskalakis, I. Dendrinos, V. Dimitriou, E. Dimitroulia, L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V. Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A. Katsaka, A. Katsiaflaka, E. Kafkoula, M. Kimouli, I. Lamprou, O. Legga, V. Mamali, M. Martsoukou, G. Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E. Oikonomopoulou, M. Orfanidou, F. Paliogianni, E. Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki, M. Papadogianni, K. Papaefstathiou, P. Papanikolaou, J. Papaparaskevas, G. Parvouleskou, E. Perivolioti, S. Pournaras, C. Silleli, T. Skalidis, E. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P. Tsolakidou, N. Charalampaki, E. Chinou, G.S. Christodoulatos, G. Chronopoulou, E. Chrysou, E. Meijer, A. Tsakris, J. Meletiadis, G. Vrioni*

EF042 09:30 – 10:30 **Arena 4**

ePoster Flash Session

CLN

Prosthetic and device-associated infections

Chair *Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)*

E0315 09:30 **Case series of gluteal Apophysomycosis post intramuscular injection** *R. Sivasankaran* (Vellore, India), R. Bandyopadhyay*

E0316 09:36 **MIGRATING mesh - an unusual cause of pyogenic liver abscess** *M. Caris* (Leiden, The Netherlands), J. Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers*

E0317 09:42 **Ceftaroline salvage monotherapy: successful treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant *Staphylococcus epidermidis* strain** *M.D. Di Trapani* (Bozen, Italy), T. Kamal Eldin, D. Drusiani, B. Ladinser, R. Aschbacher, G. Spoladore*

E0318 09:48 **Timeline of early infections post porcine xenothymokidney transplant** *H. Neumann* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta*

E0320 10:00 **Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience** *A. Pagotto**

(Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini

E0321 **10:06** **PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections** *C. Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, A. Friedrichs*

E0322 **10:12** **A complex case of pelvic bone infection caused by carbapenem-resistant *Acinetobacter baumanii* successfully treated with eravacycline** *M. Zagarrigo* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale*

E0323 **10:18** **Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?** *M. Bongiovanni* (Lugano, Switzerland), B. Barda, E. Bernasconi*

KN080 **09:30 – 10:30** **Hall 1**

Keynote Lecture

VAX

Infections after solid organ transplantation: past, present and future

Chairs *Nina Khanna (Basel, Switzerland)*
Priscilla Rupali (Vellore, India)

K0241 **09:30** *Jay Fishman (Boston, United States)*

OS044 **11:00 – 12:00** **Hall 5**

1-hour Case Session

CLN

Unusual presentations of unusual parasites

Chairs *Emmanuel Bottieau (Antwerp, Belgium)*
Marcelo Victor Radisic (Buenos Aires, Argentina)

O0329 **11:00** **Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting** *D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum*

O0330 **11:11** **An itchy awakening due to Dermanyssus infestation** *J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque*

O0331 **11:22** **Uterine Myiasis: A Rare Case of External Genitourinary Myiasis** *R. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua*

O0332 **11:33** **Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation.** *C. Norsungnern* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong*

O0333 **11:44** **If at first, you don't succeed... Treatment-resistant Fascioliasis: case report** *W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro*

OS047 **11:00 – 12:00** **Hall 11**

1-hour Oral Session

CLN

Clinical studies in UTI

Chairs *Iva Butic (Zagreb, Croatia)*
Paul Christoffer Lindemann (Bergen, Norway)

O0344 **11:00** **Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs** *I. Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H. Dallasheh, M. Paul*

O0345 **11:12** **Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecraid POS-cUTI study** *C. Kats* (Utrecht, The Netherlands), J.M. Bravo-Ferrer, T.T. Doesschate, P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio, P. Clevenbergh, A. Barac, A. Cano, E. Merino, P. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D. Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D. Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J. Rodríguez-Baño*

O0346 **11:24** **Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study** *L. Onorato* (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B. Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R. Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello Vicario, R. Nasti, A. Voza, N. Coppola*

O0347 **11:36** **Weekly sequential antibioprophylaxis for UTI in neurogenic bladder** *R. Calin* (Paris, France), C. Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F. Adda, C. Palacios, G. Amarenco, G. Pialoux*

O0348 **11:48** **Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review** *L. Cordes* (Geneva, Switzerland), R. Calin, K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B. Trautner, A. Huttner*

OS048 **11:00 – 12:00** **Hall 12**

1-hour Oral Session

AMR CLN

Complexities of infections in solid organ transplantation

Chairs *Silvia Corcione (Turin, Italy)*
Monica Slavin (Melbourne, Australia)

O0349 **11:00** **Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales** *A. Cona* (Palermo, Italy), C. Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni*

O0350 **11:12** **Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers** *M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella*

O0351 **11:24** **Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors.** *O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette*

O0352 **11:36** **Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients** *A. Dahl* (KøbenhaVn V, Denmark), M. Koller, O.J. Manuel, J. Reekie, K.S. Moestrup, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg*

O0353 **11:48** **Burden of non-microbiologically confirmed infections in solid organ transplant recipients** *M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos*

OS043 **11:00 – 12:00** **Hall 3**

1-hour Oral Session

AMR IPC

Navigating disinfection challenges: resistance, outbreaks, and efficacy

Chairs *Hillary A. Craddock (Dublin, Ireland)*
Stephanie J. Dancer (Glasgow, United Kingdom)

O0324 **11:00** **Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review** *Â.R. Fernandes* (Porto, Portugal), A. Gonçalves Rodrigues, L. Cobrado*

O0325 **11:12** **Sink-associated outbreak of verona integron-**

encoded metallo-??-lactamase-producing carbapenem-resistant *Pseudomonas aeruginosa* in a Dutch intensive care unit *M. Van Den Bos Kromhout* (Zwolle, The Netherlands), S. Debast, M. Van Den Bos-Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter, B. Immeker, K. Zuur, M. Hijmering, J.W.A. Rossen*

O0326 11:24 **Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience.** *A.L. Engsbro* (Slagelse, Denmark), K.H. Hansen, M.F.J. Larsen, N. Kling, H.T. Larsen, R. Kjølsen, B. Hansen, L.K. Vejrum, A.L. Laugesen, M. Kemp*

O0327 11:36 **Tolerance of *Klebsiella pneumoniae* biofilms to disinfection with peracetic acid** *M. Arvand* (Berlin, Germany), A.M. Richter, D. Csertö, K. Konrat*

O0328 11:48 **Bringing balance to the formulation: disinfection efficacy and material compatibility** *J. Jennings* (Halifax, United Kingdom), T. Langford, H. Mansbridge, E. Fraser, I. Poles, J. Clarke*

LB002 **Hall 4**

11:00 – 12:00

1-hour Oral Session

IPC

Investigation of intriguing outbreaks

Chairs *Ana Raquel Freitas (Porto, Portugal)*
Marc J. Struelens (Saltsjobaden, Sweden)

L0007 11:12 **Investigation of an international pseudo-outbreak involving *Paraburkholderia fungorum* blood culture contamination** *J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone*

L0008 11:24 **Evolving cluster of severe infective endocarditis with non-toxigenic C. diphtheriae amongst people experiencing homelessness and substance misuse in the UK** *T. Anwar* (London, United Kingdom), T. Patel, R. Cordery, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham*

L0009 11:36 **AI-driven live cough rate tracking for public health surveillance** *M. Kågebäck* (Göteborg, Sweden), E. Carlsson*

OS045 **Hall 8**

11:00 – 12:00

1-hour Oral Session

AMR

Social behavioural dynamics of antibiotic use and AMR

Chairs *Sonia Lewycka (Hanoi, Vietnam)*
Filippo Medioli (Milan, Italy)

O0334 11:00 **Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey** *A. Abbara* (London, United Kingdom), H. Alhosni, F. Alahdab*

O0335 11:12 **Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ???** *S. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y. Maheshwarappa, S.S. Sc, K. Gautam, S. Srinivas, V. Swamy Gs*

O0336 11:24 **Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024** *S. Vantava* (Vientiane Capital, Lao People's democratic republic), K. Thilakoun, D. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B. Phetsamone, S. Bangthong, K. Sengchanh, S. Latsamy, S. Vanphanom, L. Annick, S. Somphou*

O0337 11:36 **High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis** *D. Samria* (Bangalore, India), D. Batheja, A. Nandi*

O0338 11:48 **Gender gaps in knowledge of antibiotics and antimicrobial resistance: evidence from India** *D. Samria* (Bengaluru, India), S.R. Umenthala, S. Goel, R. Bhagawati, B. Deepshikha*

OS046 **Hall 9**

11:00 – 12:00

1-hour Oral Session

PHEI VAX

Vaccines and prophylaxis against respiratory viral infections

Chairs *Ana Atti (London, United Kingdom)*
Sophie Schneitler (Hamburg, Germany)

O0339 11:00 **Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study (www.nirsegal.es/en)** *F. Martinón-Torres* (Santiago De Compsotela, Spain), N. Mallah, J. Pardo-Seco, O. Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L. Platero-Alonso, R.M. Alvárez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, Á. Manzanares-Casteleiro*

O0340 11:12 **Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial** *K. Feldballe Bernholm* (Copenhagen, Denmark), N. Dyrby Johansen, C. Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon, S. Samson, M.M. Loiacono, R. Harris, C. Schade Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B.L. Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-Sørensen*

O0341 11:24 **Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses** *S. Chalkias* (Cambridge, United States), C. Grassi, P. Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R. Handforth, N. Vicic, A. Rossi, R. Wahid, D. Edwards, J. Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B. Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das*

O0342 11:36 ***Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains*** *N. Shirin* (Ramat Gan, Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T. Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon, M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M. Mandelboim*

O0343 11:48 **Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation** *C. Bennett* (Gaithersburg, United States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F. Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo*

SY084 **Hall 10**

11:00 – 12:00

1-hour Symposium

CLN

Sleeping sickness and Chagas: a tale of the two trypanosomes

Chairs *Hanne Brekke (Oslo, Norway)*
Jean-Pierre Gangneux (Rennes, France)

S0247 11:00 **Human African trypanosomiasis: recent diagnostic and medical practices** *Jean-Mathieu Bart (Conakry, Guinea)*

S0248 11:30 **American trypanosomiasis: diagnosis, screening and management** *Irene Losada Galvan (Barcelona, Spain)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY085 11:00 – 12:00 **Hall 13**

DX PHEI

1-hour Symposium

Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination

Chairs *Mojca Maticic (Ljubljana, Slovenia)*
Snjezana Zidovec Lepej (Zagreb, Croatia)

S0249 11:00 **Role of reflex testing strategies in identifying patients with chronic viral hepatitis** *Oana Sandulescu (Bucharest, Romania)*

S0250 11:30 **Management and elimination of hepatitis in hard-to-reach persons** *Suda Tekin (Istanbul, Türkiye)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS

SY086 11:00 – 12:00 **Hall 14**

DX

1-hour Symposium

Impact on including a measure of viability in molecular diagnostic tests

Chairs *Fusun Can (Istanbul, Türkiye)*
Denise O'sullivan (Teddington, United Kingdom)

S0251 11:00 **Viability markers in support of development of *Chlamydia* screening recommendations** *Petra Wolffs (Maastricht, The Netherlands)*

S0252 11:30 **Measuring viability to improve the correlation of AMR markers and clinical outcomes in *Neisseria gonorrhoeae*** *Tatum Mortimer (Athens, United States)*

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

SY087 11:00 – 12:00 **Hall 16**

ANT TRN

1-hour Symposium

Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology

Chairs *Laurent Poirel (Fribourg, Switzerland)*
Jan Verhoef (Zeist, The Netherlands)

S0253 11:00 **Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials?** *Morreale Francesca Ester (London, United Kingdom)*

S0254 11:30 **Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface** *Christian Stephan Lentz (Tromsø, Norway)*

SY082 11:00 – 12:00 **Hall 6**

PRO PHEI

1-hour Symposium

How to address anti-science in our community?

Chairs *Tuba Dal (Ankara, Türkiye)*
Tyra Grove Krause (Copenhagen, Denmark)

S0243 11:00 **The rise of anti-science: lessons for the future scientist** *Marion Koopmans (Rotterdam, The Netherlands)*

S0244 11:30 **Open science for public trust** *Lisa Hansen (Ottawa, Canada)*

SY083 11:00 – 12:00 **Hall 7**

CLN DX

1-hour Symposium

Lyme neuroborreliosis: challenges in diagnosis and treatment

Chairs *Alexandra Mailles (Paris, France)*
Joanna Maria Zajkowska (Białystok, Poland)

S0245 11:00 **Challenges in diagnosis of Lyme neuroborreliosis** *Rick Dersch (Freiburg, Germany)*

S0246 11:30 **Challenges in treatment of Lyme neuroborreliosis** *Anne Marit Solheim (Kristiansand, Norway)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)

EF049 11:00 – 12:00 **Arena 2**

CLN DX VAX

ePoster Flash Session

Sometimes it's hard to be a woman

Chair *Debora Konopnicki (Brussels, Belgium)*

E0354 11:00 **Interleukins 17 and 18: Key players in Cervical Cancer Progression in Indian Population** *P. Gupta* (Bhopal, India), A. Vyas, A. Halder, S. Purwar*

E0357 11:12 **Rubella screening in pregnancy – Slovakian one-center retrospective analysis around COVID-19 pandemic** *Z. Paraličová* (Kosice, Slovakia), D. Javorská*

E0358 11:18 **The impact of maternal influenza infection and vaccination during pregnancy on birth outcomes** *B. Goundappa* (Pittsburgh, United States), X. Zhang, B. Gk, H.E.A. D'agostino, H. Liu, A.M. Rick*

E0359 11:24 **Use of valaciclovir therapy during pregnancy for the prevention of congenital cytomegalovirus infection: a monocentric experience** *G. Lorenzetti* (Rome, Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S. Mercadante, C. Tripiciano, A. Krzysztofiak, C. Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò Carducci*

E0360 11:30 **Multi-systemic long-term sequelae following SARS-CoV-2 Omicron infection in pregnancy: a population-based cohort study** *Y.Y. Tan* (Singapore, Singapore), E.X.H. Loy, A.T. Tay, J.T. Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee*

E0362 11:42 **Sex-stratified analysis of T cell activation, exhaustion, proliferation and HIV reservoir among PLWH** *L. Santinelli* (Rome, Italy), M. Andreotti, L. Maddaloni, Z. Michelini, G. Bugani, F. Romano, E. Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D'ettorre*

EF050 11:00 – 12:00 **Arena 3**

DX

ePoster Flash Session

Expanding MALDI-TOF applications

Chair *Belen Rodriguez-Sanchez (Madrid, Spain)*

E0363 11:00 **Application of MALDI-TOF Mass Spectrometry and Machine Learning for the Detection of Vancomycin-Resistant *Enterococcus faecium*** *M. Sánchez Cueto* (Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-Sánchez, M. Marín, E. Cercenado, P. Muñoz, B. Rodríguez-Sánchez, D. Rodríguez-Temporal*

E0364 11:06 **Early detection of ampicillin susceptibility in *Enterococcus faecium* with MALDI-TOF MS and machine learning** *T. Pichl* (Munich, Germany), L. Miranda, N. Wantia, K. Borgwardt, J. Sattler*

E0365 11:12 **Rapid antifungal resistance prediction based on MALDI TOF mass spectrometry** *D. Duroux* (Zurich, Switzerland), Y. Yang, J. Sattler, A. Egli*

E0366 11:18 **Rapid prediction of fluconazole resistance by machine-learning analysis of *Candida parapsilosis* MALDI-TOF mass profiles** *C. Magri* (Rome, Italy), C. Magri, V. Ivagnes, M. Sanguinetti, E. De Carolis*

E0367 11:24 **Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification** *R. Huang* (Shenzhen, China), Y. Li, Y. He, T. Ma, F. Lu*

E0368 11:30 **Rapid detection of colistin resistance in Acinetobacter baumannii by a MALDI-TOF MS-based assay** *E. Kırbaş* (Van, Türkiye), I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Hasçelik, B. Sancak*

E0369 11:36 **Discrimination of clinical *Pseudomonas* strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MS** *L. Sellami* (Duisburg, Germany), K. Teramoto, Y. Sekiguchi, M. Tohya, T. Kirikae*

E0370 11:42 **Automatic differentiation of *Clostridioides difficile* ribotypes using MALDI-TOF MS and web-based classification models** *M. Blazquez Sanchez* (Madrid, Spain), M.C. Blazquez-Sanchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodriguez-Temporal, B. Rodriguez-Sanchez*

E0371 11:48 **Identification of sepsis-causing bacteria using shotgun proteomics** *L. Meekes* (Rotterdam, The Netherlands), D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens*

EF051 **11:00 – 12:00** **Arena 4**

ANT TRN ePoster Flash Session

The enemy of my enemy: From jumbo phages to cocktails for difficult to treat infections

Chair *Paul G. Higgins (Cologne, Germany)*

E0372 11:00 **Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent *Klebsiella pneumoniae*** *M. Roch* (Geneva, Switzerland), R. Sierra, D. Andrey*

E0373 11:06 **Jumbo *Klebsiella* bacteriophage demonstrates efficient multidrug-resistant *Klebsiella pneumoniae* killing and significant clinical potential** *Y. Liu* (Singapore, Singapore), Y. Zhong, S. Thong, L.H.A. Kwa*

E0376 11:24 **A novel broad-spectrum phage cocktail effictive for carbapenem resistant *Acinetobacter baumannii* of capsular type 104/2/7 in vitro** *L. Wei* (Chengdu, China), Y. Feng, Z. Zong*

E0378 11:36 **Phages as innovative adjuvants of antibiotics therapy against *S. aureus* and *P. aeruginosa* in the context of Cystic Fibrosis** *A. Glorieux* (Brussels, Belgium), S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke*

E0379 11:42 **Evaluation of bacteriophages against *Staphylococcus aureus* strains isolated from orthopaedic infections** *S. Patpatia* (Helsinki, Finland), A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado*

E0380 11:48 **Anti-*Staphylococcus aureus* phages: assessing the risk of bacterial resistance emergence through selective pressure** *M. Degreze* (Lyon, France), M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda*

KN081 **11:00 – 12:00** **Hall 1**

AMR ANT Keynote Lecture

The new frontiers in antimicrobial stewardship

Chairs *José Ramon Pano-Pardo (Zaragoza, Spain)*
Jeroen Schouten (Nijmegen, The Netherlands)

K0242 11:00 *Karin Thursky (Carlton, Australia)*

ME089 **11:00 – 12:00** **Hall 15**

PRO Meet-the-Expert

How to teach medical mycology

M0257 11:00 *Katrien Lagrou (Leuven, Belgium)*
M0258 11:12 *Mihai Mares (Iasi, Romania)*

Co-organised with: European Confederation of Medical Mycology (ECMM)

ME088 **11:00 – 12:00** **Hall 2**

AMR Meet-the-Expert

Global AMR policy after UNGA: what do we do now!

M0255 11:00 *Gisela Robles Aguilar (Oxford, United Kingdom)*
M0256 11:12 *Mike Sharland (London, United Kingdom)*

FO090 **11:00 – 12:00** **Arena 1**

PRO Open Forum

European CM/ID exam: going forward

Chair *Siri Goepel (Tuebingen, Germany)*

F0259 11:00 **View from medical microbiology** *Maeve Doyle (Waterford, Ireland)*

F0260 11:10 **view from infectious diseases** *Eoghan De Barra (Dublin, Ireland)*

F0261 11:20 **view from trainees (TAE)** *Christian Kraef (Copenhagen, Denmark)*

F0262 11:30 **European exam - how to prepare?** *Annelies Verbon (Bosch En Duin, The Netherlands)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Professional Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section of Infectious Diseases

---

LB003 **13:30 – 14:30** **Hall 13**

CLN 1-hour Oral Session

New solutions for difficult-to-treat infection

Chairs *Shampa Das (Liverpool, United Kingdom)*
Lorena López Cerero (Seville, Spain)

L0011 13:30 **Antimicrobial CRISPR-Cas9-based treatment against antibiotic resistant extraintestinal pathogenic *E. coli* (ExPEC) ST131** *C. Morros-Bernaus* (Penryn, United Kingdom), J. Westley, E. R. Wyrsch, S. P. Djordjevic, A. F.C. Leonard, D. Sünderhauf, S. Van Houte*

L0012 13:42 **Ultra-narrow spectrum antibiotic against multi-drug resistant gonococci with novel mode of action** *N. Nguyen* (Vienna, Austria), A.K. Mix*

L0013 13:54 **Multivalent OMV-based vaccine against Klebsiella pneumoniae** *B. Cano Castaño* (Madrid, Spain), B. Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto Martin-Gil, D. Fousteris, L. Del Pozo Acebo, F. Docando Sánchez, E. Gato, A. Pérez, M.J. Mcconnell*

L0014 14:06 **Epidermicin NI01, a first-in-class peptide antibiotic candidate, has potent efficacy in a robust MRSA wound infection model and low allergic reaction liabilities** *M. Upton* (Plymouth, United Kingdom), G. Barker, V. Bennett, I. Fotheringham, S. Baxter, H. Curry*

L0015 14:18 **Minimum inhibitory concentrations of quabodepistat in Mycobacterium tuberculosis clinical isolates from patients with drug-susceptible pulmonary tuberculosis** *I. Kontsevaya* (Munich, Germany), Y. Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva*

ESCMID Global 2025 - Programme

OS052 **13:30 – 14:30** **Hall 2**

1-hour Oral Session

CLN DX

AI in infectious diseases: the lab and beyond

Chairs *Tim Inglis (Perth, Australia)*
Miranda Langendam (Amsterdam, The Netherlands)

O0381 **13:30** **Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra** *N. Macesic* (Melbourne, Australia), H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe*

O0382 **13:42** **CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacterales Using Disk-Diffusion** *L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht*

O0383 **13:54** **AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)** *G. Danoe* (Groningen, The Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brilman, L.L. Peters, M.S. Berends*

O0384 **14:06** **Predicting potentially infection-related findings in structured radiology reports** *J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre*

O0385 **14:18** **Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections** *H. Zhang* (Shanghai, China), X. Xu, J. Ai*

OS053 **13:30 – 14:30** **Hall 3**

1-hour Oral Session

TRN

Immune evasion and intracellular survival strategies

Chairs *Juliane Bubeck Wardenburg (St. Louis, United States)*
Giovanni Delogu (Rome, Italy)

O0386 **13:30** **Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in *Acinetobacter baumannii*** *H. Wang* (Beijing, China), C. Jiang*

O0387 **13:42** **Intracellular lifestyle of *Acinetobacter baumannii*: Role of phospholipase A2 and transcriptional factor EB (TFEB)** *Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha*

O0388 **13:54** **The role of peg344 of hypervirulent *Klebsiella pneumoniae* on suppressing autophagy responses of macrophages** *Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinci, F. Can*

O0389 **14:06** **c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection** *C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth*

O0390 **14:18** **Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology** *J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong*

SY093 **13:30 – 14:30** **Hall 11**

1-hour Symposium

TRN VAX

Immunosenescence and immune response to vaccination

Chairs *Petar Velikov (Sofia, Bulgaria)*
Dafna Yahav (Ramat-Gan, Israel)

S0267 **13:30** **How immunosenescence impacts vaccine response** *Andrea Cossarizza (Modena, Italy)*

S0268 **14:00** **Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly** *Inna Ovsyannikova (Rochester, United States)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)

SY094 **13:30 – 14:30** **Hall 14**

1-hour Symposium

AMR PHEI

Farm to fork: food-borne antimicrobial resistance

Chairs *Beatriz Guerra Román (Parma, Italy)*
Joel Mossong (Luxembourg, Luxembourg)

S0269 **13:30** **Foodborne risk in meat and fishery products and impact on AMR** *Anders Dalsgaard (Frederiksberg C, Denmark)*

S0270 **14:00** **Control challenges associated with food-borne multidrug resistance** *Luisa Maria Vieira Peixe (Porto, Portugal)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)

SY091 **13:30 – 14:30** **Hall 4**

1-hour Symposium

PHEI

Emerging infectious diseases: staying informed and prepared in a globalised world

Chairs *Nitin Gupta (Manipal, India)*
Pikka Jokelainen (Copenhagen, Denmark)

S0263 **13:30** **Lessons learnt from previous outbreaks** *Marta Mora-Rillo (Madrid, Spain)*

S0264 **14:00** **Disease X: preparedness for the next pandemic** *Yee Sin Leo (Singapore, Singapore)*

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY092 **13:30 – 14:30** **Hall 5**

1-hour Symposium

CLN

Sex differences in management and outcome of patients with serious bacterial infections

Chairs *Michele Bartoletti (Milan, Italy)*
Merel Lambregts (Leiden, The Netherlands)

S0265 **13:30** **Sex impacts incidence, management, and outcome in bacteraemia** *Annette Westgeest (Leiden, The Netherlands)*

S0266 **14:00** **The complex interplay between gender and sepsis** *Ines Lakbar (Montpellier, France)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

EW096 **13:30 – 15:30** **Hall 15**

Educational Session

PRO

Tools for successful development as a medical educator

Chairs *Giorgia Caruana (Sion, Switzerland)*
Yoav Keynan (Winnipeg, Canada)

W0273 **13:30** **Developing your educator professional identity** *Todd Cassese (Bronx, United States)*

W0274 **13:50** **What do IPC doctors need to learn to be prepared** *Simone Scheithauer (Göttingen, Germany)*

W0275 **14:10** **Communities of practice: successful experience of a transformative collaboration and roadmap** *Erin Bonura (Portland, United States)*

W0276 **14:30** **The critical need for ongoing innovations in medical education** *Clémentine Schilte (Paris, France)*

Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology

---

EF054 **13:30 – 14:30** **Arena 3**

AMR IPC PHEI

ePoster Flash Session

Beware the sink! Pathogen reservoirs in drains and waste water

Chair *Stephan Juergen Harbarth (Geneva, Switzerland)*

E0391 **13:30** **Genomic Epidemiology to Investigate Healthcare Environment as Reservoir for Carbapenem-Resistant Organisms in an Academic Hospital in Miami, Florida.** *A. Jimenez* (Miami, United States), S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O. Martinez, J. Colson, A. Richardson, T. Ferreira, B. Shukla*

E0392 **13:36** **Two clusters of carbapenemase-producing Enterobacterales linked to hospital wastewater drainage in utility rooms – an outbreak investigation** *I. Vock* (Basel, Switzerland), G. Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster, N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter*

E0393 **13:42** **Assessing the burden of carbapenemase and colistin antimicrobial resistance genes in hospital wastewater** *E. Au* (Calgary, Canada), N. Acosta, B. Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M. Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B. Missaghi, O. Larios, J. Vayalumkal, J. Leal, E. Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L. Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R. Hubert, M. Parkins*

E0394 **13:48** **Hospital wastewater as a reservoir for carbapenemase-producing organisms** *A. Anantharajah* (Brussels, Belgium), C. Altintas, T. Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A. Bennert, C. Schirvel, A. Verroken, H. Rodriguez-Villalobos*

E0396 **13:54** **Reversing and controlling microbial proliferation in the water system of a high-risk hospital ward after extended closure and reconstruction** *D. Chaput* (Glasgow, United Kingdom), K. Clarkson, L. Bagrade, A. Marek, D. Kelly, D. Watson, A. Leanord, T. Steele*

E0397 **14:00** **Whole-genome sequencing as part of the tracking and managing Carbapenemase producing Enterobacterales transmission in an acute hospital setting** *D. Coffey* (Cork, Ireland), R. Waldron, D. Neshev, M. Cormican, C. Clarke, L. Hayes*

E0398 **14:06** **Is there a solution for hospital acquired infections due to the aquatic reservoir in the near patient environment?** *H. Zayyad* (Poriya, Israel), R. Khouri, N. Saleh, A. Peretz*

E0399 **14:12** **Reducing Antimicrobial Resistance (AMR) across the One Health Landscape: Diverse Perspectives on AMR risks and their mitigation in sinks, drains, and wastewater** *H.A. Craddock* (Dublin, Ireland), A. Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D. Fitzgerald-Hughes*

EF055 **13:30 – 14:30** **Arena 4**

ANT CLN PHEI

ePoster Flash Session

The cutting edge in tuberculosis

Chair *Graeme Ayton Meintjes (Observatory, South Africa)*

E0400 **13:30** **Personalised risk predictions for incident TB and preventive treatment uptake.** *R. Rose-Key* (London, United Kingdom), R. Gupta, M. Noursadeghi*

E0401 **13:36** **Programmatic migrant screening for tuberculosis identifies a spectrum of clinical phenotypes and outcomes: cohort data from a national migrant screening programme** *M. Gohar* (Leicester, United Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel, L. Ahyow, B. Srini, G. Rishi, P. Mark, S. Nilesh, C. Trevithick, K. Pierun, M. Wiselka, L. Gray, I. Abubakar, R. Baggaley, A. Cooper, P. Haldar, M. Pareek*

E0402 **13:42** **An investigation into the relationship between human and animal *Mycobacterium bovis* isolates using whole genome analysis.** *M. Mansfield* (Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers*

E0403 **13:48** **Distinguishing relapse from reinfection in tuberculosis patients from Lithuania** *L. Vasiliauskaite* (Vilnius, Lithuania), L. Vasiliauskaitė, A. Zinola, F. Di Marco, V.E. Davidavičienė, B. Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T. Kačergius*

E0404 **13:54** **Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study** *P. Chheda* (Mumbai, India), S. Shivaprakash, T. Dama, G. Thandassery*

E0405 **14:00** **Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment** *A. Van Laarhoven* (Nijmegen, The Netherlands), L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullinghs, C. Magis Escurra, W. Hoefsloot, R. Van Crevel*

E0406 **14:06** **Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis** *C. Kim* (London, United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid*

E0408 **14:18** **Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers** *A.K. Pandey* (Chandigarh, India), N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma*

JS1 **13:30 – 14:30** **Hall 12**

CLN

Journal Session

Late-breaker research from CMI and CMI Communications

Chairs *Navaneeth Narayanan (New Jersey, United States)*
Erlangga Yusuf (Rotterdam, The Netherlands)

J001 **13:30** **Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)** *Gaetan Gavazzi (Grenoble, France)*

J002 **13:42** **Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial** *Thomas Holland (Durham, United States)*

J003 **13:54** **The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study** *Elise Mitri (Heidelberg, Australia)*

J004 **14:06** **Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis** *Guillermo Cuervo (Barcelona, Spain)*

J005 **14:18** **A randomised non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis** *Sang Hyub Lee (Seoul, Korea, Republic of)*

ME095 **13:30 – 14:30** **Hall 16**

AMR CLN

Meet-the-Expert

Local antimicrobials for deep infections

M0271 13:30 *Karolina Akinosoglou (Patra, Greece)*
M0272 13:42 *Pierre Tattevin (Rennes, France)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

FO097 **13:30 – 14:30** **Arena 1**

Open Forum

DX

Essential diagnostics in low-resource settings: why are we still talking?

Chair *Truls Michael Leegaard (Lørenskog, Norway)*

F0277 13:30 **Training skilled personnel in LMIC and brain drain: is the solution the problem?** *Sipho Kenneth Dlamini (Observatory, South Africa)*
F0278 13:40 **Leveraging surveillance networks to strengthen basic bacteriology** *Dissou Affolabi (Cotonou, Benin)*
F0279 13:50 **Clinical bacteriology laboratories in low-resource settings: considerations for sustainability** *Makeda Semret (Montreal, Canada)*

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission,Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiolo

---

FO098 **13:30 – 14:30** **Arena 2**

Open Forum

PRO

Best of ID Week

Chair *Tina Tan (Chicago, United States)*

F0280 *, Seth Cohen (Seattle, United States), Erin Mccreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel)*

SEL **13:30 – 15:30** **Hall 1**

Special Session

PRO

Selective Pressure

Chairs *Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)*
Joshua Nosanchuk (Bronx, United States)
José Ramon Pano-Pardo (Zaragoza, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
Anja Šterbenc (Ljubljana, Slovenia)
Suzanne Van Asten (Nijmegen, The Netherlands)
David Van Duin (Chapel Hill, Nc, United States)

OS058 **14:45 – 15:45** **Hall 16**

1-hour Case Session

CLN

In the field with fungi

Chairs *Beatriz L. Gomez (Bogota, Colombia)*
Leonardo Nimrichter (Rio De Janeiro, Brazil)

O0419 14:45 **Fosmanogepix expanded access in patients with *Fusarium* infections** *S. Dadwal* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner*
O0420 14:56 **Voriconazole's hidden toll: unveiling periostitis in a heart transplant recipient and a hematologic patient.** *G. Motoa* (Boston, United States), A. Woolley, N. Issa*
O0421 15:07 **Unveiling the Uncommon: Managing Geotrichum candidum in Pancreatic Necrosis** *L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause*
O0422 15:18 **Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections** *V. Havlicek* (Prague, Czechia), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens*
O0423 15:29 **Efficacy of novel antifungal therapies in refractory *Candida* and *Aspergillus* infections: insights from compassionate use and clinical trials** *S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes*

OS056 **14:45 – 15:45** **Hall 2**

1-hour Oral Session

PHEI

Emerging trends in viral hepatitis across Europe

Chairs *Federico Garcia (Granada, Spain)*
Neven Papic (Zagreb, Croatia)

O0409 14:45 **One of the largest outbreak of hepatitis A in the 21st century in Europe** *I. Hockickova* (Košice, Slovakia), I. Hockická, J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian*
O0410 14:57 **Higher prevalence of Cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failure – cause or consequence?** *J. Sonnenberg* (Muenster, Germany), K. Thiyagarajah, E. Görgülü, P. Lembeck, M. Glitscher, F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein, M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N. Kraus, M. Praktinjo, J. Fischer, H.P. Erasmus, J. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka, S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer*
O0411 15:09 **Delta in Denmark: current prevalence of hepatitis delta virus infection** *H. Watson* (Lyon, France), P. Jepsen, H. Vilstrup, H. Krarup*
O0412 15:21 **RatHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study** *A. Rivero-Juarez* (Córdoba, Spain), M. Casares, B. Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-Álvarez De Luna, I. Viciana, M.D.C. Domínguez, M. Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez*
O0413 15:33 **Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir** *I. Hasanoglu* (Ankara, Türkiye), R. Guner, E. Zerdali, A. Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I. Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki, T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N. Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz, S. Kaya, O. Karabay, S. Alkan, F. Tabak*

OS057 **14:45 – 15:45** **Hall 3**

1-hour Oral Session

ANT

Precision medecine: from models to patient care

Chairs *Anouk Edwina Muller (The Hague, The Netherlands)*
Sebastian Wicha (Hamburg, Germany)

O0414 14:45 **Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TB** *F. Kloprogge* (London, United Kingdom), B.T. Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S. Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D. Moore*
O0415 14:57 **Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data** *Y. Chen* (Shanghai, China), J. Zhao, J. Zhang*
O0416 15:09 **Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant *Klebsiella pneumoniae* in response to polymyxin B/zidovudine combination** *J. Zhao* (Melbourne, Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li*

O0417 15:21 **Agent-based model predictions of polymyxin B activity on Acinetobacter baumannii** *H. Soeorg* (London, United Kingdom), Y. Yuan, J. Readman, J.F. Standing*

O0418 15:33 **Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis** *C. Volk* (Madison, United States), W. Kufel, P. Hutson, R. Mahapatra, W. Rose*

SY100 **14:45 – 15:45** **Hall 12**

1-hour Symposium

TRN

The challenge of a healthy microbiota in neonates

Chairs *Maria Vehreschild (Frankfurt Am Main, Germany)*
Walter Zingg (Zurich, Switzerland)

S0283 14:45 **Infant gut microbiome development** *Debby Bogaert (Edinburgh, United Kingdom)*

S0284 15:15 **Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates** *Gautam Dantas (Saint Louis, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

SY099 **14:45 – 15:45** **Hall 4**

1-hour Symposium

AMR IPC

How innovations of AMR and HAI surveillance systems help the clinical practice

Chairs *Pascal Astagneau (Paris, France)*
Mandy Wootton (Cardiff, United Kingdom)

S0281 14:45 **The EUCAST system in surveillance of AMR** *Sören G. Gatermann (Bochum, Germany)*

S0282 15:15 **Insights into developments in the surveillance of HAIs** *Diamantis Plachouras (Solna, Sweden)*

Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)

EF059 **14:45 – 15:45** **Arena 2**

ePoster Flash Session

CLN PHEI

Bacterial infections in the post pandemic era

Chair *Özlem Kurt Azap (Ankara, Türkiye)*

E0424 14:45 **Genomic epidemiology of invasive meningococcal disease in Scotland: The impact of the COVID-19 pandemic** *N. Ahmad* (London, United Kingdom), C. Rodrigues, A. Smith, C. Cameron, L. Macdonald, R. Ure, M. Maiden*

E0425 14:51 **Targeted probe-capture culture-independent sequencing identifies emergence of Macrolide-Resistant *Bordetella pertussis* in Australia** *W. Fong* (Westmead, Australia), R. Rockett, K. Tam, T. Nguyen, E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D. Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A. Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner, A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley, Q. Wang, N. Jeoffreys, S. Chen, K. Basile, T. Golubchik, J. Kok, V. Sintchenko*

E0426 14:57 **Invasive pneumococcal disease in Spanish adults. Multicenter analysis of serotypes and lineages in the post-pandemic period.** *A. González Díaz* (Hospitalet De Llobregat, Spain), R. España-Bonilla, A. González-Díaz, J.M. Marímón, A. Manzanal, E. Cercenado, S. De La Villa, B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D. Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á. Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí, J. Càmara, C. Ardanuy*

E0427 15:03 **Group A streptococcal infections in Germany from 2017 to 2024: a post-pandemic rebound above expected numbers?** *A. Von Laer* (Berlin, Germany), J. Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A. Hoffmann, I. Noll*

E0428 15:09 **Invasive group A streptococcus infections is often preceeded by seasonal influenza.** *J. Westin* (Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell*

E0429 15:15 **Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates** *A. Cannas* (Rome, Italy), V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana*

E0431 15:21 **Incidence of Invasive *Escherichia coli* Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records** *M. Blum* (Ploiesti, Romania), C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen*

E0432 15:27 **A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers** *F. Voit* (München, Germany), L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider, D. Schult-Hannemann, M.H. Richter*

EF060 **14:45 – 15:45** **Arena 3**

ePoster Flash Session

AMR CLN

AMR in the community

Chair *Camilla Wiuff Coia (Copenhagen, Denmark)*

E0433 14:45 **Socio-demographic factors associated with community-acquired extended spectrum []-lactamase producing *E. coli* urinary tract infections at intermunicipal level in France** *G. Birgand* (Nantes, France), M. Prime, O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard*

E0434 14:51 **Prolonged community outbreak of OXA-48-producing *Escherichia coli* linked to a food premises: Lower Hutt, New Zealand, 2018-2022** *C. Thornley* (Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, A. Nesdale, R. White*

E0435 14:57 **Low rates of macrolide resistance found in *Mycoplasma pneumoniae* cases in Australia** *R. Rockett* (Westmead, Australia), K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen, J. Kok*

E0436 15:03 **Epidemiology of antibiotic resistance associated with E. coli/Klebsiella pneumoniae bloodstream infections in England 2012-2023** *S. Lipworth* (Oxford, United Kingdom), L. Gorman, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy, A. Dowsey, K. Pouwels*

E0437 15:09 **The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children.** *C. Brand* (Cape Town, South Africa), R. Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw*

E0438 15:15 **Risk factors and prevalence of AntiMicrobial Resistant microbes in the English Community (AMRIC)** *D. Lecky* (Gloucester, United Kingdom), Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown*

E0439 15:21 **Risk factors for antimicrobial resistance in community commensal *Staphylococcus aureus* isolates, a sub-analysis of the AMRIC project.** *M. Joyce* (Manchester, United Kingdom), Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky*

E0440 15:27 **Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014-2023)** *A. Mcgeer* (Toronto, Canada), A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W. Gold, R. Lovinsky, M. Muller, K. Ostrowska, D. Ricciuto, D. Richardson, C. Vermeiren, K. Hassan, M.*

Lefebvre, A.X. Li, N. Malik, M. Pejkovska, A. Sultana, T. Vikulova, C. Kandel, Z. Zhong

E0441 **15:33** **Antimicrobial resistance in *Streptococcus pneumoniae* in the Netherlands: an 11-year trend analysis of surveillance data** *I. Nauta* (Bilthoven, The Netherlands), W. Altorf-Van Der Kuil, D.W. Notermans, A.F. Schoffelen*

EF061 **14:45 – 15:45** **Arena 4**

ePoster Flash Session

CLN DX

Infections in the immunocompromised: a multifaceted overview

Chair *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

E0442 **14:45** **Impact of Donor Colonization or Infection, or preservation fluid contamination with Multiresistant Bacteria and Fungi in Solid Organ Transplantation. Multicenter registry of Argentina** *L. Barcan* (Buenos Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N. Pujato, M. Martinez, S. Villamandos, C. Niveyro, N. Lasserre*

E0443 **14:51** **Analysis of viral load kinetics and risk factors for Epstein-Barr virus DNAemia and Post-transplant lymphoproliferative disorders in pediatric liver transplant recipients - a single centre experience** *B. Kasztelewicz* (Warsaw, Poland), K. Skrok, I. Jankowska, P. Kaliciński, K. Dzierżanowksa-Fangrat*

E0444 **14:57** **Impact of pre-transplant infection on post-transplant morbidity and graft survival in liver transplant recipients: a prospective cohort study** *L. Mani-Perren* (Bern, Switzerland), S.F. Perrodin, A. Berzigotti, V. Banz, C. Hirzel, L.N. Walti*

E0445 **15:03** **Risks of live-attenuated vaccines in children with primary immunodeficiency** *S. Frigui Ep Oueslati* (Tunis, Tunisia), S. Ben Jaafar, S. Frigui, Y. Chebbi, M. Ouederni, W. Achour*

E0446 **15:09** **Chagas reactivation/ transmission in kidney transplantation.** *M. Radisic* (Buenos Aires, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del Grosso*

E0447 **15:15** **Clinical presentation and treatment of tuberculosis in solid organ transplant recipients: a multicentric retrospective analysis** *J. Moltó* (Barcelona, Spain), I. Los-Arcos, D. Ruiz Cabrera, L. López González, M. Fayos Pérez, R. Rodríquez-Alvarez, M. Murga De La Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J. Espinosa, O. Len, A. Sánchez-Montalva*

E0448 **15:21** **Clinical presentation, risk factors and outcome of non-tuberculous mycobacteria infection in hematopoietic stem-cell transplant recipients: a multinational case-control study** *M. Fernandez Ruiz* (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L. Carver, S. Rutjanawech, L.F. Aranha-Camargo, R. Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S. Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J. Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino, A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek, R. Bou Mjahed, O. Manuel, N. Kamar, A. Calvo-Cano, L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S. Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A.Y. Classen, C. Mejía-Chew, F. López-Medrano*

E0449 **15:27** **Impact of bronchoalveolar lavage results on clinical decision-making among immunocompromised, critically ill patients.** *C. Fanelli* (Sassari, Italy), R. Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales, M.M. Vera, E. Kattan*

E0450 **15:33** ***Campylobacter* spp. bloodstream infections: preliminary results from a multicenter differential clinical analysis in immunocompromised and immunocompetent patients.** *M. Paniagua-García* (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-Espejo1, S. Salto-Alejandre, A. Valiente, M.C. Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-Manrique De Lara, C. Marti-Castellote, M. Monsonis-Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed-Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martinez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía*

ME101 **14:45 – 15:45** **Hall 14**

Meet-the-Expert

PRO

How to master conflict management and negotiation in healthcare

M0285 **14:45** *Esther Calbo (Terrassa, Spain)*

M0286 **14:57** *Jan A.J.W. Kluytmans (Utrecht, The Netherlands)*

FO102 **14:45 – 15:45** **Arena 1**

Open Forum

PHEI

Navigating the future of pandemics across One Health

Chair *Xavier Lescure (Paris, France)*

F0287 **14:45** **Advancing One Health: the Quadripartite collaboration and the joint plan of action** *Chadia Wannous (Paris, France)*

F0288 **14:55** **Evidence review on One Health governance and implementation at the European level** *Tyra Grove Krause (Copenhagen, Denmark)*

F0289 **15:05** **Long-term consequences of emerging viral diseases** *Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine

---

Movie **15:00 – 18:30** **Hall 5**

Special Session

Behind the scenes: Contagion

Chairs *William Hanage (Boston, United States)*
Luigia Scudeller (Pavia, Italy)

OS063 **16:15 – 17:15** **Hall 11**

1-hour Oral Session

DX

Improving blood culture diagnostics: rethinking the basics

Chairs *Direk Limmathurotsakul (Bangkok, Thailand)*
Pilar Retamar Gentil (Seville, Spain)

O0461 **16:15** **Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany** *J. Forster* (Würzburg, Germany), A.L. Sieg, V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V. Le Saout – Chapot, M. Hogardt, B. Spielberger, E.A. Idelevich, M. Christner, S. Zimmermann, S. Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U. Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M. Krone*

O0462 **16:27** **Changing the paradigm: are two sets of blood cultures always needed?** *R. Rosa* (Miami, United States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello, L. Abbo*

O0463 **16:39** **Evaluating clinical and economic empact of reducing blood culture incubation timings: Time to shift the paradigm?** *R. Gupta (bagga)* (London, Canada), R.*

Gupta, J. Delport, T. Mazzulli

O0464 **16:51** **Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study** *S. Kwon* (Seoul, Korea, Republic of), K. Sunghoon, K. Dong Young, J. Jisung, K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan Beom*

O0465 **17:03** **Human *in vivo* footprints from blood plasma for improved diagnostics in sepsis** *M. Sonntag* (Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y. Vainshtein, S.O. Decker, T. Brenner, K. Sohn*

OS064 **Hall 16**

16:15 – 17:15

1-hour Oral Session

DX PHEI VAX

Viral immune response: nature or nurture? Exploring the limits of immune response

Chairs *Malin Flodström-Tullberg (Stockholm, Sweden)*
Florian Krammer (New York, United States)

O0466 **16:15** **Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination** *C. Van Dijck* (Antwerp, Belgium), N. Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J. Marien, L. Liesenborghs*

O0467 **16:27** **DENG-VAC study: preliminary data on immunogenity and reactogenity of Qdenga vaccine versus natural infection** *A. D'abramo* (Rome, Italy), S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle, G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M. Fabrizio, N. Emanuele*

O0468 **16:39** **Long-Lasting Immunity Followed by Natural CCHFV Infection** *H. Karakoc* (Trabzon, Türkiye), H.N. Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q. Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A. Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M. Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M. Sajadi*

O0469 **16:51** **Why does rabies virus not induce an anti-viral immune response : insights from experimental models and a human cohort** *C. Geurts Van Kessel* (Rotterdam, The Netherlands), C. Embregts, A. Gohar, B. Verstrepen, J. Aijaz, N. Salahuddin, C. Geurtsvankessel*

O0470 **17:03** **Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses** *N. Noulin* (London, United Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt, K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C. Chiu, A. Catchpole*

SY106 **Hall 14**

16:15 – 17:15

1-hour Symposium

AMR TRN

Strain dynamics in determining gut microbial colonisation resistance

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Li Yang Hsu (Singapore, Singapore)

S0295 **16:15** **Strain dynamics in serious bacterial infections in infants** *Drew Schwartz (Saint Louis, United States)*

S0296 **16:45** **Long-term colonisation dynamics of carbapenemase-producing Enterobacterales** *Niranjan Nagarajan (Singapore, Singapore)*

SY107 **Hall 15**

16:15 – 17:15

1-hour Symposium

PRO PHEI

Communicating (your) ID science for policy and societal impact

Chairs *Leonard Leibovici (Petah-Tiqva, Israel)*
Ines Steffens (Solna, Sweden)

S0297 **16:15** **Communicating to policy makers and for societal impact** *Balázs Babarczy (Budapest, Hungary)*

S0298 **16:45** **Influencing behaviour through the media and a multichannel communications strategy** *Charlotte Hutchinson (London, United Kingdom)*

Co-organised with: CMI Board of Editors

SY104 **Hall 3**

16:15 – 17:15

1-hour Symposium

IPC

Targeted vs. standard perioperative prophylaxis in solid organ transplant with MDR Gram-negative colonisation

Chairs *Elda Righi (London, United Kingdom)*
David Van Duin (Chapel Hill, Nc, United States)

S0291 **16:15** **Standard prophylaxis** *Maddalena Giannella (Bologna, Italy)*

S0292 **16:45** **Targeted approaches** *Maristela P. Freire (Sao Paulo, Brazil)*

Co-organised with: European Association for the study of the liver (EASL)

SY105 **Hall 4**

16:15 – 17:15

1-hour Symposium

AMR

Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

Chairs *Robert A. Bonomo (Cleveland, United States)*
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0293 **16:15** **Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics** *Anna Sramkova (Pilsen, Czechia)*

S0294 **16:45** **Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors** *Parikshit Prayag (Pune, India)*

Co-organised with: EUCAST Steering Committee

OS062 **Hall 13**

16:15 – 18:15

2-hour Oral Session

CLN DX TRN

Heterogeneity and complexity of sepsis

Chairs *Despoina Koulenti (London, United Kingdom)*
Sylvain Meylan (Lausanne, Switzerland)

O0451 **16:15** **A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium** *A. Moore* (Emerald Hills, United States), H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer, T. Sweeney, A. Rogers, P. Khatri*

O0452 **16:27** **BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study** *C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri*

O0453 **16:39** **Deciphering the Dynamics of *Klebsiella pneumoniae* Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients** *W. Yu* (Beijing, China)*

O0454 **16:51** **Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients** *S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas*

O0455 **17:03** **Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups** *M.H. Øvre* (Herlev And Gentofte,*

Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknecht

O0456 **17:15** **Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam – results from SPECTRA** *E. Yucel* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul*

O0457 **17:27** **Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series** *J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed*

O0458 **17:39** **Is transthoracic echocardiography required in all patients with *Staphylococcus aureus* bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis** *M. Verdejo Gómez* (Barcelona, Spain), D. Malano-Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. Garcia-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A. Martínez, L. Morata, A. Soriano*

O0460 **18:03** **Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia** *S. Doeleman* (Amsterdam, The Netherlands), D. Susanne, E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll*

LB004 **16:15 – 18:15** **Hall 9**

2-hour Oral Session

CLN

Trials in severe infections

Chairs *Lennie Derde (Utrecht, The Netherlands)*
Steven Tong (Melbourne, Australia)

L0016 **16:15** **Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial** *F. Cogliati Dezza* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Peréz, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. Lopéz-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lopez Cardenas, M.C. Goméz Sanchez, I. Peréz Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. Aller García, M.T. Peréz-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño*

L0017 **16:27** **HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study** *M. Ju* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang*

L0018 **16:39** **Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant *Acinetobacter baumannii*** *G.E. Dale* (Basel, Switzerland), F. Fratzeskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakynthinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer*

L0019 **16:51** **Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial** *M. Canetti* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav*

L0020 **17:03** **Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reduction** *L.A. Edwards* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall1, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross*

L0021 **17:15** **Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients coinfected with HIV and tuberculosis: a multicentre, open-label, randomised trial** *Y. Shen* (Shanghai, China), X. Le*

L0022 **17:27** **Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: the TAPER-V randomised controlled trial** *E.G. Mcdonald* (Montreal, Canada), Y. Chen, B. Coburn, N. Daneman, S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin, V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L. Valiquette, T.C. Lee*

L0023 **17:39** **Beneficial effects of a clinical metagenomics intervention on clinical outcomes, healthcare economics, and quality of life in patients with sepsis/septic shock: results of the DigiSep-trial** *T. Brenner* (Essen, Germany), A. Skarabis, S.J. Schaller, T. Von Groote, C. Putensen, U. Günther, M. Sauer, S.O. Decker, F. Dusse, M. Weiss, K. Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer, M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M. Feißt, U. Marschall, P. Brandenburg, J. Englisch, P. Stevens, J. Schmidt, M.W. Pletz, J. Brands, A. Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G. Marx, J. Mossanen, T. Breuer, H. Häberle, K. Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T. Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B. Pasieka, U. Jaekel, T. Brandenburger, F. Bach, H. Mutlak, S. Utzolino, M.M. Berger*

L0024 **17:51** **Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial** *S. Bastrup Israelsen* (Hvidovre, Denmark), L. Hagens Mygind, F. Al-Zergani, B. Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-Ussing, I. S Johansen, H. Nielsen, P. Ravn, T. Benfield*

L0025 **18:03** **High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial** *R. Van Crevel* (Nijmegen, The Netherlands), D. Meya, R. Rovina, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A. Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M. Kabahubya, S. Marais, Y. Moosa, N. Bahr, E. Svensson, L. Te Brake, R. Aarnoutse, D. Boulware*

EW109 **16:15 – 18:15** **Hall 2**

Educational Session

CLN VAX

Infections in cancer patients: tips for daily practice

Chairs *José Molina Gil-Bermejo (Seville, Spain)*
Stefan Schwartz (Berlin, Germany)

W0301 **16:15** **Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi** *Janne Vehreschild (Frankfurt, Germany)*

W0302 **16:35** **Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours** *Konrad Klinghammer (Berlin, Germany)*

W0303 **16:55** **The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients** *Şiran Keske (Istanbul, Türkiye)*

W0304 **17:15** **HTLV-1 and T-cell lymphoma - predict & prevent** *Lucy Cook (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EF065 **16:15 – 17:15** **Arena 1**

ANT TRN

ePoster Flash Session

The antibiotic bakery: novel compounds in the pipeline

Chair *Susanne Haeussler (Braunschweig, Germany)*

E0471 **16:15** **_In vitro_ activity and _in vivo_ proof-of-efficacy of epimutilin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens** *S. Paukner* (Vienna, Austria), W.W. Wicha*

E0472 **16:21** **SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections** *Y. Hui Hui* (Taipei, Taiwan), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu*

E0473 **16:27** **_In vitro_ potency of ceftibuten with xeruborbactam against []-lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme** *O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley*

E0474 **16:33** **Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on _Pseudomonas aeruginosa_ biofilm formation.** *A. Fontanot* (Rotterdam, The Netherlands), P. Croughs, A. De Bruijn, C. Falciani, A. Pini, R. Ecker, I. Ellinger, W. Unger, J. Hays*

E0475 **16:39** **Broad spectrum coverage of serine []-lactamase and high _in vitro_ potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabycciccloctane []-lactamase inhibitor ANT3310** *L. Sánchez-Peña* (A Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-Martín, L. González-Pinto, M. Outeda-García, P. Aja-Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G. Bou, A. Beceiro, J. Arca-Suárez*

E0476 **16:45** **Antibacterial potential of D-limonene and diallyl disulfide and their interaction with gentamicin against multidrug-resistant _Pseudomonas aeruginosa_ in rat pneumonia model** *Y. Almuhanna* (Shaqra, Saudi Arabia), M. Asad*

E0477 **16:51** **_In vivo_ pharmacokinetic/pharmacodynamic targets of a novel macrolide antibiotic nafithromycin, determined in neutropenic murine lung infection model of _Streptococcus pneumoniae_** *A. Muller* (The Hague, The Netherlands), R. Chavan, S. Takalkar, V. Zope, K. Umarkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel, B. Veeraraghavan*

E0478 **16:57** **NiPharmins: novel low resistance-inducing antimicrobials with antibiofilm activity against _Staphylococcus aureus_** *A. Nunes* (Lisbon, Portugal), B. Alves, J.P. Carrilho, N.R. Candeias*

EF066 **16:15 – 17:15** **Arena 2**

VAX

ePoster Flash Session

Modelling infectious disease burden and impact of vaccination

Chair *David Fisman (Toronto, Canada)*

E0480 **16:15** **Evaluating the Impact of Re-vaccination on Pneumococcal Disease in Individuals Previously Vaccinated with PPSV23 in Germany: Comparative Approach** *O. Sharomi* (Rahway, Nj, United States), M. De Lepper, S. Mihm, T.C. Reuter, C. Solleder, G. Meleleo, T. Malik, K. Bakker, R. Oidtman*

E0481 **16:21** **Modeling the public health impact of a 21-valent PCV in the Canadian adult population** *O. Sharomi* (Rahway, United States), R. Oidtman, M.C. Meilleur, S. Weinrich, K. Bakker*

E0482 **16:27** **Estimating the health and economic burden of pneumococcal diseases attributable to PCV21 (V116) vs. PCV20 or PPSV23 serotypes among adults in Norway** *A.A. Tajik* (Oslo, Norway), Z. Yi, S.T. Klitkou, E. Tsoumani, K. Owusu-Edusei*

E0483 **16:33** **Shifting from risk-based to age-based approach for pneumococcal vaccination in adults in France: a comprehensive evaluation** *O. Sharomi* (Mt Carmel, United States), S. Oluwaseun, M. Breau-Brunel, F. Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O. Rachel, M. Tufail, B. Kevin*

E0484 **16:39** **The socio-economic value of adult respiratory immunisation programmes in the United Kingdom – Are we measuring what matters to society?** *C. Harrison* (Tadworth, United Kingdom), T. Hu, J. Yang, J. Vietri, D. Mendes, S. Chowdhury, C. Theakston, S. Brassel, L. Steuten*

E0485 **16:45** **Improving Danish all-cause mortality monitoring by nowcasting weekly deaths** *A. Kalnæs* (Copenhagen, Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard*

E0486 **16:51** **Modelling to identify an optimal ring vaccination strategy to mitigate a smallpox outbreak** *V. Costantino* (Sydney, Australia), M. Kunasekaran, T. Leroyd, K. Yeo, R.C. Macintyre*

E0487 **16:57** **The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study** *F. Günther* (Berlin, Germany), U. Reinacher, S. Chisholm, M. Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O. Wichmann, T. Harder, F.G. Sandmann*

E0488 **17:03** **Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis** *L. Geng* (Singapore, Singapore)*

EF067 **16:15 – 17:15** **Arena 3**

CLN

ePoster Flash Session

Blood parasitology at its best

Chair *Miriam José Álvarez-Martínez (Barcelona, Spain)*

E0489 **16:15** **Unexpected P.malariae diagnosis in Italian woman with no history of travel to endemic areas** *A. Busni* (Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara*

E0490 **16:21** **A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with _Plasmodium vivax_ and _Plasmodium falciparum_** *U.A. Zainulabid* (Pahang, Malaysia), X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris*

E0491 **16:27** **Trick or Treat? An unrelenting malaria case** *C. Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy, A. Brown*

E0492 **16:33** **"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"** *F. Murphy* (Dublin, Ireland), A. Albadi, P. Coakley, C. Mcnally*

E0493 **16:39** **Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)** *F. Sabaini* (Milan, Italy), A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori*

E0494 **16:45** **The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients** *S. Vita* (Rome, Italy), A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri*

E0495 **16:51** **Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study** *J. De Larminat* (Paris, France), N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye*

E0496 **16:57** **Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement** *A. Mohta* (Bikaner, India)*

E0497 **17:03** **Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection** *T. Kanagiri* (Jodhpur, India), N. T R, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra*

EF068 **16:15 – 17:15** **Arena 4**

ePoster Flash Session

AMR PHEI

A global perspective on antimicrobial resistance surveillance

Chair *Mirfin Mpundu (Lusaka, Zambia)*

E0498 **16:15** **Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS)** *E. Van Kleef* (Geneva, Switzerland), O. Tosas Auguet, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolio*

E0499 **16:21** **Comparative analysis of antimicrobial resistance (AMR) burden across european countries** *A. Dörre* (Berlin, Germany), A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns*

E0500 **16:27** **Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities** *C. Van Rossum* (Nijmegen, The Netherlands), C. Meijer, P. Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs-Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Tostmann, C. Van Der Veer, S. Pas*

E0501 **16:33** **Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade** *R. Janssen* (Bilthoven, The Netherlands), S. Woudt, D. Boudville, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M. Gelormini, C. Ruesen*

E0502 **16:39** **Global, regional, and national temporal trends in mortality for carbapenem-resistant bacteria from 1990 to 2021: An age-period-cohort analysis** *Y. Sun* (Shanghai, China), C. Zhihui, Z. Mingchen, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong*

E0503 **16:45** **Global Trends and Impact of Antimicrobial Resistance in Paediatric Populations: An Analysis Using WHO AWaRe Classification and Priority Pathogens** *Joseph Harwell (North Melbourne, Australia)*

E0504 **16:51** **Antibiotic resistance profile and comparative evaluation of WHO AWaRe Guidelines at the Emergency's Children's Surgical Hospital in Uganda** *L. Barcellini* (Milan, Italy), F. Riccaboni, V. Fabiano, F. Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A. Mohammed Zain, G.V. Zuccotti, L. Folgori, L. Napolitano*

E0505 **16:57** **Initiatives in antimicrobial resistance surveillance: Using automated bacteraemia surveillance for hospital-wide multidrug resistance monitoring** *F.D. Ruether* (Berlin, Germany), L.A. Peña Diaz, M. Behnke, C. Geffers, S.J.S. Aghdassi*

E0506 **17:03** **Global and regional prevalence of antimicrobial resistance in GLASS target bacterial pathogens for bloodstream, urinary tract and gastrointestinal infections: a systematic review of the global literature (2019-2024)** *B. Caddey* (Calgary, Canada), G. Lazarus, A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly, H.W. Barkema, E. Van Kleef, O. Tosas-Auguet, S. Bertagnolio, D.B. Nobrega, R.L. Hamers*

KN103 **16:15 – 17:15** **Hall 1**

Keynote Lecture

CLN

Tuberculosis: where are we now and where should we be

Chairs *Jon S. Friedland (London, United Kingdom)*
Delia Goletti (Rome, Italy)

K0290 **16:15** *Guy Thwaites (Ho Chi Minh City, Vietnam)*

ME108 **16:15 – 17:15** **Hall 12**

Meet-the-Expert

CLN

Navigating travel medicine: expert tips for safe international travel

M0299 **16:15** *Sophie Schneitler (Hamburg, Germany)*

M0300 **16:27** *Andreas Neumayr (Basel, Switzerland)*

OS073 **17:30 – 18:30** **Hall 16**

1-hour Case Session

CLN

Still going viral

Chairs *Ursula Hofer (London, United Kingdom)*
Yee Sin Leo (Singapore, Singapore)

O0527 **17:30** **Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions.** *A. Tessitore* (Trieste, Italy), N. Maximova, S. Braidotti, M. Granzotto, R. Simeone*

O0528 **17:41** **Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia** *J. Heylen* (Leuven, Belgium), B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters*

O0529 **17:52** **Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina.** *R. Gago* (Pilar, Argentina), S. Villamandos, M. Aguirre, A. Martinoia, A. Patterer, M. Uranga, C. Sarkis, L. Barcán, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio*

O0530 **18:03** **Rash without borders: waning immunity in a travelling physician** *R. Ville Benavides* (Mexico City, Mexico), R. Ville-Benavides, I. Avendaño-Gutiérrez*

O0531 **18:14** **A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient** *A. Kaya* (Izmir, Türkiye), G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan*

OS070 **17:30 – 18:30** **Hall 12**

1-hour Oral Session

CLN DX

What's new in antifungal guidelines and management

Chairs *Sharon Chen (Sydney, Australia)*
Helmut Salzer (Linz, Austria)

O0512 **17:30** **Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM** *R. Sprute* (Cologne, Germany), O.A. Cornely, M. Bassetti, C. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E. Santolaya, L. White, L.P. Zhu*

O0514 **17:42** **An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI)** *O.A. Cornely* (Cologne, Germany), B.D. Alexander, P.G. Pappas, T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo*

O0515 **17:54** **Novel immunotherapy approach using pan-*Candida* monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR** *Y. Zhao* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil*

O0516 **18:06** **Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis.** *K. Stott* (Liverpool, United Kingdom), D. Tembo, C. Kajanga, A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T. Harrison, J. Jarvis, D. Namakhwa, D. Lalloo, W. Hope, H. Mwandumba*

O0513 **18:18** **Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay** *A. Soriano* (Barcelona, Spain), G.R. Thompson, M. Bassetti, S. Dickerson, I. Bielicka, O.A. Cornely*

OS071 **17:30 – 18:30** **Hall 14**

1-hour Oral Session

CLN

Intestinal parasitic uncovered: epidemiology and treatment success

Chairs *Kurt Hanevik (Bergen, Norway)*
Pavla Tůmová (Praha, Czechia)

O0518	17:30	**Giardiasis: Who gets it? Experience from a Central London Teaching Hospital.** *A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, N. Longley, G. Godbole, S. Eisen, L. Nabarro*
O0517	17:42	**Giardia- Does the treatment work? The experience from a national tertiary referral centre** *A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, N. Longley, G. Godbole, S. Eisen, L. Nabarro*
O0519	17:54	**Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting E. histolytica cfDNA** *P. Datta* (Chandigarh, India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S. Khurana*
O0520	18:06	**Longitudinal observation of *Blastocystis* sp. and *Dientamoeba fragilis* in children: a very rare occurrence in chronic diseases with gut dysbiosis** *J. Hurych* (Prague, Czechia), J. Havlova, V. Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M. Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P. Saavalainen, H. Malcova, D. Cebecauerova, P. Dřevínek, Z. Sumnik, O. Cinek*
O0521	18:18	**High prevalence of the zoonotic Angiostrongylus cantonensis in rats in Spain** *J. Caballero Gómez* (Córdoba, Spain), T. Fajardo-Alonso, I. García-Bocanegra, M. Gonzálvez, A. Beato-Benítez, R. Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R. Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A. González, P. Foronda, J. Caballero-Gómez*

OS072 **17:30 – 18:30** **Hall 15**

1-hour Oral Session

PRO

Training models: a new model for training

Chairs *Erin Bonura (Portland, United States)*
Casandra Bulescu (Bucharest, Romania)

O0522	17:30	**Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases ?** *S. Villard* (Paris, France), C.A. Hobson, Y. Guedj, L. Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, D. Bouzid, M. Thy, N. Peiffer-Smadja*
O0523	17:42	**Large language model in real-world clinical infectious diseases: are we there yet?** *G. Carra* (Switzerland, Switzerland), M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco*
O0524	17:54	**Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3** *S. Ahmad* (Tampere, Finland)*
O0525	18:06	**A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines** *J. Pano-Pardo* (Zaragoza, Spain), J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller*
O0526	18:18	**Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis** *S. Angirekula* (Jodhpur, India), R. Modi, R. Bora, R. Lohiya, S.K. Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. Bohra*

OS069 **17:30 – 18:30** **Hall 4**

1-hour Oral Session

AMR ANT

Determining new and revising old breakpoints

Chairs *Jaroslav Hrabak (Plzen, Czechia)*
Erika Matuschek (Växjö, Sweden)

O0507	17:30	**EUCAST disk diffusion testing of ten additional species of anaerobic bacteria** *J. Ahman* (Växjö, Sweden), J. Åhman, E. Matuschek, B.J. Holzknecht, P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T. Morris, G. Kahlmeter*
O0508	17:42	**Standardised antimicrobial susceptibility testing protocol for *Legionella pneumophila* validated across ten European reference laboratories.** *M. Sewell* (Cardiff, United Kingdom), C. Farley, A.V. Krøvel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller*
O0509	17:54	**Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods** *L. Chan* (Hong Kong, Hong Kong), D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow*
O0510	18:06	**Determination of optimal disk diffusion mass for zosurabalpin** *M. Castanheira* (North Liberty, United States), J. Maher, Y. Edah, A. Trauner*
O0511	18:18	**The clinical significance of aminoglycoside susceptibility breakpoints modification** *O. Henig* (Tel Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-Ami*

SY112 **17:30 – 18:30** **Hall 1**

1-hour Symposium

PHEI

Year in public health

Chairs *Catherine Moore (Cardiff, United Kingdom)*
Marc J. Struelens (Saltsjobaden, Sweden)

S0309	17:30	*Li Yang Hsu (Singapore, Singapore)*
S0310	18:00	*Rita Oladele (Lagos, Nigeria)*

SY111 **17:30 – 18:30** **Hall 11**

1-hour Symposium

ANT

PK/PD in drug development: what's in it for me?

Chairs *Sandrine Marchand (Poitiers, France)*
Sebastian Wicha (Hamburg, Germany)

S0307	17:30	**PK/PD from the EUCAST/regulatory perspective: what tools do we need?** *Joseph Meletiadis (Athens, Greece)*
S0308	18:00	**PK/PD for new anti-TB drugs** *Elin Svensson (Uppsala, Sweden)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

SY110 **17:30 – 18:30** **Hall 3**

1-hour Symposium

VAX

Immune reconstitution syndrome in infectious diseases: Who. Are. You?

Chairs *Elisa Borghi (Milan, Italy)*
Justyna Kowalska (Warsaw, Poland)

S0305 17:30 **IRIS in HIV immunocompromised hosts: a failure of success** *Paola Maria Cinque (Milan, Italy)*

S0306 18:00 **Dysregulated host responses to infection** *Michal Holub (Praha, Czechia)*

EF074 17:30 – 18:30 **Arena 1**

ePoster Flash Session

DX PHEI

New methods for rapid pathogen detection and typing

Chair *Sylvain Brisse (Paris, France)*

E0532 17:30 **Rapid detection of Shiga toxin-producing *Escherichia coli* (*stx2a* and *stx2d*) in korean diarrheal stool samples: a performance evaluation** *L. Hyeonji* (Seoul, Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J. Choo, H.J. Huh, E.J. Won*

E0533 17:36 **Global prevalence of O-serotypes and antibiotic resistance among extraintestinal pathogenic *Escherichia coli* isolated from older adult patients with bacteraemia (2011–2021)** *V. Oriol Mathieu* (Leiden, The Netherlands), M. De Been, O. Go, M. Aitabi, C. Willame, E. Weerdenburg, J. Geurtsen*

E0534 17:42 **Strategy for the rapid typing of *Salmonella* spp using infrared spectroscopy: a one health perspective** *J. Jiménez* (Santiago, Chile), D. Fredes, A. Piña, I. Mercado, J. Miranda, S. Henríquez, T. González, A. Adell, A. Moreno-Switt, A. Wozniak, P. García*

E0535 17:48 **WGS-based surveillance as a paradigm shift in outbreak detection, AMR monitoring and source attribution in *Campylobacter*** *A. Nunes* (Lisbon, Portugal), M.L. Lemos, S. Ortiz, I. Santos, S. Ramos, M. Oleastro*

E0536 17:54 **Prevalence of *Staphylococcus aureus* clonal complex 97 amongst BORSA isolates in a large UK hospital** *H. Gareth* (Birmingham, United Kingdom)*

E0537 18:00 **The effectiveness of clinical laboratory tools in the surveillance of nontuberculous mycobacterium isolations within different counties in Taiwan** *H.W. Chu* (Taipei, Taiwan), T.F. Lee, C.C. Shu, Y.T. Huang*

E0538 18:06 **Rapid detection of oxazolidinone-resistance-related mutations in *Enterococcus* spp. by using High Resolution Melting-qPCR-typing analysis** *R. Musumeci* (Monza, Italy), E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza*

E0539 18:12 **An automated pipeline to genotype bacteriophages using third generation sequencing** *Z. Halász* (Debrecen, Hungary), E. Szoták, L. Dr. Laczkó, G. Dr. Kardos*

E0540 18:18 **Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy** *N. Mauder* (Bremen, Germany), M. Cordovana, M. Kostrzewa*

EF075 17:30 – 18:30 **Arena 2**

ePoster Flash Session

IPC PHEI VAX

Healthcare (workers') safety revisited

Chair *Daniel Diekema (Harpswell, United States)*

E0541 17:30 **Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study** *B. Beishuizen* (Bilthoven, The Netherlands), M. Stein, A. Tostmann, C. Rovers, A. Timen*

E0542 17:36 **Preparing First-Line health care workers for 'Virus X' through targeted training (FILI-VI-X)** *A. Mondelaers* (Antwerp, Belgium), Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe*

E0543 17:42 **Analysis of the current situation of hospital inspection practices by German health authorities** *A. Schwabe* (Bonn, Germany), J. Dannenberg, A.D. Wollkopf, F. Droop, S. Engelhart, N.T. Mutters*

E0545 17:54 **High level of measles immunity among Dutch healthcare workers with self-reported "unknown" measles immunity status.** *C. Meijer* (Nijmegen, The Netherlands), J. Leijser, M. Mccall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann*

E0546 18:00 **Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland** *C. Anderson* (Dublin, Ireland), D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend*

E0549 18:18 **Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits?** *A. Kearney* (Dublin, Ireland), H. Humphreys, D. Fitzgerald Hughes*

EF076 17:30 – 18:30 **Arena 3**

ePoster Flash Session

ANT CLN

Knowing me, knowing you: behaviour influencing AMS

Chair *Elena Carrara (Verona, Italy)*

E0550 17:30 **Exploring determinants in deciding the optimal antimicrobial dose in patients recieving CRRT: a mixed method study** *T. Yanık Yalçın* (Ankara, Türkiye), A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö. Azap, H. Arslan, B. Başgut, P. Zeyneloğlu*

E0551 17:36 **Behaviour change vs policy change: Key drivers of inappropriate antibiotic use among health care professionals in LMICs – insights from Indian community setting** *N. P Mathew* (Manipal, India), U. B, M. Varma, V. K E, R. Ruiter, G. Thunga, C. Mukhopadhyay*

E0552 17:42 **Contextual determinants to antimicrobial stewardship implementation in 16 hospitals: a four-country analysis in Asia** *H. Vu Thi Lan* (Ha Noi, Vietnam), R. Limato, H.Y. Duong, S. Manandhar, D. Limmathurotsakul, A. Apisarnthanarak, N.T. Pham, V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A. Karkey, M.K. Upadhyaya, E. Dodds Ashley, D. Anderson, H.R. Van Doorn, H. Vu*

E0553 17:48 **SpeakAB, a pilot study to encourage nurses to speak up about antibiotic care** *M. Bos* (Nijmegen, The Netherlands), J. Schouten, H. Vermeulen, M. Hulscher, C. De Bot*

E0554 17:54 **Understanding what matters to patients in antimicrobial stewardship in hospitals. PERSPEcT study update** *B. Jacob* (Dublin, Ireland), E. De Barra*

E0555 18:00 **Determinants of antibiotic prescribing in hospitals from low, middle and high-income countries in Asia** *S. Chhabra* (Singapore, Singapore), S. Nair, A. Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo*

E0557 18:12 **Addressing Antimicrobial Resistance: Expert Insights and Policy Recommendations for Effective Interventions** *B. Madran* (Istanbul, Türkiye), F. Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira, G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S. Sakarya*

E0558 18:18 **Implementation of hospital antimicrobial stewardship in Europe using a data-driven behaviour change approach: insights from the drive-AMS EU project** *I. Pauwels* (Antwerp, Belgium), R. Janssen, E. Iosifidis, N. Milevska-Kostova, M. Lupşe, J.A. Paiva, E. Roilides, T. Schoffelen, R. Valinteliene, A. Versporten, E. Vlieghe, J. Schouten*

EF077 17:30 – 18:30 **Arena 4**

ePoster Flash Session

CLN DX PHEI

Viral aphrodites

Chair *Rémi Charrel (Marseille, France)*

E0559	17:30	**Potential for international spread of Oropouche virus via commercial air travel** *M. Torres Portillo* (Toronto, Canada), I. Bogoch, A. Marwah, M. Kraemer, A. Thomas, K. Khan*
E0560	17:36	**Estimating mpox Clade Ib outbreak size in the Democratic Republic of the Congo to attenuate surveillance gaps during the early stages of the 2024 outbreak** *M. Torres Portillo* (English, Canada), A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan*
E0561	17:42	**Disparate epitope recognition between MPXV-infected and Smallpox-vaccinated individuals** *A. Otter* (Salisbury, United Kingdom), S. Jones, B. Hicks, B. Hallis, C. Rowe*
E0562	17:48	**Diverse residual and late-onset symptoms of severe fever with thrombocytopenia syndrome: insights from a multicenter questionnaire study in Western Japan** *S. Ryuichi Minoda* (Suita, Osaka, Japan), R.M. Sada, S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna*
E0563	17:54	**Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study** *J.T. Lim* (Singapore, Singapore), I. Wee, W.Z. Tan*
E0564	18:00	**Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina** *G. Mendez* (Posadas (misiones), Argentina), J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely, G.A. Méndez*
E0565	18:06	**Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever** *D. Yigci* (Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündağ, M. Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıravcı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu, Ö. Ergönül*
E0566	18:12	**Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India** *P. Venkata Swathi Kiran* (Udupi, India), S.K. Pothumarthy, P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra*
E0567	18:18	**Unravelling the aetiology of summer flu-like illness in Czechia** *M.F. Kříha* (Ceske Budejovice, Czechia), V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek*

Monday, 14 April 2025

OS078 — **08:30 – 10:30** — **Hall 5**

2-hour Oral Session

CLN DX TRN

Trending topics in tuberculosis

Chairs — *Delia Goletti (Rome, Italy)*, *Sean Wasserman (London, United Kingdom)*

O0568	08:30	**Lineage-specific immune responses to *Mycobacterium tuberculosis*: insights into L4 and L6 pathogenesis** *M. Silva* (Porto, Portugal), J. Couto, M. Cardoso, B. Cá, M. Saraiva*
O0569	08:42	**Deciphering the functional role of distinctive *Mycobacterium tuberculosis* peptidoglycan modifications in modulating antibiotic resistance and the immune response** *C. Silveiro* (Lisbon, Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes, M.J. Catalão*
O0570	08:54	**Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitis** *J. Barnacle* (London, United Kingdom), K. Wilkinson, C. Stek, M. Maxebengula, N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S. Wasserman, G. Meintjes, A. O' Garra, A. Davis, R.J. Wilkinson*
O0571	09:06	**Subpopulations in clinical samples of *Mycobacterium tuberculosis* can give rise to rifampicin resistance and shed light on how resistance is acquired** *V. Brunner* (Oxford, United Kingdom), P. Fowler*
O0572	09:18	**A systematic comparison of automated *Mycobacterium tuberculosis* complex whole genome sequencing analysis pipelines** *R. Spies* (Ho Chi Minh City, Vietnam), D. Crook, T. Peto, P. Fowler, R. Turner, H. Thai, J. Watson, T. Walker*
O0573	09:30	**Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretation** *V. Suttels* (Lausanne, Switzerland), T. Brokowski, J. Wolleb, P. Wachinou, A. Hada, G. Makpemikpa, E. Garcia, T. Brahier, O. Opota, D. Affolabi, M.A. Hartley, N. Boillat-Blanco*
O0574	09:42	**Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of *Mycobacterium tuberculosis*: Evaluating Novel Benzothiazinone Derivatives.** *A. Vocat* (Lausanne, Switzerland), A. Luraschi-Eggemann, C. Antoni, G. Cathomen, D. Cichocka, G. Greub, O. Riabova, V. Makarov, O. Opota, A. Mendoza, S. Cole, A. Sturm*
O0575	09:54	**Rapid drug susceptibility testing of *Mycobacterium tuberculosis* directly from clinical samples using targeted next-generation sequencing** *E. Rosendal* (Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo*
O0576	10:06	**Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studies** *K. Jadhav* (Sas Nagar, India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma*
O0577	10:18	**Multi-drug resistant tuberculosis among migrants in Europe** *S. Hayward* (London, United Kingdom), K. Rustage, L.B. Nellums, J.S. Friedland, S. Hargreaves*

SY114 — **08:30 – 10:30** — **Hall 13**

2-hour Symposium

CLN

Sepsis Global 2025

Chairs — *Brigitte Lamy (Bobigny, France)*, *Willem Joost Wiersinga (Amsterdam, The Netherlands)*

S0315	08:30	**The ESCMID-ISF Sepsis Award Lecture** *Andrew Moore (Emerald Hills, United States)*
S0316	08:45	**The WHO Global Maternal Sepsis Study** *Carolina Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)*
S0317	09:15	**Sepsis: year in review** *Sylvain Meylan (Lausanne, Switzerland)*
S0318	09:45	**How to design and implement a Sepsis National Action Plan (SNAP)** *Erika Vlieghe (Antwerp, Belgium)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY115 — **08:30 – 10:30** — **Hall 14**

2-hour Symposium

CLN DX

Challenges in infection management, prevention and antimicrobial stewardship in long-term care facilities

Chairs — *Gaetan Gavazzi (Grenoble, France)*, *Giusy Tiseo (Pisa, Italy)*

S0319	08:30	**The burden of nosocomial infections in long-term facilities** *Virginie Prendki (Geneva, Switzerland)*
S0320	09:00	**Pneumonia in the elderly: management and prevention** *Marcos Restrepo (San Antonio, United*

States)

S0321	09:30	**Challenges in the clinical diagnosis of infection in the elderly** *Maheen Abidi (Denver, United States)*
S0322	10:00	**Challenges in implementing antimicrobial stewardship in long-term care facilities** *Elena Carrara (Verona, Italy)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

---

SY116 **08:30 – 10:30** **Hall 15**

2-hour Symposium

PHEI

Climate Change: changing risks and adaptation strategies for a world on the move

Chairs *Rachel Lowe (Barcelona, Spain)*
Giacomo Stroffolini (Lausanne, Switzerland)

S0323	08:30	**Vector-borne diseases in Europe and clinical consequences** *Tuba Dal (Ankara, Türkiye)*
S0324	09:00	**Rising temperatures and risks of fungal disease** *Anuradha Chowdhary (New Delhi, India)*
S0325	09:30	**Strategies for climate prevention and adaptation in a moving world** *Kristie Ebi (Seattle, United States)*
S0326	10:00	**AMR in climate change-affected countries** *Esmita Charani (London, South Africa)*

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

SY117 **08:30 – 10:30** **Hall 16**

2-hour Symposium

AMR CLN

Survival of the parasites: is treatment failure due to antimicrobial resistance?

Chairs *Hanne Brekke (Oslo, Norway)*
Jaco J. Verweij (Tilburg, The Netherlands)

S0327	08:30	**Nitroimidazole refractory *Giardia intestinalis* infection** *Pavla Tůmová (Praha, Czechia)*
S0328	09:00	**Treatment failure in scabies** *Francisco Bravo (Lima, Peru)*
S0329	09:30	***Enterobius vermicularis*: nuisance or neglected disease?** *Sarah Eisen (London, United Kingdom)*
S0330	10:00	**Recent advances in the treatment of Visceral Leishmaniasis and PKDL** *Shyam Sundar (Varanasi, India)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY113 **08:30 – 10:30** **Hall 3**

2-hour Symposium

PHEI

Haemorrhagic viral infections

Chairs *Önder Ergönül (Istanbul, Türkiye)*
Catherine Houlihan (Porton Down, United Kingdom)

S0312	09:00	**Jack in the box: re-emergence of Kyasanur forest disease in India** *Kavitha Saravu (Manipal, India)*
S0313	09:30	**Crimean-Congo haemorrhagic fever: newer insights into pathogenesis leading to new vaccines and therapeutics** *Ali Mirazimi (Stockholm, Sweden)*
S0314	10:00	**Venezuelan equine encephalitis: impact of newer strategies for vector control** *Carlos Seas (Lima, Peru)*

EW119 **08:30 – 10:30** **Hall 11**

Educational Session

AMR DX

This bacterium might harbour AmpC, what should I do?!

Chairs *Sören G. Gatermann (Bochum, Germany)*
Pranita Tamma (Ellicott City, United States)

W0335	08:30	**Laboratory identification of AmpC and its impact on /i>in vitro resistance** *Ana Gales (Sao Paulo, Brazil)*
W0336	08:50	**Divergent levels of AmpC expression in Gram-negative pathogens** *Antonio Oliver (Palma De Mallorca, Spain)*
W0337	09:10	**Rational choice of antimicrobial therapy against AmpC-producing pathogens** *Patrick Harris (Herston, Australia)*
W0338	09:30	**Novel antimicrobials active against AmpC: what RCTs tell us in support of their use?** *Amy Mathers (Charlottesville, United States)*

EW118 **08:30 – 10:30** **Hall 2**

Educational Session

DX IPC

How can we infer and track plasmid outbreaks?

Chairs *Alessandra Carattoli (Rome, Italy)*
Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)

W0331	08:30	**Evolutionary modelling of plasmids** *Manuel Ares Arroyo (Paris, France)*
W0332	08:50	**How plasmids shape the emergence of nosocomial pathogens** *Jukka Corander (Oslo, Norway)*
W0333	09:10	**Understanding the complexity of plasmid outbreaks using bioinformatics** *Torsten Seemann (Melbourne (VIC), Australia)*
W0334	09:30	**Plasmid transmission at the One Health interface** *Nicole Stoesser (Oxford, United Kingdom)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EF079 **08:30 – 09:30** **Arena 1**

ePoster Flash Session

CLN

AMS around the world: what we can learn from each other

Chair *Benedikt Huttner (Geneva, Switzerland)*

E0578	08:30	**Battlefield Stewardship: Implementing Antimicrobial Management in the Ukrainian Trauma Pathway** *H. Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych*
E0579	08:36	**Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study** *M. Alyazji* (Abudhabi, United Arab Emirates), A. Sadeq, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljasmi, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali, J. Shamseddine, Z.O.E. Babiker*
E0580	08:42	**Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza a H1N1 season in northern Italy** *R. Corsini* (Reggio Emilia, Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri*
E0582	08:54	**Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study** *M.S. Kabir* (Dhaka, Bangladesh), S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh, R. Farzana*
E0583	09:00	**Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital** *P. Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco*
E0584	09:06	**Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment** *G. Brunhofer-Bolzer* (Vienna, Austria), M. Krauss, C. Labut, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E.*

Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler

E0585 09:12 **Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CArbapenem Sparing Antimicrobial Stewardship) Project** *M. Bongiovanni* (Lugano, Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi*

E0586 09:18 **"Prescribing antibiotics is a gamble...": A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital** *L. Jung* (Leipzig, Germany), L. Atikoro, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo, D. Owachi*

EF080 08:30 – 09:30 **Arena 3**

AMR ANT IPC

ePoster Flash Session

Acinetobacter baumannii, still a strong knight to be knocked

Chair *Parikshit Prayag (Pune, India)*

E0587 08:30 **Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against Acinetobacter baumannii** *H. Haddad* (Sousse, Tunisia)*

E0588 08:36 **Clonal dissemination of highly resistant *Acinetobacter baumannii* ST2: Insights from the BALANCE study** *C. Abdellaoui* (Oxford, United Kingdom), M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh, R. Farzana*

E0589 08:42 **Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant Acinetobacter baumannii in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam** *D. Nurjadi* (Luebeck, Germany), S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P. Velavan*

E0590 08:48 **In vitro activity of nitroxoline among *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* clinical isolates** *E. Wohlfarth* (Cologne, Germany), P.G. Higgins, M. Kresken*

E0591 08:54 **Assessing biocide resistance genes and susceptibility to biocides in carbapenem-resistant *Acinetobacter baumannii* isolates from Thai hospitals** *M.R.D. Wiradiputra* (Bangkok, Thailand), K. Thirapanmethee, P. Khuntayaporn, M.T. Chomnawang*

E0592 09:00 **Epidemiological and Genomic Characteristics of *Acinetobacter baumannii* in a Hospital in Zhejiang, China: A Study from 2015 to 2020** *Y. Zhang* (Hangzhou, China), X. Hua*

E0593 09:06 **Evaluation of the susceptibility of Carbapenem-resistant *Acinetobacter baumannii* to sulbactam-durlobactam** *J. Caierão* (Porto Alegre, Brazil), L. Silva Dornelles, G. Da Silva Collar, M. Preussler Mott, A. Luís Barth*

E0595 09:18 **Insight into *Acinetobacter baumannii*'s phenotypic and genotypic traits in oncological patients** *F. Sivori* (Rome, Italy), I. Cavallo, M. Truglio, G. Fabrizio, M. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico, F. Pimpinelli*

SY120 09:30 – 10:30 **Hall 1**

DX

1-hour Symposium

Year in clinical microbiology

Chairs *Fidelma Fitzpatrick (Dublin, Ireland)*
Maurizio Sanguinetti (Rome, Italy)

S0339 09:30 *Mario Ramirez (Lisbon, Portugal)*

S0340 10:00 *Anna Papa-Konidari (Thessaloniki, Greece)*

EF081 09:30 – 10:30 **Arena 2**

ANT DX

ePoster Flash Session

Clinical features and outcome of invasive fungal infections

Chair *Marcus De Melo Teixeira (Brasília, Brazil)*

E0596 09:30 **Management, outcomes and predictors of mortality of *Cryptococcus* infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand** *J. Coussement* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen*

E0597 09:36 **Incidence of invasive fungal infections in hospitalised paediatric patients in England** *A. Warris* (Exeter, United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz, M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J. Owczarek, C. Castillo, I. Jimenez*

E0598 09:42 **Invasive fungal disease in critically ill patients with cirrhosis: an autopsy study** *L. Maessen* (Leuven, Belgium), J. Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, M. Peetermans, G. Hermans, Y. Debaveye, E. Van Wijngaerden, S. Van Der Merwe, G. De Hertogh, A. Wilmer, P. Meersseman, J. Wauters*

E0599 09:48 **Non-*Aspergillus* mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomes** *C.F. Neoh* (Melbourne, Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Douglas, K. Urbancic, M. Menon, A. Stewart, P. Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, T. Spelman, L. Worth, M. Slavin*

E0600 09:54 **Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective study** *L. Nwankwo* (London, United Kingdom), N. Pinnock, A. Shek, C. Hemsley, J. Periselneris, S. Schelenz, D. Armstrong-James*

E0601 10:00 **How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 years** *S. Wurster* (Houston, United States), T.M. John, J. Ying, D.P. Kontoyiannis*

E0602 10:06 **Emergence of *Wickerhamomyces anomalus* invasive infections in injecting drug users** *M. Lefranc* (Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Imbert*

E0603 10:12 **Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French CandidICU multicenter study** *J.P. Gangneux* (Rennes, France), F. Reizine, J. Henry, L. Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, G. Eustache, T. Belleville, A. Marc, J. Malherbe, P. Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A. Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. Launey, C. Aubron*

E0604 10:18 **Population-based longitudinal study over two decades of *Candida* and *Candida*-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance** *A. Stewart* (Boston, United States), K. Laupland, F. Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, M. Slavin, S. Chen*

OS084 | **11:00 – 12:00** | **Hall 8**

1-hour Case Session

CLN

Weird and unusual infections

Chairs *Murat Akova (Ankara, Türkiye)*
Muge Cevik (St Andrews, United Kingdom)

O0615	11:00	**Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases** *E. Hasivirwe Vakaniaki* (Kinshasa, Congo, the Democratic Republic of the), N.R. Swar Kuispond, H. Yuichiro, E. Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti Nundu, S. Tadaki, R. Bulakali Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni*
O0616	11:11	**First case of Oropouche fever in the South of Spain** *I. Pérez Hernández* (Málaga, Spain), I.A. Pérez-Hernández, E. Basallote Leal, M.A. Sempere Alcocer, B. O´donell Cortés*
O0617	11:22	**Wild hippopotamus bite and *Aeromonas* spp. infection: a treatment challenge. First case report.** *J. Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon, M.V. Montoya Garcia, A. Múnera-Echeverri, F.F. Jiménez Quiroz, J. Alza-Arcila*
O0618	11:33	**From the sea to the land: an emerging species** *K. Rodríguez Martínez* (Santo Domingo, Dominican Republic), K. Rodríguez, A. Fernández, K. Espaillat, J. Cruz, X. Rodríguez, T. Flores*
O0619	11:44	**The first findings of Wohlfahrtiimonas chitiniclastica and Ignatzschineria species bacteremia in two cases with maggot infested wounds in Scandinavia** *A.L. Engsbro* (Slagelse, Denmark), C. Mortensen, R. Jul, W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp*

OS085 | **11:00 – 12:00** | **Hall 10**

1-hour Oral Session

CLN PHEI

Planes, pains, and pathogens: the perils of travel medicine

Chairs *Anu Kantele (Helsinki, Finland)*
Carlos Seas (Lima, Peru)

O0620	11:00	**Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology** *S. Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori*
O0621	11:12	**Tracing the itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data** *S. Gupta* (Auckland, New Zealand), S. Thornley, G. Sundborn, C. Grant*
O0622	11:24	**Molecular epidemiological characterization of enterotoxigenic and enteroaggregative *Escherichia coli* causing traveller's diarrhoea and their relationship with clinical features** *P. Oliveras Julia* (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath, R.M. Albarracín, M.E. Valls, M.J. Álvarez-Martínez, M. Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J. Vila*
O0623	11:36	**Bites and bytes – can digital surveillance of travellers' illness predict outbreaks?** *N. Hedrich* (Zürich, Switzerland), T. Lovey, P. Schlagenhauf*
O0624	11:48	**Travel-associated infections and diseases: a retrospective cross-sectional study** *M. Trojanek* (Prague, Czechia), M. Trojánek, V. Grebenyuk, V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K. Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O. Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z. Uhříková, M. Vidlička, M. Štefan, F. Stejskal*

OS086 | **11:00 – 12:00** | **Hall 11**

1-hour Oral Session

DX TRN

Marker based diagnostics: forget the pathogen

Chairs *Virginie Prendki (Geneva, Switzerland)*
Suzanne Van Asten (Nijmegen, The Netherlands)

O0625	11:00	**A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infections** *N. Whitfield* (Sunnyvale, United States), C. Lu, O. Liesenfeld*
O0626	11:12	**Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infection** *T. Gottlieb* (Tirat Carmel, Israel), L. Bont, A. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden, B.P. Muller*
O0627	11:24	**Diagnostic accuracy of combined urine lipocalin 2 and copper test in acute pyelonephritis or cystitis** *V. Havlicek* (Prague, Czechia), J. Hrbacek, T. Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A. Stevens, J. Novak, R. Dobias, R. Zachoval*
O0628	11:36	**Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung Disease** *P. Escalante* (Rochester, Mn, United States), B. Piatkowski, B. Pathakumari, V. Van Keulen, N. Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T. Peikert*
O0629	11:48	**Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort study** *M. Trojanek* (Prague, Czechia), O. Beranek, Z. Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan, V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V. Grebenyuk, R. Prusa, M. Trojánek*

OS087 | **11:00 – 12:00** | **Hall 15**

1-hour Oral Session

AMR TRN

Antimicrobial resistance around birth

Chairs *Julia Anna Bielicki (London, United Kingdom)*
Surbhi Malhotra-Kumar (Antwerp, Belgium)

O0630	11:00	**Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs** *A. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray*
O0631	11:12	**Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk** *A. Chakraborty* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora*
O0632	11:24	**Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units** *A. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar*
O0633	11:36	**Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut** *V. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg*
O0634	11:48	**Dynamics of gut resistome and mobilome in early life: A meta-analysis** *V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov*

OS088 | **11:00 – 12:00** | **Hall 16**

1-hour Oral Session

CLN DX VAX

Advancing diagnostics and preventive measures in hemato-oncological patients

Chairs *Dina Averbuch (Jerusalem, Israel)*
Malgorzata Mikulska (Genoa, Italy)

O0635	11:00	**Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy** *M. Freire* (Sao Paulo, Brazil), A. Villani. Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin*
O0636	11:12	**Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the cause of fever?** *A. Douglas* (Melbourne, Australia), I. Savic, J. Moselen, A. Aziz, G. Papadakis, G. Ng, J. Druce, K. Thursky, L. Caly, M.A. Slavin*
O0637	11:24	**Results of Optifil study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosis** *F. Lanternier* (Paris, France), C. Maunoury, F. Montravers, F. Marquant, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E. Blanchard, S. Poiree, C. Elie, O. Lortholary*
O0638	11:36	**Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort study** *S. Haggenburg* (Amsterdam, The Netherlands), J. Schnyder, H. Garcia Garrido, M. Schoordijk, A. Reiners, B. Meek, M. Hazenberg, A. Goorhuis*
O0639	11:48	**Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantation** *J. Lötscher* (Basel, Switzerland), C.S. Walti, S. Heller, S. Schmid, K. Leuzinger, J. Halter, N. Khanna*

OS082 — **11:00 – 12:00** — **Hall 2**

CLN DX

1-hour Oral Session

New insights in bloodstream infections and endocarditis

Chairs — *Barbara Hasse (Zurich, Switzerland)*, *José M. Miro (Barcelona, Spain)*

O0605	11:00	**Different from the start – Sex differences in Staphylococcus aureus bacteremia mortality** *A. Westgeest* (Leiden, The Netherlands), M. Lambregts, F. Ruffin, V.G. Fowler, J.T. Thaden*
O0606	11:12	**Tracking evolution in action during invasive *Staphylococcus aureus* infections: the BARISTA study** *S. Giulieri* (Melbourne, Australia), D. Daniel, M. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A. Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen, M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S. Tong, J. Kwong, B. Howden*
O0607	11:24	**Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trial** *S. Ong* (Melbourne, Australia), R. Pinto, A. Rishu, S. Tong, R. Commons, J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-Wiens, T. Lee, S. Lother, D. Macfadden, J. Marshall, V. Martel-Laferrière, M. Mayette, E. Mcdonald, J. Neary, J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L. Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young, R.A. Fowler, N. Daneman*
O0608	11:36	**Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology study** *N. Macesic* (Melbourne, Australia), J. Hawkey, J.A. Wisniewski, A. Peleg*
O0609	11:48	**Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohort** *A. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D. Monzón, M. Valerio, M. Hernandez Meneses, J.M. Miró, M. Cobo Belastegui, A. De Alarcón, R. Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L. Garcia-Alvarez, L. Boix*

OS083 — **11:00 – 12:00** — **Hall 5**

CLN DX PHEI

1-hour Oral Session

Don't 'rash' it

Chairs — *Heli Harvala (Turku, Finland)*, *Catherine Moore (Cardiff, United Kingdom)*

O0610	11:00	**Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024** *B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca, A. Toyran, S. Aydoğan, B. Dinç*
O0611	11:12	**Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study** *M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffioti*
O0612	11:24	**The dark side of the „fifth disease" endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases** *B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko*
O0613	11:36	**Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024** *A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey*
O0614	11:48	**Measles virus in the context of subacute sclerosing panencephalitis (SSPE)** *J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous*

SY126 — **11:00 – 12:00** — **Hall 13**

CLN

1-hour Symposium

Why is the concept of complicated UTI so complicated?

Chairs — *Gernot Bonkat (Basel, Switzerland)*, *Maeve Doyle (Waterford, Ireland)*

S0350	11:00	**The concept of complicated UTI: underlying conditions matter** *Suzanne Geerlings (Amsterdam, The Netherlands)*
S0351	11:30	**The concept of complicated UTI: the site of infection matters most** *Jesús Rodríguez-Baño (Seville, Spain)*

Co-organised with: ESCMID Education Subcommittee

SY122 — **11:00 – 12:00** — **Hall 3**

DX VAX

1-hour Symposium

Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?

Chairs — *Pavel Drevinek (Prague, Czechia)*, *Helle Krogh Johansen (Copenhagen, Denmark)*

S0342	11:00	**The lung microbiome of people with cystic fibrosis receiving modulator therapy** *Sebastien Boutin (Lübeck, Germany)*
S0343	11:30	**Cystic Fibrosis patients on CFTR modulator therapy: present and future** *Alessandra Bragonzi (Milano, Italy)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology

SY123 — **11:00 – 12:00** — **Hall 4**

IPC

1-hour Symposium

Infection prevention and control and intensive care: challenges and solutions

Chairs — *Antonios Katsounas (Bochum, Germany)*, *Claire Roger (Nimes, France)*

S0344	11:00	**Intensive care unit (ICU) and infection: two sides of a coin** *Reto Schuepbach (Zurich, Switzerland)*
S0345	11:20	**Ventilator- associated pneumonia (VAP) and ICU**

enviroment: how can we improve practices? *Despoina Koulenti (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee

---

SY124 **11:00 – 12:00** **Hall 6**

1-hour Symposium

CLN

Antimicrobial prescribing: myths or pearls?

Chairs *Massimo Fantoni (Rome, Italy)*
Spyros Pournaras (Athens, Greece)

S0346 **11:00** **Why treat IV when PO is possible?** *Bradley Spellberg (Los Angeles, United States)*

S0347 **11:30** **De-escalation of antibiotic therapy to narrow-spectrum IV drugs** *Flaminia Olearo (Hamburg, Germany)*

Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee

---

SY125 **11:00 – 12:00** **Hall 7**

1-hour Symposium

DX

Cutting edge methods in mycology

Chairs *Katrien Lagrou (Leuven, Belgium)*
Antonio Vena (Genova, Italy)

S0348 **11:00** **Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT** *Ana Fernández-Cruz (Majadahonda (Madrid), Spain)*

S0349 **11:30** **Exploring the intersection of fungal metagenomics and medical mycology** *Marcus De Melo Teixeira (Brasília, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP), Società Italiana per la Terapia Antinfett

---

EF089 **11:00 – 12:00** **Arena 2**

ePoster Flash Session

PHEI

Emerging infectious diseases, zoonoses and outbreaks

Chair *Xavier Lescure (Paris, France)*

E0640 **11:00** **Seasonality of Influenza and Respiratory Syncytial Virus related hospital contacts in Denmark (1999-2021)** *O. Rezahosseini* (Hillerod, Denmark), C.L. Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C. Roed, J.G. Holler, B. Lindegaard Madsen, D.M. Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B. Harboe*

E0641 **11:06** **Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?** *I. Sanz* (Valladolid, Spain), I. Sanz-Muñoz, J. Sánchez-Martínez, C. Rodriguez-Crespo, I. Arroyo-Hernántes, C.S. Concha-Santos, M.L. De Diego, S. Rojo-Rello, M. Domíguez-Gil, M. Hernández-Pérez, A. Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M. Eiros, A. Nogales*

E0642 **11:12** **The UK Imported Fever Service (IFS): National VHF testing 2023-2024** *A. Belfield* (Salisbury, United Kingdom), A. Thompson, H. Umpleby, B. Hack, S. Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou, T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E. Warrel*

E0643 **11:18** **Reemergence of Poliovirus in Pakistan: Challenges and Implications for Global Health Security** *S. Ahmad* (Tampere, Finland)*

E0644 **11:24** **Preparing an emerging infectious diseases unit for high-consequence infectious diseases** *A. Silva-Pinto* (Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L. Santos*

E0645 **11:30** **Correlation between clinical and wastewater measles positivity rate in three towns of karachi, pakistan** *F. Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S. Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J. Gauld, S. Kroiss, J. Giles*

E0646 **11:36** ***Salmonella* serovars in wild European hedgehogs (*Erinaceus europaeus*): an over 12-year monitoring in the Ferrara Province, Italy** *E. Massella* (Piacenza, Italy), M. Munari, S. Russo, L. Cirasella, C. Torreggiani, R. Taddei, A. Luppi, S. Rubini*

E0647 **11:42** **Clinico-epidemiological and Microbiological Investigation of Diphtheria Outbreak in Odisha, India, 2024** *I. Praharaj* (Bhubaneswar, India), S. Panda, S. Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S. Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati*

E0648 **11:48** **Seroprevalence of nine causes of acute febrile illness in rural Cambodia and Thailand using a multiplex assay** *M. Zhang* (Bangkok, Thailand), R. Tripura, L. Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon, S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude, S. J. Lee, Y. Lubell, T. J. Peto*

EF090 **11:00 – 12:00** **Arena 3**

ePoster Flash Session

DX

Addressing the need for speed: advances in point-of-care testing

Chair *Jennifer Dien Bard (Los Angeles, United States)*

E0649 **11:00** **Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT** *E. Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe*

E0650 **11:06** **Evaluation of the prototype BIOFIRE® nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid hoSt gene expression test** *G. Storch* (Saint Louis, Missouri, United States), M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin*

E0651 **11:12** **Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnossis of bacterial intestinal infections** *P. Lehours* (Bordeaux, France), Q. Beaufils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain*

E0652 **11:18** **Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis** *N. Younes* (Doha, Qatar), G. Nasrallah*

E0653 **11:24** **A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)** *S.Y. Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park*

E0654 **11:30** **Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device** *A. Van Der Linden* (Eindhoven, The Netherlands), Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko*

E0655 **11:36** **Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens** *C. Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri*

E0656 **11:42** **Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein** *L. Pommiès* (Gif Sur Yvette, France), H. Boutal, D. Fras, H. Volland*

E0657 **11:48** **A smartphone app for point-of-care quantification of lateral flow assays** *R. Armiger* (London, United Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg*

KN121 **11:00 – 12:00** **Hall 1**

Keynote Lecture

PHEI

ESCMID Global 2025 - Programme

HIV: from needle parks to injectables

Chairs *Mary Horgan (Dublin, Ireland)*
Gülsen Özkaya Sahin (Lund, Sweden)

K0341 **11:00** *Huldrych Günthard (Zürich, Switzerland)*

ME128 **11:00 – 12:00** **Hall 14**

Meet-the-Expert

TRN

How to apply organoid models to study infectious disease

M0354 **11:00** *Jennifer Rohn (London, United Kingdom)*
M0355 **11:12** *Nathalie Sauvonnet (Paris, France)*

ME127 **11:00 – 12:00** **Hall 9**

Meet-the-Expert

AMR DX

EUCAST: what's new in susceptibility testing

M0352 **11:00** *Erika Matuschek (Växjö, Sweden)*
M0353 **11:12** *Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

FO129 **11:00 – 12:00** **Arena 1**

Open Forum

PRO

Predatory journals in CM/ID: from symptoms to cure

Chair *Emily G. Mcdonald (Montreal, Canada)*

F0356 **11:00** **The genesis of predatory journals: symptoms and root problems** *Leonard Leibovici (Petah-Tiqva, Israel)*
F0357 **11:10** **The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals?** *Till Bärnighausen (Heidelberg, Germany)*
F0358 **11:20** **The roles of authors and academic institutions: towards governance and regulation** *Luigia Scudeller (Pavia, Italy)*
F0359 **11:30** **Bibliometric literacy in scientific publication** *Lauren Maggio (Chicago, United States)*

Co-organised with: CMI Communications Board of Editors

PM2 **11:00 – 12:00** **Hall 12**

Panel Discussion

AMR VAX

AMR and vaccines

Chairs *Charlotte Vernhes (Brussels, Belgium)*
Ghada Zoubiane (London, United Kingdom)

L005 **11:00** **Overview of the current evidence of the impact of vaccines on AMR** *Adam Cunningham (Birmingham, United Kingdom)*
L006 **11:20** **Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR**, *Adam Cunningham (Birmingham, United Kingdom), Sipho Kenneth Dlamini (Observatory, South Africa), Erin Duffy (Boston, United States), Mateusz Hasso-Agopsowicz (Geneva, Switzerland)*

OS092 **13:30 – 14:30** **Hall 14**

1-hour Case Session

CLN

Mycobacterial mayhem

Chairs *Seif Al-Abri (Muscat, Oman)*
Linda Aulin (Leiden, The Netherlands)

O0663 **13:30** **Limitations of the Xpert® MTB/RIF assay: A series of four clinical cases** *A. Haas* (Salt Lake City, United States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C. Church, M. Narita, V. Escuyer, S. Shakir*
O0664 **13:41** **Pharmacokinetic analysis of blood and cerebrospinal fluid contezolid concentrations in a patient with tuberculous meningoencephalitis** *W. Nie* (Beijing, China), N. Chu*
O0665 **13:52** **Is this the first case of Mycobacterium stephanolepidis infection in humans?** *S. Pérez-Recio* (Barcelona, Spain), M.D. Grijota-Camino, A. Lérida, A. Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé Fernández, F. Alcaide, M. Santin*
O0666 **14:03** **Diagnostic Aspects of a Bacillus Calmette-Guërin Infection Following Intravesical Treatment for Bladder Cancer** *K.J. Kim* (Seoul, Korea, Republic of), J.H. Cha, S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho*
O0667 **14:14** ***Mycobacterium abscessus*: Is Shorter Antibiotic Therapy Combined with Surgery Sufficient?** *M.J. Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M. Caixeiro, M. Alves, R. Macedo, P. Pacheco*

OS091 **13:30 – 14:30** **Hall 5**

1-hour Oral Session

AMR TRN

Genomic and molecular drivers of bacterial virulence and resistance

Chairs *Ecaterina Noroc (Chisinau, Moldova, Republic of)*
Guido Werner (Wernigerode, Germany)

O0658 **13:30** **Characterization of the virulence shaping and adaptability in the methicillin-resistant *Staphylococcus aureus* ST9 lineage.** *Y. Chen* (Hangzhou, China), L. Sun*
O0659 **13:42** **Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology** *S. David* (Oxford, United Kingdom), C. Seddon, J. Wong, N. Ishimoto, S. He, J. Bradshaw, W.W. Low, D. Aanensen, G. Frankel, K. Beis*
O0660 **13:54** **Clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) strains carrying a mutH mutation are hypermutators that have heightened virulence and readily develop []-lactam/[]-lactamase resistance** *S. Cheng* (Pittsburgh, United States), B. Hao, G. Liu, C. Clancy, M.H. Nguyen*
O0661 **14:06** **Genomic insights into the new prophages of MDR *Pseudomonas aeruginosa*: an example of phage-host-phage interaction** *A. Uskudar Guclu* (Ankara, Türkiye), S. Unlu*
O0662 **14:18** **Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis** *R. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk*

SY132 **13:30 – 14:30** **Hall 13**

1-hour Symposium

AMR DX

Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art

Chairs *Werner Ruppitsch (Vienna, Austria)*
Balaji Veeraraghavan (Vellore, India)

S0363 **13:30** **Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment** *Thomas Schön (Kalmar, Sweden)*
S0364 **14:00** **Antimicrobial resistance prediction using whole genome sequencing** *Patricia Simner (Rochester, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee

SY133 13:30 – 14:30 **Hall 15**

1-hour Symposium

ANT

Probiotics in infectious diseases: current state-of-play

Chairs *Nicolas Benech (Lyon, France)*
Silvia Corcione (Turin, Italy)

S0365 13:30 **Probiotics in infectious diseases: the perfect complement to antimicrobial therapies?** *Lena Biehl (Cologne, Germany)*

S0366 14:00 **The horizon of next generation probiotics for infectious diseases** *Cormac Gahan (Cork, Ireland)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

SY131 13:30 – 14:30 **Hall 2**

1-hour Symposium

AMR PHEI VAX

Vaccines and antimicrobial resistance

Chairs *Iva Butic (Zagreb, Croatia)*
Zitta Barrella Harboe (Hillerød, Denmark)

S0361 13:30 **The impact of current and future vaccines on AMR: from pneumococcal to COVID-19** *Mateusz Hasso-Agopsowicz (Geneva, Switzerland)*

S0362 14:00 **Can vaccines against AMR be translated into policy?** *William Hausdorff (Washington DC, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)

EW135 13:30 – 15:30 **Hall 3**

Educational Session

PRO

Transforming your research idea into an appropriate study design

Chairs *Casandra Bulescu (Bucharest, Romania)*
Mary Horgan (Dublin, Ireland)

W0369 13:30 **Designing high-quality research studies: methodological skills and knowledge** *Mical Paul (Haifa, Israel)*

W0370 13:50 **How to design and run scientific studies using AI agents as research assistants** *Alyssa Bilinski (Cambridge, United States)*

W0371 14:10 **Designing your first study: how to construct a workable project when your work environment may not help** *Thomas Tängdén (Uppsala, Sweden)*

W0372 14:30 **Bridging early-career professionals with partners and seniors** *Giorgia Caruana (Sion, Switzerland)*

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee

EF093 13:30 – 14:30 **Arena 2**

ePoster Flash Session

CLN DX

Real world experience with modern HIV treatment: the art of ART

Chair *Cristina Mussini (Modena, Italy)*

E0668 13:30 **Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysis** *M. Bongiovanni* (Lugano, Switzerland), B. Barda, G. Barilaro, E. Bernasconi*

E0669 13:36 **Assessment of HIV-DNA, immune activation and senescence biomarkers during injectable cabotegravir/rilpivirine treatment** *M. Mazzitelli* (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset, D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan*

E0670 13:42 **Impact of Cabotegravir plus Rilpivirine Long-Acting on Body Composition: Results from a Prospective Study** *A. De Vito* (Sassari, Italy), A. Marongiu, A. Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A. Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A. Spanu, G. Madeddu*

E0671 13:48 **Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Older Woman with Polypharmacy and Comorbidities** *M. Suarez Robles* (Madrid, Spain), M. Rosas Cancio-Suárez, A. Moreno, S. Del Campo Terrón, M.J. Vivancos, A. G. García De Morales, J. Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano, R. Ron, M.J. Cárdenas-Isasi, M. Vélez-Díaz-Pallarés, S. Moreno, M.J. Pérez-Elías*

E0672 13:54 **Two-year comparative analysis of lipid profile changes between INSTI-based single tablet regimens in treatment-naïve people living with HIV: real-world evidence from South Korea** *S.Y. Lim* (Seoul, Korea, Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J. Bang*

E0673 14:00 **Long-acting antiretroviral therapy in PLWH with prior HBV exposure** *J. Mateo Gonzalez* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D. Martinez-Perez, J. Martinez-Andres, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, M. Garcia-Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro*

E0674 14:06 **Protease inhibitors in today's antiretroviral landscape: are we tracking resistance?** *J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-Martín, M. Montero-Alonso, J.L. López-Hontangas*

E0675 14:12 **Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial** *L. Srikham* (Sakon Nakhon, Thailand), S. Sriphoosanaphan, O. Putcharoen*

E0676 14:18 **Impact of maternal dolutegravir on growth outcomes of HIV-exposed uninfected children: A prospective study** *E. Yoram* (Morongoro, Tanzania, United republic of), E. Luoga, S. Glanzman, E. Dotto, G.J. Mollel, G. Sigalla, E. Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris, F. Vanobberghen, M. Weisser*

EF094 13:30 – 14:30 **Arena 3**

ePoster Flash Session

CLN DX PHEI

Speed, convenience and performance of virus diagnostic methods

Chair *Hans H. Hirsch (Basel, Switzerland)*

E0677 13:30 **Prospective evaluation of a rapid diagnostic test in a tertiary hospital and prospects for reinforced dengue surveillance in Catalonia (Northeastern Spain)** *L. Horvath* (Barcelona, Spain), L. Horvath Ruiz, J. Navero, M. Navarro, M. Pujada, A. Navarro, M. Garrido, B. Herrerías, P. Rodríguez, N. Zancada, B. Escudero-Perez, M.J. Martinez*

E0678 13:36 **Sequence-Independent Single-Primer Amplification (SISPA) followed by Next-Generation Sequencing for Diagnosing Viral Respiratory Tract Infections** *P. Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A.V. Schwarzbold*

E0679 13:42 **Seasonal trends and co-infection dynamics of respiratory pathogens: insights from a yearlong study** *Z. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Meletis, A. Greco, T. Chatziantoniou, R. Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*

E0680 13:48 **Speed meets reliability in respiratory infections diagnosis with a new nucleic acid extraction workflow** *L. Pastor-Bernad* (San Mateo De Gállego, Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-Rodríguez, H. Alonoso, C. Giménez-Rota*

E0681 13:54 **Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms** *L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchì, M.*

Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri

E0682 **14:00** **Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR** *C. Cuesta Chasco* (Barcelona, Spain), C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina, S. Alex, M. Mª Ángeles*

E0683 **14:06** **Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment** *E. Vanhulle* (Bilthoven, The Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Benschop*

E0684 **14:12** **Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States.** *A. Cuber* (Los Angeles, United States), S. Butler-Wu*

E0685 **14:18** **Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma** *F. Garcia* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. García, M. Buti Ferret*

KN130 **13:30 – 14:30** **Hall 1**

Keynote Lecture

PHEI

Infectious disease challenges in an ever-changing environment

Chairs *Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)*
Annelies Zinkernagel (Zurich, Switzerland)

K0360 **13:30** *Pamela Rendi Wagner (Stockholm, Sweden)*

ME134 **13:30 – 14:30** **Hall 16**

Meet-the-Expert

CLN VAX

The older solid organ transplant recipient: between frailty, immunosenescence and infection

M0367 **13:30** *Maheen Abidi (Denver, United States)*

M0368 **13:42** *Alaa Atamna (Petah-Tikva, Israel)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

PM3 **13:30 – 14:30** **Hall 12**

Meet-the-Innovators

CLN

Future prospects of electronic clinical decision support systems in stewardship programs

L007 **13:30** **Opportunities for clinical decision support systems in infectious disease management** *Nathan Peiffer-Smadja (Paris, France)*

L008 **14:00** **CDSS and AMS programs: the Lumed example** *Louis Valiquette (Sherbrooke, Canada)*

FO136 **13:30 – 14:30** **Arena 1**

Open Forum

PRO

Diversity in CM and ID: gender gaps and policy traps

Chair *Andre Fuchs (Augsburg, Germany)*

F0373 **13:30** **How to avoid parity traps in ID/CM research?** *Muge Cevik (St Andrews, United Kingdom)*

F0374 **13:40** **Gender gaps in visibility at scientific conferences** *Sarah Delliere (Paris, France)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission

---

OS098 **14:45 – 15:45** **Hall 15**

1-hour Case Session

CLN

Opportunistic infections in the immunocompromised

Chairs *Aleksandra Barac (Belgrade, Serbia)*
Olivier Lortholary (Paris, France)

O0701 **14:45** **Dog scratch disease? A case of *Vibrio vulnificus* in a liver transplant patient** *A. Covington* (Galveston, United States), E. Kim*

O0702 **14:56** **Mpox infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility.** *J. Bini Viotti* (Miami, United States), J. Bini*

O0703 **15:07** **Histoplasmosis in Hansen's Disease: Thalidomide for TNF-alpha Inhibition in ENL with a Risk of Opportunistic Infections** *K.K. Vaitheeswaran* (Delhi, India), M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal, R. Kumar, Y. Dharmashaktu*

O0704 **15:18** **Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid** *M. Pellegrino* (Modena, Italy), V. Todisco, S. Generoso, L. Benassi, E. Franceschini, F. Damiano, G. Donati, C. Mussini, A. Cervo*

O0705 **15:29** **Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges** *M. Meroi* (Verona, Italy), M. Morra, M.E. De Rui, E. Tacconelli, F. Soldani*

OS097 **14:45 – 15:45** **Hall 14**

1-hour Oral Session

PHEI

Update on zoonotic and enteric infections

Chairs *Steen Ethelberg (Copenhagen, Denmark)*
Kavitha Saravu (Manipal, India)

O0696 **14:45** **A large-scale epidemiological study of *Campylobacter* employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK.** *B. Lopes* (Middlesbrough, United Kingdom), A.S. Boaitey-Biko*

O0697 **14:57** **Population dynamics and evolution of multidrug resistant clones of *Shigella sonnei* in Metropolitan France** *C. Silva Nodari* (Paris, France), I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill*

O0698 **15:09** **Shiga toxin-producing *Escherichia coli* O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data** *L. Mcgeoch* (London, United Kingdom), O. Quinn, C. Sawyer, A. Douglas, C. Jenkins, S. Balasegaram*

O0699 **15:21** **Incidence, clinical presentation, and outcomes of Pasteurella infections: a population-based Danish study** *L. Øbo Larsen* (8200, Denmark), L.Ø. Larsen, H.L. Nielsen, K.K. Søgaard*

O0700 **15:33** **Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study** *H. Wang* (Shanghai, China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang*

OS095 **14:45 – 15:45** **Hall 2**

1-hour Oral Session

CLN PHEI

Community respiratory tract infections: latest trends and approaches

Chairs *Catia Cilloniz (Barcelona, Spain)*

Aurélien Dinh (Garches, France)

O0686 14:45 ***Mycoplasma pneumoniae*** **increase in 2023/24 causes disease in adults in Europe***B.M.M. Streng* (Utrecht, The Netherlands), L. Bont, P. Meyer Sauteur, M. Bonten, A. Van Rossum, C. Prat Aymerich*

O0687 14:57 **Serotype distribution of pneumococcal community-acquired pneumonia in hospitalized adults in Germany***D. Karssen* (Utrecht, The Netherlands), L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich*

O0688 15:09 **Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis***J. Wei* (Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker, D. Eyre*

O0689 15:21 **Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia.***F. Al-Zergani* (Hvidovre, Denmark), C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield*

O0690 15:33 **Oropharyngeal carriage of gut-derived Enterobacterales increases RTI risk in long-term aged care residents***S. Miller* (Adelaide, Australia), F. Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers*

OS096 **Hall 5**

14:45 – 15:45

1-hour Oral Session

AMR

Trends in antifungal resistance

Chairs *Alexandre Alanio (Paris, France)*
Ana Alastruey-Izquierdo (Madrid, Spain)

O0691 14:45 **Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies***K. Schmidlin* (Tempe, United States), K. Geiler-Samerotte*

O0692 14:57 **Role of the C2585G substitution in the *MRR1* gene in the development of azole resistance in *Candida parapsilosis sensu strictu*.***I. Franconi* (Pisa, Italy), P. Noemi, R. Cosmeri, L. Maltinti, M. Falcone, A. Tavanti, A. Lupetti*

O0693 15:09 **Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years***J. Guinea* (Madrid, Spain), P. Escribano, M. Machado, A. Burillo, P. Muñoz, G. Jesús*

O0694 15:21 **A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against Candida auris with EUCAST broth microdilution reference methodology***J. Meletiadis* (Haidari, Greece), J. Guinea, S. Arikan-Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup*

O0695 15:33 **Decoding *Candida auris* Resistance in Latin America: Candida.app vs. Pathogenwatch***J. Acosta España* (Quiro, Ecuador), P. Eduarda, A. Herrera-Yela, J.D. Acosta-España*

SY139 **Hall 16**

14:45 – 15:45

1-hour Symposium

CLN DX

How to manage bacterial meningitis in low resource settings

Chairs *Joseph Donovan (Ho Chi Minh City, Vietnam)*
Christina Obiero (Kilifi, Kenya)

S0379 14:45 **Bacterial meningitis diagnosis and surveillance***Divya Deodhar (Muscat, Oman)*

S0380 15:05 **Clinical presentation and management of CNS infections***Kartika Maharani (Jakarta, Indonesia)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)

SY138 **Hall 4**

14:45 – 15:45

1-hour Symposium

AMR

Global clones and evolving resistance mechanisms towards newer beta-lactams: where are we heading?

Chairs *Yesim Besli (Istanbul, Türkiye)*
Spyros Pournaras (Athens, Greece)

S0377 14:45 ***Carbapenemase*****-producing Enterobacterales: the not so good, the bad and the ugly.***Arjana Tambic Andrasevic (Zagreb, Croatia)*

S0378 15:15 **The *P. aeruginosa* frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome***Katy Jeannot (Besançon, France)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EF099 **Arena 1**

14:45 – 15:45

ePoster Flash Session

AMR IPC

Infection prevention in action: innovations, insights, and global intervention

Chair *Allison Mcgeer (Toronto, Canada)*

E0706 14:45 **A *Candida auris* cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking***C. Harless* (Silver Spring, United States), E. Horishny, J. Stam, B. Corey, A. Ong, Y. Kwak, J. Bennett, P. Mcgann, F. Lebreton*

E0707 14:51 **Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios***A. Rearte* (Buenos Aires, Argentina), F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi*

E0708 14:57 **Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter season***C. Savulescu* (Paris, France), M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone*

E0709 15:03 **Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital***N. Khanafer* (Lyon, France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud*

E0711 15:09 **Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay***V. Khillan* (New Delhi, India), V.G. Nag P, P. Kale, A. Paul, A. Saran*

E0712 15:15 **Air and surface sampling around mpox Clade 1b in hospitals in the UK***S. Gould* (Liverpool, United Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning*

E0713 15:21 ***Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024****A. Baller* (Geneva, Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton*

Hurwitz, M. Moon

E0714 **15:27** **The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization** *M. Colaneri* (Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, R. Bruno*

EF100 **14:45 – 15:45** **Arena 2**

ePoster Flash Session

ANT

Cefiderocol: an efficient Trojan horse?

Chair *Anna Sramkova (Pilsen, Czechia)*

E0715 **14:45** **Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System** *B. Li* (Beijing, China), S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang*

E0716 **14:51** **The hidden link between cefiderocol resistance and increased virulence in *Klebsiella pneumoniae*: insights from a TraDIS-based investigation** *E. Eger* (Greifswald, Germany), J.U. Müller, B. Jana, M. Schwabe, Y. Ma, M. Pirolo, L. Guardabassi, K. Schaufler*

E0717 **14:57** **Resistance profiles of Carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?** *I. Baltas* (London, United Kingdom), T. Patel, A.L. Soares*

E0718 **15:03** **Impact of cefiderocol therapy on patient survival across different multi-drug resistant Gram-negative bacilli infections: insights from the SUSANA cohort.** *N. Corti* (Monza, Italy), E. Ricci, M. Faltoni, L. Mezzadri, M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro, S. Rusconi, A. Mastroianni, M.A. Carleo, G. Cenderello, L. Bisi, G. Madeddu, P. Bonfanti*

E0719 **15:09** **Decoding resistance: investigating cefiderocol's battle against carbapenem-resistant *Acinetobacter baumannii*** *Y.T. Lee* (Taipei, Taiwan)*

E0720 **15:15** **Long-read sequencing reveals novel genetic factors in cefiderocol resistance in *Pseudomonas aeruginosa* ATCC 27853: A stepwise adaptive evolution study** *M. Cardoso* (Groningen, The Netherlands), A. Kumar Bari, T. T. Severs, B.B. Xavier, B. Sinha, J. W. A. Rossen*

E0721 **15:21** **Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales clinical isolates causing infection in hospitals in Europe and adjacent regions** *R. Mendes* (North Liberty, United States), A. Scullin, D. Beekman, Z. Kockler, J.M. Maher, H.S. Sader, M. Castanheira*

E0722 **15:27** **Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing *Pseudomonas aeruginosa* from people with cystic fibrosis** *G. Fabrizio* (Rome, Italy), M. Truglio, I. Cavallo, F. Sivori, M. Francalancia, R. Riveros Cabral J, S. Petrolo, L. Pamparau, M. Comar, D. Compagnino, M. Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F. Pimpinelli, E.G. Di Domenico*

E0723 **15:33** **Activity of cefiderocol against clinical isolates of *Pseudomonas aeruginosa* collected from five European countries as part of SENTRY antimicrobial surveillance program 2020-2023** *C. Longshaw* (London, United Kingdom), J. Maher, R. Mendes, H. Yamashiro, Y. Yamano*

EF101 **14:45 – 15:45** **Arena 3**

ePoster Flash Session

VAX

Immunology of bacterial pathogens

Chair *David Ong (Zoetermeer, The Netherlands)*

E0724 **14:45** **Serotype 38 *Streptococcus pneumoniae* emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands** *K. Hajji* (Bilthoven, The Netherlands), I. Wróbel-Pawelczyk, J. Van Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens, N. Van Sorge, K. Trzciński, M. Van Der Linden, A. Skoczyńska, L. Visser*

E0725 **14:51** **Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116: a secondary analysis of five phase 3 studies** *M.A. Esteves Jaramillo* (Rahway, United States), J. Li, H. Platt, W. Hu, W. Xu, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald*

E0727 **15:03** **Protection against invasive meningococcal disease and gonorrhoea, 5 years post introduction of a 4CMenB immunisation program in infants and adolescents in South Australia** *H. Marshall* (Adelaide, Australia), B. Wang, L. Giles, P. Andraweera, M. Mcmillan, S. Almond, R. Beazley, J. Mitchell, J. Sisnowski, C. Bell, L. Flood, J. Ward*

E0728 **15:09** **Molecular epidemiology and correlates of protection among group B *Streptococcus* from carriage and disease: assessing vaccine coverage in Brazil** *T. Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E. Bressan, A. Rio Tinto, S. Fracalanzza, L. Teixeira*

E0729 **15:15** **Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants.** *R. Namakula* (Bergen, Norway), V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik*

E0730 **15:21** **Immune signature against *Klebsiella pneumoniae* proteins in a mother-baby cohort from Blantyre, Malawi** *E. Heinz* (Glasgow, United Kingdom), J. Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey*

E0731 **15:27** **A comprehensive computational mapping of B-cell epitopes in the *Klebsiella pneumoniae* porinome** *S. Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín Galiano*

E0732 **15:33** **Chronic infection induces a broadly neutralizing antibody response to Elastase B of *Pseudomonas aeruginosa*** *A. Albus* (Cologne, Germany), D. Kolling, K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybniker, A. Simonis*

KN137 **14:45 – 15:45** **Hall 1**

Keynote Lecture

TRN

Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development

Chairs *Werner Ruppitsch (Vienna, Austria)*
Annelies Zinkernagel (Zurich, Switzerland)

K0376 **14:45** *Juliane Bubeck Wardenburg (St. Louis, United States)*

ME140 **14:45 – 15:45** **Hall 11**

Meet-the-Expert

DX TRN

Bioinformatic tools from start to finish

M0381 **14:45** *Vítor Borges (Lisbon, Portugal)*
M0382 **14:57** *Clare Sloggett (Melbourne, Australia)*

ME141 **14:45 – 15:45** **Hall 13**

Meet-the-Expert

AMR CLN

AI use in antimicrobial stewardship

M0383 **14:45** *Shruti Gohil (Irvine, United States)*
M0384 **14:57** *José Ramon Pano-Pardo (Zaragoza, Spain)*

OS102 **16:15 – 17:15** **Hall 2**

1-hour Oral Session

AMR DX

AI tools empowering AMR prediction in WGS and MALDI-TOF

Chairs *Oliver Nolte (Zürich, Switzerland)*
Patricia Simner (Rochester, United States)

O0733 **16:15** **A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data** *Y. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope*

O0734 **16:27** **Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for *Klebsiella pneumoniae* from Clinical NGS Data** *Q. Yang* (Beijing, China), X. Jia, J. Zhang, J. Chen*

O0735 **16:39** **AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing** *E. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban*

O0736 **16:51** **MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence *K. pneumoniae*** *L. Dortet* (Le Kremlin-Bicêtre, France), L. Mancera Pascual, M.J. Arroyo*

O0737 **17:03** **Predicting rifampicin resistance in *Mycobacterium tuberculosis complex* with a machine learning based MALDI-TOF MS approche** *J. Yu* (Hsinchu, Taiwan), P. Huang, B. Tsou, Y.W. Sun, S.C. Chang, C.W. Lu, C.C. Chen*

LB005 **16:15 – 17:15** **Hall 3**

1-hour Oral Session

CLN

Emerging pathogens in humans, animals and vectors

Chairs *Anna J Henningsson (Jönköping, Sweden)*
Ikechukwu Benjamin Moses (Abakaliki, Nigeria)

L0026 **16:15** **Genome-wide association study identifies *ABCG1* as a susceptibility locus for tick-borne encephalitis** *P. Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek, N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová, P. Bogovic˘, J. Zajkowska, L. Krbková, V. Štruncová, A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová, M. Berankova, M. Pychova, D. Zavadska, N. Sallah, A. Pichler, D. Sedlácek, A. Chrdle, C. Haudum, B. Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L. Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A. Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz*

L0027 **16:27** **First detection of tick-borne encephalitis virus in Belgian ticks, May 2024** *E. Portell Buj* (Brussels, Belgium), C. Philippe, E. Portell-Buj, S. Terryn, S. Van Gucht, F. Dufrasne*

L0028 **16:39** **Spread of a fusidic acid and methicillin-resistant *Staphylococcus aureus* clone causing impetigo in Europe** *A.R. Larsen* (Copenhagen, Denmark), A. Petersen, L. Roer, K. Vendrik, R. Zwittink, D. Notermans, N. Yin, M. Perrin, K. Khonyongwa, A. Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H. Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M. Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K. Moganeradj, B.J. Holzknecht, H.B. Eriksen, M. Hoppe, M.D. Bartels, J.A. Samaniego Castruita*

L0029 **16:51** **Increase of PVL-positive livestock-associated MRSA in the Netherlands: a growing concern beyond livestock settings** *K. Vendrik* (Bilthoven, The Netherlands), S. Witteveen, D.W. Notermans, S.C. De Greeff, C.C. Wielders, E. Van Duijkeren, A.S. Schoffelen, A.P. Hendrickx, R.D. Zwittink*

L0030 **17:03** **H5N1 human infection in the United Kingdom: a One-Health approach** *N. Hamzaoui* (London, United Kingdom), S. Hayward, W. Proto, E. Booth, C. Kennedy, C. Beck, A. Lackenby, K. Spence, M. Beadsworth, N. Wong, M. Samuel, A. Singanayagam, K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook, N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins, C. Arevalo, D. Blackman, L. Guiness, C. Chatt, M. Mcgivern, A. Edwards, A. Banyard, R. Jorquera, K. Saville, S. Van Helvoort, R. Benee, E. Brown, L. Leighton Mcteague, M. Chand, S. Rokadiya, S. Hopkins, H.I.M. Team, N. National Response Center Team, R. Puleston*

OS103 **16:15 – 17:15** **Hall 5**

1-hour Oral Session

AMR TRN

Polymicrobial interactions and competition

Chairs *Alessandra Bragonzi (Milano, Italy)*
Kimberly Kline (Genéve, Switzerland)

O0738 **16:15** **The *Klebsiella pneumoniae* type VI secretion system effector Tle4 facilitates adaptation survival by damaging the cell membrane of competing bacteria** *W. Li* (Shanghai, China), J. Zhang*

O0739 **16:27** ***Candida albicans* promotes TSST-1 production in *Staphylococcus aureus* by depleting glucose and lifting carbon catabolite repression** *M. Carriou* (Lyon, France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A. Frugier, K. Dufresne, G. Lina*

O0740 **16:39** **Understanding polymicrobial biofilm dynamics: focus on *Pseudomonas aeruginosa* and its molecular interactions** *S. Kansal* (Chandigarh, India), U. Dutta, A. Angrup, P. Ray*

O0741 **16:51** **Intra- and interspecific antagonism inhibits growth of *Staphyloccous aureus* in human nasal microbial communities** *L. Brülisauer* (Zurich, Switzerland), M. Boumasmoud, S. Brugger, A.R. Hall*

O0742 **17:03** **Combination therapy against drug resistance biomimetic dual-species biofilm model of *Pseudomonas aeruginosa* and *Staphylococcus aureus*** *P. Mojarrad* (Helsinki, Finland), P. Tammela, T. Laaksonen, Z. Gounani*

SY143 **16:15 – 17:15** **Hall 11**

1-hour Symposium

VAX

ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients

Chairs *Elisa Cordero Matia (Seville, Spain)*
Zitta Barrella Harboe (Hillerød, Denmark)

S0389 **16:15** **Vaccination against respiratory pathogens** *Albert Vollaard (Bilthoven, The Netherlands)*

S0390 **16:45** **Other vaccines** *Olivier Epaulard (Grenoble, France)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)

SY144 **16:15 – 17:15** **Hall 14**

1-hour Symposium

PHEI VAX

What's the role of infant and maternal immunisation for paediatric RSV prevention?

Chairs *Joanne M. Langley (Halifax, Canada)*
Peter Openshaw (London, United Kingdom)

S0391 **16:15** **Pros and cons of passive infant immunisation with mAb before their first RSV season** *Federico Martinón-Torres (Santiago De Compostela, Spain)*

S0392 **16:45** **Pros and cons of maternal vaccination in preventing severe RSV infections in infants.** *Anne Vergison (Luxembourg, Luxembourg)*

SY142 **16:15 – 18:15** **Hall 4**

2-hour Symposium

DX TRN

Precision genomics to improve infectious diseases management

Chairs *Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)*
Nicole Stoesser (Oxford, United Kingdom)

S0385	16:15	**Human genomics approaches to infection immunity** *Fergus Hamilton (Bristol, United Kingdom)*
S0386	16:45	**Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance** *Marco Galardini (Hannover, Germany)*
S0387	17:15	**Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections** *Stefano Giulieri (Melbourne, Australia)*
S0388	17:45	**Machine learning in bacterial genomics and metagenomics** *Francesco Asnicar (Trento, Italy)*

EA — **16:15 – 17:30** — **Hall 1**

Awards

PRO

Excellence Award Lectures

Chairs *Jon S. Friedland (London, United Kingdom)*
Robert Leo Skov (Copenhagen, Denmark)

A006	16:15	**Towards pandemic prevention, moonshot or utopia?** *Marion Koopmans (Rotterdam, The Netherlands)*
A007	16:50	**Can global warming bring new infectious diseases?** *Arturo Casadevall (Baltimore, United States)*

EW146 — **16:15 – 18:15** — **Hall 13**

Educational Session

IPC

How to detect, manage and communicate hospital outbreaks

Chairs *Margaret Ip (Shatin, Hong Kong)*
Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)

W0395	16:15	**How to detect hospital outbreaks** *David Fisman (Toronto, Canada)*
W0396	16:35	**How to confirm hospital outbreaks using genomics** *John W. A. Rossen (Groningen, The Netherlands)*
W0397	16:55	**How to rapidly respond to an ongoing hospital outbreak** *Ermira Tartari (Msida, Malta)*
W0398	17:15	**How to communicate hospital outbreaks via scientific publication** *Ines Steffens (Solna, Sweden)*

EF104 — **16:15 – 17:15** — **Arena 1**

ePoster Flash Session

DX PHEI

Cutting-edge technologies to improve viral diagnostics

Chair *Patricia Alvarez (Rio De Janeiro, Brazil)*

E0743	16:15	**How straightforward is the switch from qPCR to dPCR in a routine lab setting for quantification of Varicella-zoster virus in CSF samples** *A. Baumhögger* (Bochum, Germany), T. Bähr, G. Geis, S. Gatermann*
E0744	16:21	**A novel biosensor for the detection of RSV infection** *C. Zannella* (Naples, Italy), F. Passeggio, F. Napolitano, A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L. Zeni, M. Galdiero, G. Portella, N. Cennamo*
E0745	16:27	**Insufficient sexual health bloods don't always need throwing away!** *S. Hutchings* (Bristol, United Kingdom), R. Hopes, P. North, W. Stoate, M. Murphy, G. Beckley, J. Gabb*
E0746	16:33	**A comparison of 4 HAV serology assays: the value of consensus results as a reference standard** *T. Chin* (Ghent, Belgium), E. Padalko*
E0747	16:39	**Advancing herpesvirus diagnostics: clinical evaluation of a high-performance real-time PCR assay** *H. Alonso-Ezcurra* (Zaragoza, Spain), S. Lucea, C. Escolar, H. Alonso*
E0748	16:45	**Evaluation of microbiological techniques for the diagnosis of West Nile Virus in the Virgen del Rocío hospital area (Sevilla, Spain).** *M. Aznar Fernandez* (Seville, Spain), M. Aznar, C. Lozano, L. Merino, M.J. Pérez, J.L. Garcia, C. Cintora, J.A. Lepe*
E0749	16:51	**Development of Non-Cross-Reactive Monoclonal Antibodies Against West Nile Virus and Usutu Virus Non-Structural Protein 1 to Improve Early Diagnosis** *M. Ceconi* (Antwerp, Belgium), K. Ariën, P. Delputte*
E0750	16:57	**Enhancing Diagnostics and Global Standards through the QCMD Viral Metagenomics EQA** *G. Sutton* (Glasgow, United Kingdom), D. Montgomery, E. Mcculloch, A. Ricketts*
E0751	17:03	**Analysis of HIV-1 drug-resistence in newly diagnosed subjects using Next Generation Sequencing** *V. Micheli* (Milan, Italy), F. Bracchitta, L. Morelli, A. Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci*

EF105 — **16:15 – 17:15** — **Arena 2**

ePoster Flash Session

ANT CLN TRN

New data in non-tuberculous mycobacterial disease

Chair *Lorenzo Guglielmetti (Paris, France)*

E0752	16:15	**Deciphering genotypic resistance to amikacin in *Mycobacterium abscessus* using whole genome sequencing and a specific pipeline (GenoMAB)** *C. Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau*
E0753	16:21	***Pseudomonas aeruginosa* rapidly kills *Mycobacterium abscessus* in dual-species biofilms *in vitro*** *M. Mcdaniel* (Nijmegen, The Netherlands), J. Scoffield, J. Van Ingen*
E0754	16:27	**Distribution of contezolid in different tissues of mice and human patients infected with *Mycobacterium abscessus*** *W. Nie* (Beijing, China), N. Chu*
E0755	16:33	**Exploration of clofazimine and bedaquiline activity against clinical strains of *Mycobacterium abscessus* to advance innovative therapeutic strategies** *M. Cano Fernández* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea*
E0756	16:39	**Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria** *S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan*
E0757	16:45	**Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany** *N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus*
E0758	16:51	**Deciphering the Epidemiology of *Mycobacterium chimaera*: Genetic Lineages, Environmental Sources, and Infection Prevention Insights** *G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo*
E0759	16:57	**Evaluation of a novel media for susceptibility testing of *Mycobacterium avium-intracellulare* complex isolates** *T. Grams* (Salt Lake City, United States), S. Shakir*
E0760	17:03	**Emerging cases of *Mycobacterium chelonae* endocarditis associated with *BioIntegral* bioprostheses** *J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter*

EF106 — **16:15 – 17:15** — **Arena 3**

ePoster Flash Session

ANT CLN

The ABC (allergy, bloodstream infections and clinical decision support) in AMS

Chair *Céline Pulcini (Nancy, France)*

E0761 **16:15** **Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study** *D. Wets* (Leuven, Belgium), G. Van De Sijpe, L. Gilissen, C. Breynaert, T. Ieven, P. De Munter, R. Schrijvers, I. Spriet*

E0762 **16:21** **Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial.** *J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt*

E0763 **16:27** **Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage** *X. Li* (Toronto, Canada), K. Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky*

E0764 **16:33** **Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus* (PRIMEKA): A Retrospective Single-Center Cohort Study.** *F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti*

E0765 **16:39** **The inappropriate use of antibiotics for blood culture contamination and colonisation by multidrug-resistante microorganisms: the role of counselling on antibiotic prescription** *R.R. Peña-Zalbidea* (Palma (balearic Islands), Spain), L. Martin, H. Vilchez, L. Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera, X. Mulet, A. Oliver, J. Murillas*

E0766 **16:45** **Factors influencing meropenem prescription following the 2020 EUCAST « I » definition update : a multicentric observational study in Belgian hospitals** *L. Catteau* (Brussels, Belgium), L. Bonacini*

E0767 **16:51** **Impact of an Antimicrobial Stewardship Mobile Application on Antimicrobial Prescribing, Length of Hospital Stay, and Cost Savings** *Z.O.E. Babiker* (Abu Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, R. Ali, J. Shamseddine*

E0768 **16:57** **Evaluation of a model-based clinical decision support system for empirical antimicrobial therapy** *M.L. Mogensen* (Aalborg, Denmark), S.N. Søgaard, L. Ward, H. Skjøt-Arkil*

E0769 **17:03** **A rapid systematic review of criteria to facilitate prompt intravenous-to-oral antimicrobial switch in children and young people in England.** *R. Oettle* (London, United Kingdom), S. Patel, A. Demirjian, M. Mcleod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-Oredope*

JS2 **Hall 16**

16:15 – 17:15

Journal Session

CLN

Late-breaker research from the Lancet group: new interventions for familiar and new infectious diseases

Chairs *Syeda Saleha Hassan (London, United Kingdom)*
Ursula Hofer (London, United Kingdom)

J011 **16:15** **Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1)** *Janet Wilson (Leeds, United Kingdom)*

J012 **16:30** **The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America** *Jan Felix Drexler (Berlin, Germany)*

J013 **16:45** **The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistance** *Hatim Sati (Geneva, Switzerland)*

J014 **17:00** **Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three RSV seasons: a randomized trial** *Alberto Papi (Ferrara, Italy)*

Co-organised with: The Lancet group

ME145 **Hall 15**

16:15 – 17:15

Meet-the-Expert

CLN DX

Fungal meningitis: recognition and current status of management

M0393 **16:15** *Olivier Lortholary (Paris, France)*

M0394 **16:27** *Janis Blair (Phoenix, United States)*

OS109 **Hall 16**

17:30 – 18:30

1-hour Oral Session

PRO

Training CM/ID: a global view

Chairs *Mihai Mares (Iasi, Romania)*
Priya Nori (New York, United States)

O0780 **17:30** **Specialist training in infectious diseases in Europe** *J. Salmanton-Garcia* (Cologne, Germany), J. Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró, A. Verbon, O.A. Cornely, N. Beeching*

O0781 **17:42** **Infectious Diseases Residency Training over the World** *P. Irkören* (Zeytinburnu/istanbul, Türkiye), P. Irkoren, C. Cimen, S. Keske, Ö. Ergönül*

O0782 **17:54** **Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network.** *A. Tostmann* (Nijmegen, The Netherlands), E. Schoeman, B. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman, C. Azzouz, S. Mehtar*

O0783 **18:06** **Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe.** *D. Hettle* (Harare, Zimbabwe), T. Mwaturura, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer*

O0784 **18:18** **Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings.** *H. Pailhoriès* (Angers, France), H. Pailhories, C. Zins, R. Chenouard, M. Kempf, M. Eveillard*

OS107 **Hall 3**

17:30 – 18:30

1-hour Oral Session

VAX

Novel vaccines in clinical development

Chairs *Paul Adepoju (Ibadan, Nigeria)*
Mateusz Hasso-Agopsowicz (Geneva, Switzerland)

O0770 **17:30** **Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years** *M. Messier* (Lyon, France), L. Wagner, R. Hochreiter, J. Larcher-Senn, E. Lamberth, R. Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach*

O0771 **17:42** **Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial** *H. Hiruy* (Cambridge, United States), R. Lazarus, K. Mccafferty, K. Cohen, R. Dhar, T. Rizk, A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav*

O0772 **17:54** **Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial** *A. Hannaford* (Boston, United States), D. Leitner, M. Desjardins, M. Suzuki, L. Carr,*

D. Slater, H. Levine, H. Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B. Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S. Walsh, M. Waldor, L. Baden

O0773 **18:06** **Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years** *L. Oostvogels* (Frederiksberg, Denmark), A. Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux-Roels*

O0774 **18:18** **Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme** *L. Tindale* (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell*

OS108 **17:30 – 18:30** **Hall 5**

1-hour Oral Session

CLN IPC

Novel approaches to preventing device-related infections

Chairs *Natividad Benito (Barcelona, Spain)*
Preeti Malani (Ann Arbor, United States)

O0775 **17:30** **Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.** *M. Sanz De Mena* (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada*

O0776 **17:42** **Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial AntiRedMen** *S. Scheithauer* (Goettingen, Germany), N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr, O. Moerer, V. Rohde*

O0777 **17:54** **Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis** *A. Mahajan* (Melbourne, Australia), C. Robson*

O0778 **18:06** **A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients** *J. Guerrero* (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go*

O0779 **18:18** **Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients** *N. Imhasly* (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein*

SY147 **17:30 – 18:30** **Hall 11**

1-hour Symposium

PHEI

Avian influenza in mammals: jumps under the radar

Chairs *Patricia Antunes (Porto, Portugal)*
Ana Vale (Dublin, Ireland)

S0399 **17:30** **Threat of highly pathogenic avian influenza to non-traditional hosts, including humans** *Thijs Kuiken (Rotterdam, The Netherlands)*

S0400 **18:00** **Recent changes in the epidemiology of avian influenza in relation to human health risks** *Ron Fouchier (Rotterdam, The Netherlands)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

SY148 **17:30 – 18:30** **Hall 15**

1-hour Symposium

CLN

Echinococcosis: neglected but expanding

Chairs *Daniel Grupel (Jerusalem, Israel)*
Francesca Tamarozzi (Negrar-Verona, Italy)

S0401 **17:30** **Expansion and diversity of cystic echinococcosis** *Pedro Legua (Lima, Peru)*

S0402 **18:00** **Management of echinococcosis: evidence, eminence and new developments** *Beate Grüner (Ulm, Germany)*

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

EF110 **17:30 – 18:30** **Arena 1**

ePoster Flash Session

ANT CLN DX

Advancing diagnostics and treatment of endocarditis

Chair *Benoit Guery (Lausanne, Switzerland)*

E0785 **17:30** **18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditis** *J.M. Prins* (Amsterdam, The Netherlands), S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff*

E0786 **17:36** **Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials** *M. Papadimitriou Olivgeris* (Sion, Switzerland), M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourré, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse*

E0787 **17:42** ***In vivo* Dalbavancin efficacy against methicillin-resistant *Staphylococcus aureus* (MRSA) and high-level aminoglycoside resistant (HLAR) *Enterococcus faecalis* (EFAE) experimental endocarditis model.** *C. Garcia De La Maria* (Barcelona, Spain), C. García De La Mària, M.A. Cañas, M. Brunet, J. García-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro*

E0788 **17:48** **Identification and validation of clinical phenotypes in Staphylococcus aureus blood stream infection and their association with mortality (FEN-AUREUS study)** *J. Rodríguez-Baño* (Seville, Spain), B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés*

E0789 **17:54** **Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes** *M. Singh* (London, United Kingdom), C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias*

E0790 **18:00** **Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort** *C. Meyer-Schwickerath* (Cologne, Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung*

E0791 **18:06** **The optimal management of *Enterococcus faecium* catheter-related bloodstream infections: a gap to bridge** *I. Rancan* (Florence, Italy), M. Rinaldi, F. Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella*

E0792 **18:12** **Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant *Enterococcus faecalis*** *O. Funk* (Brooklyn, United States), I. Khan, J. Li, J. Cusumano*

E0793 18:18 **Risk factors for in- hospital mortality in 500 cases of infective endocarditis** *C. Lamas* (Rio De Janeiro, Brazil), G. Pompeo, T. De Almeida, M. De Carvalho, N. Feijoó, R. Garrido, G. Barbosa, B. Zappa, C. Weksler, M. Correia, W. Golebiovski*

EF111 **17:30 – 18:30** **Arena 2**

ePoster Flash Session

CLN

Don't blink: STIs are everywhere

Chair *Mathew Beale (Hinxton, United Kingdom)*

E0794 17:30 **Neurosyphilis and Mpox co-infection mimic HIV encephalitis** *L. Mejdoubi* (Vienna, Austria), A. Nader, L. Mautner, A. Bahrami, F. Hofer*

E0798 17:42 **Ocular Syphilis, an uncommon presentation form of syphilis: two cases** *R. Kardashi* (Dresden, Germany), A. Frenz, K. De With*

E0799 17:48 **Case report of a severe skin infection in a young man on PrEP and DoxyPEP** *M. Holub* (Prague, Czechia), M. Zlámal, Z. Bartovská, B. Lacmanová*

E0800 17:54 **Serowaffling in PrEP Users: The Difficulty of HIV Diagnosis – A Case Report.** *P. Pillado Alonso* (Badalona, Spain), G. Fernández Rivas, A. Rivero Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J. Martínez-Picado*

E0801 18:00 **Severe disseminated mpox in a patient with advanced HIV: A case report** *M.A. Quadros Flores* (Lisbon, Portugal), R. Diogo, F. Gonçalves, T. Marques, S. Paulo, F. Cota Medeiros, D. Mendes Pedro*

E0802 18:06 **Sensorimotor polyneuropathy in a patient affected by HIV-1: an atypical presentation of neurosyphilis associated to anti-SOX-1 antibodies** *A. Lippi* (Siena, Italy), L. Ancillotti, M. Fabbiani, L. Migliorini, S. Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C. Puttini, F. Montagnani*

EF112 **17:30 – 18:30** **Arena 3**

ePoster Flash Session

AMR ANT CLN

Clinical considerations in resistant organisms

Chair *Divya Deodhar (Muscat, Oman)*

E0803 17:30 **Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicenter clinical experience** *F. Serapide* (Catanzaro, Italy), R. Serraino, L. Spadafora, M. Bernardi, G. Brucci, G. Cattardico, S. Corcione, I. De Benedetto, M. Del Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M. Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo, A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C. Mussini, A. Russo*

E0804 17:36 **Clinical outcomes of MSSA bacteremia exhibiting the cefazolin inoculum effect and development of a novel diagnostic method** *S. Yoshizawa* (Ota-Ku, Japan), T. Sato, K. Komori, K. Yamada, T. Yamaguchi, K. Tateda*

E0805 17:42 **Third- and fourth-generation cephalosporins for the treatment of infections due to OXA48 carbapenemase-producing Enterobacterales** *A. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Sastre-Escolà, J. Camara Mas, F. Tubau Quintano, R. Costa, A. Padulles, E. Shaw, C. Gudiol, M. Puig-Asensio*

E0806 17:48 **Are meropenem or imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections?** *A. Peters* (Santiago, Chile), S. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino, L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L. Rioseco, J. Moreno, R. Araos, P. Garcia, P.D. Tamma, J.M. Munita*

E0807 17:54 **Oral Fosfomycin after Carbapenems as de-escalating therapy in Complicated Urinary Tract Infection: A randomized controlled trial** *K. Angkanavisan* (Bankgkok, Thailand), B. Sakboonyarat, C. Ungthammakhun*

E0808 18:00 **Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and *Pseudomonas aeruginosa* infections on hospital discharge: the next frontier for oral switch?** *C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve*

E0809 18:06 ***Metallo-[]-lactamase* colonization and subsequent risk of infection: a retrospective study.** *C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni*

E0810 18:12 **Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study** *M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyol, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi*

E0811 18:18 **Prognostic factors and role of clinical management in carbapenem-resistant *Acinetobacter baumannii* bacteraemia: results from a prospective, international, multicentre cohort (EURECA)** *F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goosens, M.J.M. Bonten, J. Rodríguez-Baño*

ME149 **17:30 – 18:30** **Hall 2**

Meet-the-Expert

AMR DX

How to perform molecular surveillance of multidrug resistant bacteria

M0404 17:30 *Henrik Hasman (Copenhagen, Denmark)*

M0403 17:42 *Martina Lengerova (Brno, Czechia)*

Tuesday, 15 April 2025

OS113 **08:30 – 10:30** **Hall 11**

2-hour Oral Session

AMR ANT TRN

Knockin' on science's door: new antimicrobial solutions

Chairs *Sandrine Marchand (Poitiers, France)*
Ursula Theuretzbacher (Vienna, Austria)

O0812 08:30 **Chimerbactin: a hybrid antibiotic for persistent Gram-positive infections that overcomes resistance development** *R. Lee* (Memphis, United States), Y. Zhao, A. Arya, R. Conlin, G. Phelps, C. Dunn, E. Griffith, J. Portelinha, N. Chumbler, V. Loudon, I. Lister, S. Zia, K. Urish, K. Lewis, M. Lafleur*

O0813 08:42 **A Novel Klebicin Cocktail to Treat Lung Infection Caused by *Klebsiella pneumoniae*** *V.D. Paul* (Bangalore, India), A. Ambady, U. Chopra*

O0814 08:54 **Thiophene derivatives: A promising solution against MDR Gram-negative bacilli** *Y. Smani* (Seville, Spain), I. Molina Panadero, Á. Rey Hidalgo, M. Morales-Tenorio, A. García-Rubia, T. Samernate, P. Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón, C. Gil*

O0815 09:06 **Molecular insight into non-lytic polyproline peptide**

		disruption of *Klebsiella pneumoniae* biofilms *R. Fleeman* (Orlando, United States), R. Beckman Iv, B. Victoria, L. Suits, P. Eswara*
O0816	09:18	**Reverting cefotaxime resistance in CTX-M-15-producing *Escherichia coli* using Targeted-Antibacterial-Plasmids (TAPs): a CRISPR-Cas9 approach.** *N. Roson Calero* (Barcelona, Spain), N. Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P. Bogaerts, C. Lesterlin*
O0817	09:30	**Structural and functional characterization of LysSM5: An innovative endolysin from Salmonella Phage vB_SenA_SM5** *K. Sharma* (Chandigarh, India), H. Kaur, N. Chaudhary, S. Prajapati, B. Mohan, N. Taneja*
O0818	09:42	**Rational step-by-step design of a two-phage cocktail against a contemporary *A. baumannii* strain recovered from a burned patient at CHUV.** *G. Resch* (Lausanne, Switzerland), H. De Villiers De La Noue, G. Golliard, X. Vuattoux*
O0819	09:54	**A novel antibiotic class targeting the enolase of *Acinetobacter baumannii*** *I. Molina Panadero* (Seville, Spain), A. Moreno Rodríguez, Á. Rey Hidalgo, L. Tomás Gallardo, M. De La Cruz, P. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic, O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani*
O0820	10:06	**Reviving antibiotic potency: Pharmacological Assessment of JS238 a newly designed potentiator against *P. aeruginosa*** *P. Rasouli* (Brussels, Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke*
O0821	10:18	**Advancements in combating tularemia: Novel therapeutic strategies targeting *Francisella tularensis*** *S. Guillier* (Brétigny-Sur-Orge, France), M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde, C. Demeure, J. Pizarro Cerda, G. Guichard, G. Compain, D. Burnouf, O. Gorgé, J. Wagner*

SY152 — **Hall 12**

08:30 – 10:30

2-hour Symposium

PHEI VAX

Out of the spotlight or out of reach? Vaccination of hard-to-reach groups

Chairs — *Olivier Epaulard (Grenoble, France)*, *Justyna Kowalska (Warsaw, Poland)*

S0413	08:30	**Ukrainian war refugees and vaccination attitudes: experience from Poland** *Maria Ganczak (Zielona Gora, Poland)*
S0414	09:00	**Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama** *Alfonso J. Rodriguez-Morales (Pereira, Colombia)*
S0415	09:30	**Are penitentiary systems ready for introducing vaccination programmes?** *Lara Tavoschi (Pisa, Italy)*
S0416	10:00	**HPV and other essential vaccinations for sex workers** *Debora Konopnicki (Brussels, Belgium)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SY153 — **Hall 13**

08:30 – 10:30

2-hour Symposium

CLN

Breaking new ground in febrile neutropaenia management

Chairs — *Murat Akova (Ankara, Türkiye)*, *Stefan Schwartz (Berlin, Germany)*

S0417	08:30	**Do we need to redefine the concept of febrile neutropaenia in the era of immunotherapy?** *Manuela Aguilar-Guisado (Seville, Spain)*
S0418	09:00	**Should some patients be empirically treated with combination therapy?** *Dina Averbuch (Jerusalem, Israel)*
S0419	09:30	**Role of new antibiotics in febrile neutropaenia** *Malgorzata Mikulska (Genoa, Italy)*
S0420	10:00	**Can treatment strategies be personalised using AI or new diagnostic tools?** *Carolina Garcia Vidal (Barcelona, Spain)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)

SY154 — **Hall 14**

08:30 – 10:30

2-hour Symposium

AMR PHEI

Using mathematical and epidemiological models to identify the drivers of AMR

Chairs — *Marc J.M. Bonten (Utrecht, The Netherlands)*, *Sarah Tschudin Sutter (Basel, Switzerland)*

S0421	08:30	**Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution?** *Roger Kouyos (Zürich, Switzerland)*
S0422	09:00	**Inferring the determinants of AMR dynamics across bacterial pathogens** *Lulla Opatowski (Paris, France)*
S0423	09:30	**Modelling the evolution of resistance** *Erida Gjini (Lisbon, Portugal)*
S0424	10:00	**Assessing the associations of microbiome and socio-demographic dynamics on AMR** *Katariina Pärnänen (Helsinki, Finland)*

SY150 — **Hall 3**

08:30 – 10:30

2-hour Symposium

ANT

Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges

Chairs — *Lindsey Ann Edwards (London, United Kingdom)*, *Ed J. Kuijper (Leiden, The Netherlands)*

S0405	08:30	**How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?** *William Fusco (Rome, Italy)*
S0406	09:00	**What to check? – An attempt at evidence-based donor screening** *Elisabeth Terveer (Leiden, The Netherlands)*
S0407	09:30	**What are the right bugs – Developing LBPs out of FMTs** *Lena Biehl (Cologne, Germany)*
S0408	10:00	**What's up next? – Hot LBP candidates** *Ilan Youngster (Beer Yaakov, Israel)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)

SY151 — **Hall 4**

08:30 – 10:30

2-hour Symposium

CLN

News in endocarditis care

Chairs — *Michele Bartoletti (Milan, Italy)*, *Pilar Retamar Gentil (Seville, Spain)*

S0409	08:30	**Endocarditis guidelines: what is new?** *Siegbert Rieg (Freiburg, Germany)*
S0410	09:00	**Oral therapy and outpatient care** *Laura Escolà-Vergé (Barcelona, Spain)*
S0411	09:30	**PK/PD aspects of endocarditis antibiotic therapy** *Fekade Bruck Sime (Brisbane, Australia)*
S0412	10:00	**The Endocarditis Team: there is no way to work alone** *Barbara Hasse (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)

EW157 — **Hall 15**

08:30 – 10:30

Educational Session

DX PHEI

Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases

Chairs *Ana Alastruey-Izquierdo (Madrid, Spain)*
Rita Oladele (Lagos, Nigeria)

W0433	**08:30**	**Advances and gaps in the diagnosis and treatment of histoplasmosis** *Diego Rodrigues Falci (Porto Alegre, Brazil)*
W0434	**08:50**	**Paracoccidioidomycosis: an update on diagnostic challenges** *Beatriz L. Gomez (Bogota, Colombia)*
W0435	**09:10**	**What is new in Talaromycosis** *Brown Lottie (London, United Kingdom)*
W0436	**09:30**	**Mycetoma: treatment challenges of a unique neglected tropical disease** *Borna Nyaoke-Anoke (Nairobi, Kenya)*

EW155 **08:30 – 10:30** **Hall 2**

Educational Session

DX PHEI

An update on arboviral disease challenges

Chairs *Misa Korva (Ljubljana, Slovenia)*
Anna Papa-Konidari (Thessaloniki, Greece)

W0425	**08:30**	**The global epidemiology of arboviral diseases** *Chantal B.E.M. Reusken (Bilthoven, The Netherlands)*
W0426	**08:50**	**Arboviral diseases transmitted by mosquitoes** *Luisa Barzon (Padua, Italy)*
W0427	**09:10**	**Aboviral diseases transmitted by ticks** *Joanna Maria Zajkowska (Białystok, Poland)*
W0428	**09:30**	**Arboviral diseases transmitted by sandflies** *Rémi Charrel (Marseille, France)*

Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists

---

EW156 **08:30 – 10:30** **Hall 5**

Educational Session

PRO

The rules of the game: how to tackle the peer-review and publication process

Chairs *Christian Kraef (Copenhagen, Denmark)*
Oana Sandulescu (Bucharest, Romania)

W0429	**08:30**	**Communicating with journals, editors and reviewers** *Angela Huttner (Geneva, Switzerland)*
W0430	**08:50**	**The Wild West of predatory journals** *Ursula Hofer (London, United Kingdom)*
W0431	**09:10**	**Communicating your publications on social media** *Neil Stone (London, United Kingdom)*
W0432	**09:30**	**Re-imagining peer review** *Amelia Joseph (Nottingham, United Kingdom)*

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors

---

EF114 **08:30 – 09:30** **Arena 1**

ePoster Flash Session

DX

Innovations and insights in diagnosing parasitic infections

Chair *Pikka Jokelainen (Copenhagen, Denmark)*

E0822	**08:30**	**Evaluation of a multiplex beads assay for the simultaneous detection of serum antibodies in neurocysticercosis patients.** *A. Lopez Alva* (Lima, Peru), P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H. Garcia Lescano*
E0823	**08:36**	**Development and evaluation of real-time loop mediated isothermal amplification assay for rapid detection of hookworm (Ancylostoma duodenale) in human fecal samples** *M. Thakur* (Chandigarh, India), S. Khurana, A. Mewara, L. Pvm*
E0824	**08:42**	**Exploring Genotypic Prevalence and Transmission of Cryptosporidium and Giardia in Immunocompromised Patients: A Dual Approach with Modern Molecular Methods: MLST & nested real-time HRM** *P. Rani* (Chandigarh, India), P. Datta, S.L. Bhasin, P. Malhotra, S.S. Rana, R. Sehgal*
E0825	**08:48**	**Prevalence and diagnostic accuracy of different diagnostic tests for Chagas disease in the Paraguayan Chaco** *S. Ardiles Ruesjas* (Saarbruecken, Germany), S. Ardiles-Ruesjas, V. Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C. Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S. Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I. Losada*
E0826	**08:54**	**Development and validation of an artificial intelligence model for detection of gastrointestinal parasites from concentrated wet-mount stool examinations** *M.R. Couturier* (Salt Lake City, Ut, United States), B. Mathison, K.A. Knight, J.R. Potts, F. Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L. Bess, W. Hymas*
E0827	**09:00**	**Evaluation of KU-F40 automated microscope for diagnosis of intestinal parasitic infections : will AI rescue old-time microscopy ?** *A. Aupaix* (Hornu, Belgium), L. Filippin, I. Mansoor, M. Chemais, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner*
E0828	**09:06**	**Improving vector surveillance: evaluating a real-time PCR assay for *Leishmania* DNA detection in sandflies** *H. Alonso-Ezcurra* (Zaragoza, Spain), M.P. Peris, I. Ruiz-Arrondo, J.A. Castillo, D. Martínez-Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso*
E0829	**09:12**	**Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess** *R. Fleury* (Besançon, France), M.P. Brenier-Pinchart, P. Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet*

EF115 **08:30 – 09:30** **Arena 3**

ePoster Flash Session

DX PHEI

New genomic methods in clinical microbiology

Chair *Natacha Couto (Oxford, United Kingdom)*

E0831	**08:30**	**Prediction of antimicrobial minimum inhibitory concentration from *Escherichia coli* whole genome sequence data using machine learning** *A. Gerada* (Liverpool, United Kingdom), N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope*
E0832	**08:36**	**Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing** *A. Ramette* (Bern, Switzerland), L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander*
E0833	**08:42**	**Prediction of antibiotic resistance in *Pseudomonas aeruginosa*, *Escherichia coli* and *Klebsiella pneumoniae* from genomic data using machine learning and deep learning approaches** *E. Denakpo* (Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga*
E0834	**08:48**	**Machine learning pipeline accelerates identification of diagnostic targets for *Neisseria gonorrhoeae*** *A. Verich* (Sydney, Australia), P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany, T. Applegate, D. Bauer*
E0835	**08:54**	**Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cgMLST Polisher** *N. Scherff* (Muenster, Germany), J. Rothgänger, D. Harmsen*
E0836	**09:00**	**Developing a core genome MLST (cgMLST) for *Mycoplasma pneumoniae*** *C. Dixon* (Cardiff, United Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauteur, G. Greub, N. Couto, M.L. Beeton*
E0837	**09:06**	**Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space** *S. Branders* (Hamar,*

Norway), M. Grabherr, R. Ahmad

E0838 09:12 **VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome** *J. Li* (Shenzhen, China), F. Yang, L. Xiong, X. Feng, H. Zhong*

E0839 09:18 **Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens** *A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, A. Hatzigeorgiou*

CGR **08:30 – 10:30** **Hall 1**

Special Session

CLN

Clinical Grand Round

Chair *Robert C. Read (Southampton, United Kingdom)*

Experts *Nina Khanna (Basel, Switzerland)*
Dimitrios P. Kontoyiannis (Houston, Tx, United States)
Lior Nesher (Beersheba, Israel)
David L. Paterson (Singapore, Singapore)
Priscilla Rupali (Vellore, India)
Monica Slavin (Melbourne, Australia)

CGR01 **Case 1** *L. Bertolino* (Napoli, Italy), R. Gallo, A.M.C. Peluso, F. Patauner, O. Infante, F. Luciano, A. Vulcano, L. Panico, E. Durante Mangoni*

CGR03 **Case 2** *Sima Sharara (Baltimore, United States)*

CGR02 **Case 3** *J.A. Lee* (Taipei, Taiwan), C.T. Yuan, Y.T. Huang, C.Y. Huang, Y.H. Wang, M. Tseng*

CGR07 **Case 4** *C. Wong* (Victoria, Australia), M. Tang, C. Aboltins, L. Gardner, Y. Hersusianto*

CGR13 **Stealth pathogens: cough and confusion** *K. Malur* (Mumbai, India), N. Shah, A. Sunavala, S. Basu, C. Rodrigues, U. Agrawal*

CGR04 **Case 6** *F. Pinto Ferreira* (Porto, Portugal), F. Faria, D. Nogueira, M. Pinto Alves, S. Almeida, C. Miranda, I. Furtado, A. Ludgero Vasconcelos*

CGR06 **Case 7** *Armani Hawes (Baltimore, United States)*

Co-organised with: Infectious Diseases Society of America (IDSA)

EF116 **09:30 – 10:30** **Arena 2**

ePoster Flash Session

CLN DX TRN

Sepsis revolutions: from machines to molecules

Chair *Pierluigi Del Vecchio (Rome, Italy)*

E0840 09:30 **Machine learning enabled prediction of blood stream infection in emergency department attendees.** *C. Rosato* (Liverpool, United Kingdom), S. Aston, A. Velluva, A. Howard, W. Hope*

E0841 09:36 **Utilizing Automation to Streamline the Blood Culture Process: Enhancing Efficiency and Patient Outcomes** *J. Qin* (Shanghai, China), M. Li, Z. Shen*

E0842 09:42 **Implementation of a bundle for Gram-negative bloodstream infection: impact on mortality and MDT/DTT carriage** *C. Bonazzetti* (Bologna, Italy), A. Grechi, D. Gibertoni, L. Mangione, F. Todisco, N. Caroccia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi, A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P. Viale, M. Giannella*

E0843 09:48 **A matter of time: impact of time to first follow-up blood cultures in patients with candidemia and *Staphylococcus aureus* bacteremia from a retrospective cohort** *P. Valsecchi* (Pavia, Italy), E. Bono, A. Valeretto, S. Resuli, M. Corbella, P. Cambieri, E. Seminari, R. Bruno*

E0844 09:54 **Characteristics of infections and outcomes in patients with left ventricular assist devices** *N. Sarı* (Ankara, Türkiye), E. Ateş, Ç. Sarıkaş, Ö. Kurt Azap, Ç. Erol, A. Sezgin*

E0845 10:00 **$Nb_2(Sn_{0.7}Cu_{0.3})C$ MAX phase for anti-infection therapy via hyperthermia-mediated bacterial metabolic interference** *M. Yang* (Chengdu, China)*

E0846 10:06 **Age-Dependent Plasma Lipidomic Alterations and Immune Correlations in Sepsis: Insights into Disease Severity and Biomarker Potential** *Y. Sun* (Shanghai, China), K. Lin, L. Wang, J. Ai, J. Zhao, X. Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin*

E0847 10:12 **Aberrant integrin activation causes transmigration defects in S100A9$^{-/-}$ neutrophils during sepsis** *S. Mülder* (Münster, Germany), N. Ludwig, J. Rossaint, T. Vogl*

E0848 10:18 **Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo-ß-lactamase-producing *Pseudomonas aeruginosa*.** *S. Herrera-Espejo* (Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos-Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-Ibáñez, P. Nordmann*

EF117 **09:30 – 10:30** **Arena 4**

ePoster Flash Session

CLN IPC

C. diff challenges: insights into treatment, monitoring, and infection prevention

Chair *Kerrie Davies (Leeds, United Kingdom)*

E0849 09:30 **Epidemiology, risk factors, and outcomes of nosocomial *Clostridioides difficile* infections: a cohort study in a tertiary hospital.** *L. Ruiz Salazar* (Madrid, Spain), T. Mata Forte*

E0850 09:36 **Long-read or short-read sequencing in *Clostridioides difficile* infection surveillance?** *M. Brajerová* (Prague, Czechia), M. Brajerova, P. Kinross, P. Drevinek, M. Krutova*

E0851 09:42 **"Beyond C. difficile Colitis": Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with Clostridioides difficile colitis.** *D.F. Bavaro* (Milan, Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Medioli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti*

E0853 09:48 **Comparison of bezlotoxumab versus no-bezlotoxumab on recurrence in high-risk patients with *Clostridioides difficile* infection** *C. Arena* (Detroit, United States), A. Abed, R. Kenney, A. Shallal, S. Davis, M. Veve*

E0854 09:54 **Exploring bacterial contributors to *C. difficile* colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice** *E. Montenegro-Borbolla* (Lausanne, Switzerland), L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery*

E0855 10:00 **An optimised vancomycin dosing regimen is effective against *C. difficile*, reduces gut microbiota impact and prevents recurrent *C. difficile* infection in a human in vitro gut model.** *J. Freeman* (Leeds, United Kingdom), C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies*

E0856 10:06 **Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory Clostridioides difficile infection** *M. Engelhard* (Cologne, Germany), I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff*

E0857 10:12 **Impact of a cohorting intervention on the incidence of hospital-acquired Clostridioides difficile infection (CDI): an interrupted time series analysis** *C.D. Moschopoulos* (Athens, Greece), M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha*

OS119 **11:00 – 12:00** **Hall 7**

1-hour Case Session

CLN

Looking inside endovascular infections

Chairs *Claus Moser (Copenhagen, Denmark)*
Matthaios Papadimitriou Olivgeris (Sion, Switzerland)

O0863 11:00 **A Case of Persistent *Legionella micdadei* Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges** *V. Zwart* (Breda, The Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen*

O0864 11:11 **Management and Prognosis of Vascular Endograft Infections: Case Series** *N. Scarpulla* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni*

O0865 11:22 **Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis** *I. Cafarella* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-Mangoni*

O0866 11:33 **Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by *Enterococcus* spp.: Experience from Seven Cases in a Referral Center** *F. Frondizi* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti*

O0867 11:44 **Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital** *G. Oliva* (Rome, Italy), F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti*

OS122 **11:00 – 12:00** **Hall 16**

PRO

1-hour Oral Session

Serious games: a serious business

Chairs *Christian Kraef (Copenhagen, Denmark)*
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)

O0878 11:00 **The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands.** *A. Tostmann* (Nijmegen, The Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers*

O0879 11:12 **Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge Platform** *A. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García*

O0880 11:24 **Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study** *T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon*

O0881 11:36 **'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game.** *C. Uhomoibhi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra*

O0882 11:48 **Improvement of learners' confidence in antibiotic management by an interdisciplinary annual multi-centred webinar** *A. Friedrichs* (Kiel, Germany), T. Koch, J. Jochum, A. Van Der Linde, H. Gerth, F. Jahn, A. Neubert, E. Kramme*

OS118 **11:00 – 12:00** **Hall 6**

AMR ANT

1-hour Oral Session

Plasmids as a powerful tool of antibiotic resistance spread

Chairs *Monika Dolejska (Pilsen, Czechia)*
Guido Werner (Wernigerode, Germany)

O0859 11:12 **The emergence of *tet*(X4) and *mcr* co-harbored on the same plasmid and its clinical significance** *N. Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T. Walsh*

O0860 11:24 **The plasmidome of a global collection of convergent *K. pneumoniae* and its impact on virulence** *F. Lebreton* (Silver Spring, United States), M. Martin, A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B. Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann*

O0861 11:36 **Factors that affect plasmid transfer in multispecies biofilms** *H.Y. Liu* (Norwich, United Kingdom), M. Yasir, E. Trampari, G. Langridge, M. Webber*

O0862 11:48 **Identification of the *czc* metal efflux operon on a new plasmid type in a *Pseudomonas aeruginosa* clinical isolate belonging to ST357 O11** *A. Valcek* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst*

OS120 **11:00 – 12:00** **Hall 8**

AMR TRN

1-hour Oral Session

Exploring host-pathogen interactions and immune dynamics in bacterial virulence

Chairs *Giovanni Delogu (Rome, Italy)*
Simon Foster (Sheffield, United Kingdom)

O0868 11:00 **Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid pvirhs1 in hypervirulent Carbapenem-resistant Klebsiella pneumoniae** *Y. Zhang* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang*

O0869 11:12 **Presence and role of hypervirulence-associated markers in *Klebsiella pneumoniae* groups based on LD50 value in mouse septic model** *A. Avdeeva* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, V. Ageevets, S. Sidorenko*

O0870 11:24 **Meta-transcriptomic Insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis** *T. Vashist* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora*

O0871 11:36 **Unveiling the hidden virulence of *Acinetobacter baumannii*: how the lipooligosaccharide core modulates immune responses and enhances interferon-[] production** *Y.T. Lee* (Taipei, Taiwan), Y.C. Wang*

O0872 11:48 **Platelets drive neutrophil-mediated neuroinflammation in tuberculous meningitis** *K. Skolimowska* (London, United Kingdom), D. Kirwan, T. Reid, D. De Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed, A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P. Renner, M. Panchoo, C. Stek, R. Johnson, M. Maxebengula, R. Wilkinson, J.S. Friedland*

OS121 **11:00 – 12:00** **Hall 9**

AMR IPC

1-hour Oral Session

Shaping the future of IPC: digitalisation of surveillance

Chairs *Diamantis Plachouras (Solna, Sweden)*
Maaike S.M. Van Mourik (Utrecht, The Netherlands)

O0873 11:00 **PRAISE hospital-onset bacteraemia and fungaemia algorithm as novel automated surveillance indicator: results from four European university hospitals** *S. Van Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, G. Catho, M. Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D. Dinis Teixeira, D. Sjöholm, P. Nauclér, M. Behnke, M.S.M. Van Mourik*

O0874 11:12 **Transforming hospital-onset bacteremia and fungemia data to the OMOP common data model** *H. Düsseldorf* (Vienna, Austria), G. Duftschmid, E. Presterl*

O0876 11:24 **Dutch Electronic Health Records in primary care: the Nivel general practisioners database** *F.F. Stelma* (Utrecht, The Netherlands), J. Van Summeren, M. Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S.*

Van Beusekom

O0877 **11:36** **Local signs at catheter insertion sites: insights from the multicenter DeepCath cohort study with 4,256 pictures** *N. Buetti* (Geneva, Switzerland), S. Ruckly, A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar, J.F. Timsit*

O0875 **11:48** **Prospective evaluation of a machine learning-based real-time multidrug-resistant organism prediction system** *V. Vasikasin* (Bangkok, Thailand), R.L. Peach, K. Bhangananda, A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee, J. Price, B. Mauricio, T.M. Rawson, W. Nasomsong, A. Holmes*

SY162 **11:00 – 12:00** **Hall 11**

1-hour Symposium

AMR

Antimicrobial stewardship across the lifespan from paediatrics to geriatrics

Chairs *Lucy Catteau (Brussels, Belgium)*
Priya Nori (New York, United States)

S0444 **11:00** **Antimicrobial Stewardship in paediatrics across different settings** *Taylor Morrisette (Charleston, United States)*

S0445 **11:30** **Stewardship in geriatrics: an exceedingly important target** *Dafna Yahav (Ramat-Gan, Israel)*

SY163 **11:00 – 12:00** **Hall 14**

1-hour Symposium

AMR

People-centred approach to strengthening the AMR response at primary care

Chairs *Benedikt Huttner (Geneva, Switzerland)*
Mirfin Mpundu (Lusaka, Zambia)

S0446 **11:00** **Implementation of WHO's people-centred interventions** *Nienke Van De sanDe Bruinsma (Geneva, Switzerland)*

S0447 **11:30** **Opportunities for strengthening AMR interventions in primary healthcare** *Sholpan Kaliyeva (Karaganda City, Kazakhstan)*

Co-organised with: World Health Organisation (WHO)

SY164 **11:00 – 12:00** **Hall 15**

1-hour Symposium

CLN VAX

dsDNA virus infections in immunocompromised patients

Chairs *Mario Fernandez Ruiz (Madrid, Spain)*
Lior Nesher (Beersheba, Israel)

S0448 **11:00** **Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR?** *Hans H. Hirsch (Basel, Switzerland)*

S0449 **11:30** **Clinical burden and unmet needs of managing multiple concurrent dsDNA viruses post transplantation** *Michelle Yong (Melbourne, Australia)*

SY159 **11:00 – 12:00** **Hall 2**

1-hour Symposium

CLN TRN

Beat the cancer by beating the infections

Chairs *Daniela Maric (Novi Sad, Serbia)*
Mojca Maticic (Ljubljana, Slovenia)

S0438 **11:00** **Prevention of infection-associated cancer: learning from each other** *Catharina Alberts (Amsterdam, The Netherlands)*

S0439 **11:30** **Test and treat early to prevent cancer: hepatitis B and hepatitis C** *Francesco Negro (Geneva, Switzerland)*

SY160 **11:00 – 12:00** **Hall 4**

1-hour Symposium

CLN IPC

Personalised patient management and infection prevention: current evidence and future perspectives

Chairs *Agnes Hajdu (Budapest, Hungary)*
Iris K. Minichmayr (Vienna, Austria)

S0440 **11:00** **The dosing perspective: towards individualised treatment strategies** *Thomas Tängdén (Uppsala, Sweden)*

S0441 **11:30** **The infection control perspective: advancing patient-centred approaches** *Alessia Savoldi (Verona, Italy)*

SY161 **11:00 – 12:00** **Hall 5**

1-hour Symposium

CLN

Emerging fungal diseases in children: global challenges and approach to management

Chairs *Andreas H. Groll (Münster, Germany)*
Adilia Warris (Exeter, United Kingdom)

S0442 **11:00** **Emerging fungal infections in immunocompromised and geographically exposed children** *Laura Ferreras-Antolin (London, United Kingdom)*

S0443 **11:30** **Best available treatments and options for children in resource-limited settings** *Fabianne Carlesse (Sao Paulo, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMykG)

EF123 **11:00 – 12:00** **Arena 2**

ePoster Flash Session

ANT CLN

Advancing antimicrobials: trials and therapies for resistant infections

Chair *Ursula Theuretzbacher (Vienna, Austria)*

E0888 **11:00** **Efficacy of High Dose Tigecycline-Containing Regimens for the Combination Treatment of Carbapenem Resistance *Enterobacterales* Bacteremia: a propensity score-matched study** *V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, P. Wanloptaree*

E0883 **11:06** **Evaluation of CRS3123 compared to vancomycin for the treatment of *Clostridioides difficile* infection (CDI)** *J. Bruss* (Pagosa Springs Co, United States), M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C. Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T. Jarvis, U. Ochsner, M. Wilcox, T. Louie*

E0884 **11:12** **Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in paediatric patients with gram-negative bacterial infection** *J. Bradley* (San Diego, United States), C.T. Norice, E. Roilides, A. Shevelev, B. Jurkiewicz, J.A. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young, D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno*

E0885 **11:18** **A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Intravenous Ertapenem (ERT) with Zidebactam (ZID) in Combination (WCK 6777) in Healthy Adult Subjects** *T. Lodise* (Albany, United States), R. Chavan, A. Patel, R. Yeole, S. Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan, M. Kankam, A. Jaunarajs, E. Hammett, H. Howell, R.A. Bonomo*

E0886 **11:24** **Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing *K. pneumoniae* infections – Results from a retrospective multicentre study** *A. Marino* (Catania, Italy), A.E. Maraolo, M. Mazzitelli, A. Oliva, N.*

Geremia, A. De Vito, C. Gullotta, V. Scaglione, E. Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori, P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G. Madeddu, B. Cacopardo, G. Nunnari

E0887 **11:30** **Phase 3 study of oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese female participants (EAGLE-J)** *Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura*

E0889 **11:36** **Efficacy of Ceftolozane/Tazobactam vs. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by *Pseudomonas aeruginosa*: a multicentric retrospective study from the SUSANA cohort.** *A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu*

E0890 **11:42** **Experience of dalbavancin use for unlicensed indications in a UK tertiary infectious diseases setting** *C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong*

E0891 **11:48** **Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired gram-negative bacterial bloodstream infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons** *M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris*

EF124 **11:00 – 12:00** **Arena 3**

DX

ePoster Flash Session

Thinking outside the box in urinary tract infection

Chair *Angela Huttner (Geneva, Switzerland)*

E0892 **11:00** **Targeted NGS: a promising approach for pathogen detection of urinary tract infection** *W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang*

E0893 **11:06** **Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics** *A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner, R. Ahmad*

E0895 **11:18** **A New Approach In Diagnosis Of Urinary Tract Infections** *B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazcı, Ö. Uslu, N. Çöplü*

E0896 **11:24** **Diagnosis of urinary tract infections: from machine learning to clinical practice** *E. Flores* (Alicante, Spain), R. Torrreblanca, I. Gutierrez, L.G. Maite, A. Blasco, R. Carbonell*

E0897 **11:30** **Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting** *S. Sarika* (Chennai, India), B. Rithik Dharan*

E0898 **11:36** **Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics** *S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore*

E0899 **11:42** **Unraveling the complexity: Corynebacterium diversity and antimicrobial resistance hub in the urinary tract ecosystem** *E. Alves Cappelli* (Porto, Portugal), E. Cappelli, A. Morais, T. Ribeiro, L. Peixe*

E0900 **11:48** **Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures** *A. Castellano Verdasco* (Lleida, Spain), E. Sánchez Báscones, E. López González, A. Blanquero-Porras, M. Riesgo Magaña, A. Bernet Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A. Bellés-Bellés, M. García González*

EF125 **11:00 – 12:00** **Arena 4**

CLN TRN

ePoster Flash Session

Bugs breaking the blood-brain barrier

Chair *Markus Zeitlinger (Vienna, Austria)*

E0901 **11:00** **Pharmacologic depletion of meningeal macrophages worsens disease in a mouse model of meningitis** *U. Koedel* (Munich, Germany), S. Dyckhoff-Shen, I. Masouris, H.W. Pfister, M. Klein*

E0902 **11:06** ***Pgm1* modulates the inflammatory response of macrophages in experimental pneumococcal meningitis** *D. Bakker* (Amsterdam, The Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van De Beek*

E0903 **11:12** **Heparin-binding protein in cerebrospinal fluid as a biomarker for bacterial meningitis: a study of diagnostic accuracy** *S. Olie* (Amsterdam, The Netherlands), S.L. Staal, A.C. Da Cruz Campos, J. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer*

E0904 **11:18** **Efficacy Analysis of Intraventricular/Intrathecal Polymyxin B sulphate Injections in the Treatment of Post-neurosurgical CNS Infections in Neurocritical Ill Patients:a prospective observational study** *L. Yang* (Shanghai, China), J. Song, M. Wang, H. Yuan, Q. Yuan, Z. Du, G. Wu, J. Hu, W. Chen*

E0905 **11:24** **Ventriculitis characteristics and outcomes (VELCRO): an international retrospective cohort study** *D. Luque Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L. Escaut, G. Martin-Blondel, B. Sarton, P. Jaquet, F. Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L. Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B. Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher, F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R. Sonneville, F. Valour, P. Tattevin*

E0906 **11:30** **Clinical Features and Outcomes of *Staphylococcus aureus* Brain Abscess** *E. Eriksen* (Aalborg, Denmark), M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, M. Brouwer, J. Bodilsen*

E0907 **11:36** **Epidemiology of Adult Intracranial Bacterial Abscess in the Republic of Ireland (2010-2021)** *S. Kilgarriff* (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey, S. O Donnell, B. Dinesh, C. O Connor, A. Doherty*

E0908 **11:42** **Corticospinal tract involvement in Neuromelioidosis: A Retrospective cohort Study from South India and a Systematic Review of Literature** *P.K. Tirlangi* (Manipal, India), N. Gupta, V. Muralidhar, C. Mukhopadhyay*

E0909 **11:48** **A multicenter prospective study to develop and validate clinical prediction models for diagnosis of scrub typhus and treatment with doxycycline in children with acute encephalitis syndrome in southern India** *T. Damodar* (Bangalore, India), M. Jose, U. Kinhal, B. Singh, A. L, S. Marate, N. Prabhu, L. A V, F.S. D'souza, S.V. Sajjan, K. Mallesh, R.S. Mani, T. Solomon, V.K. Gowda, R. Vasanthapuram, R. Yadav, L. Turtle, R. Kolamunnage-Dona*

KN158 **11:00 – 12:00** **Hall 1**

TRN

Keynote Lecture

What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer

Chairs *Emmanuelle Cambau (Paris, France)*
Holger Rohde (Hamburg, Germany)

K0437 **11:00** *Stewart T. Cole (Paris, France)*

ME165 **11:00 – 12:00** **Hall 12**

Meet-the-Expert

PHEI

How to use citizen science for public health

M0450 **11:00** *Anna Noel-Storr (Leamington Spa, United Kingdom)*
M0451 **11:12** *Jani Sormunen (Turku, Finland)*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

ME166 **11:00 – 12:00** **Hall 13**

Meet-the-Expert

DX

Implementing AI in microbiological diagnostics: practical steps and quality control

M0452 **11:00** *Oliver Nolte (Zürich, Switzerland)*
M0453 **11:12** *Jennifer Dien Bard (Los Angeles, United States)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

FO167 **11:00 – 12:00** **Arena 1**

Open Forum

PHEI VAX

Vaccine rollout in low resource settings

Chair *Asma Nasim (Karachi, Pakistan)*

F0454 **11:00** **Typhoid vaccine roll out** *Nginache Nampota (Baltimore, United States)*
F0455 **11:10** **Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriers** *Bernhards Ogutu Ragama (Nairobi, Kenya)*
F0456 **11:20** **The story of COVID-19 vaccines in LMIC** *Paul Adepoju (Ibadan, Nigeria)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

OS130 **13:30 – 14:30** **Hall 16**

1-hour Oral Session

CLN DX

Advances in fungal diagnostics

Chairs *Sarah Delliere (Paris, France)*
Lisa Marie Kriegl (Graz, Austria)

O0935 **13:30** **BAL galactomannan dynamics predict survival in critically ill patients with virus-associated pulmonary aspergillosis** *V. Delanote* (Leuven, Belgium), J. Heylen, H.M. Lauwers, C. Jacobs, L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans, P. Meersseman, M. Peetermans, E. Van Wijngaerden, A. Wilmer, K. Lagrou, J. Wauters, S. Feys*

O0936 **13:42** **Retrospective Assessment of a New Chemiluminescence Immunoassay for Serum (1, 3)-[]-D-Glucan Levels in Patient with Invasive Fungal Infections** *Z. Zhou* (Tianjin, China), K. Yuan, L. Ye, S. Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q. Wang, G. Zhang, H. Wang, Y. Zhao, G. Li*

O0937 **13:54** **Evaluation of a multiplex PCR assay using barcoded magnetic bead technology for detection of fungal pathogens in bronchoalveolar lavage fluid: a diagnostic aid for invasive fungal infections** *S. Zhang* (Baltimore, United States)*

O0938 **14:06** **Combined use of (1,3)-[]-D-glucan and PCR in oral wash for *Pneumocystis jirovecii* pneumonia diagnosis in non-HIV population** *A. Falcó Roget* (Mataró, Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez*

O0939 **14:18** **Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort study** *H. Lamberink* (Amsterdam, The Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk*

OS127 **13:30 – 14:30** **Hall 6**

1-hour Oral Session

PHEI

The good, the bad and the itchy: update on STIs

Chairs *Tatum Mortimer (Athens, United States)*
Marcos Rust (Feldkirch, Austria)

O0920 **13:30** **High frequency of Nichols-like strains of *Treponema pallidum* subsp. *pallidum* circulating in Barcelona, Spain** *P. Nadal-Baron* (Barcelona, Spain), P. Nadal-Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M. Valverde Espinal, A. Canals Quintana, J.J. González-López, A. Antón, M. Alberny, O. Mitjà, N. Larrosa, Y. Hoyos-Mallecot*

O0921 **13:42** **Doxycycline post-exposure prophylaxis (doxy-PEP) use and outcomes in metropolitan Detroit** *C. Arena* (Detroit, United States), N. Everson, R. Kenney, I. Brar, S. Gudipati, N. Yared, S. Davis, M. Veve*

O0922 **13:54** **The Gonococcus Bacterial Load Measured by the Cycle Threshold (Ct) in Urinary Samples Correlates with Symptomatology** *G. Beraud* (Orleans, France), L. Barhoum, H. Meyjonnade, J. Effa, L. Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E. Carbonelle, C. Guillaume, T. Prazuck*

O0923 **14:06** **STI pathogen interactions and viability in men who have sex with men (MSM)** *E. Rayo* (Zurich, Switzerland), D. Onorini, C. Leonard, H. Marti, T. Pesch, B. Hampel, N. Low, N. Borel*

O0924 **14:18** **Epidemiology of bacterial genitourinary infections among women with recurrent vulvovaginal Candidiasis (RVVC) in Nigeria.** *S. Fayemiwo* (Ibadan, Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-Richardson*

OS129 **13:30 – 14:30** **Hall 7**

1-hour Oral Session

TRN

Biofilm biology and control

Chairs *Margherita Cacaci (Rome, Italy)*
Laura Escolà-Vergé (Barcelona, Spain)

O0930 **13:30** **Influence of non-coding small RNA00203 in biofilm cells of *Acinetobacter baumannii*: Transcriptomic and phenotypic** *D. Gebrelibanos* (Hong Kong, China), A.M. Shenkutie, F. Chow, P. Leung*

O0931 **13:42** **Sub-MIC antibiotic effects on *Pseudomonas aeruginosa* biofilm streamer formation** *A. Di Claudio* (Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G. Savorana*

O0932 **13:54** **Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of Klebsiella pneumoniae** *X. Chu* (Beijing, China), Q. Yang*

O0933 **14:06** **Exploring structural differences in biofilms of smooth and rough *Mycobacterium abscessus* clinical strains through confocal laser scanning microscopy** *M. Cano Fernández* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea*

O0934 **14:18** **Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsions** *Z. Najmi* (Novara, Italy), A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin*

OS128 **13:30 – 14:30** **Hall 9**

1-hour Oral Session

ANT CLN

AI aiding AMS

Chairs *Marlieke De Kraker (Geneva, Switzerland)*
Bhanu Sinha (Groningen, The Netherlands)

O0925	13:30	**Using natural language processing to understand free-text antibiotic prescriptions** *A. Martin* (Middlesbrough, United Kingdom), L. Christopher*
O0926	13:42	**Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease Experts** *H.M. Wei* (Taichung, Taiwan), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang*
O0927	13:54	**Augmented Intelligence in Infectious Diseases (AI^{2}D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infections** *J.L. Lim* (Singapore, Singapore), S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y. Zhou, Y. Wang, P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.J. Chung, L.H.A. Kwa*
O0928	14:06	**Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learning** *K. Yuan* (Oxford, United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre*
O0929	14:18	**Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switching.** *W. Bolton* (London, United Kingdom), R. Wilson, P. Georgiou, A. Holmes, T.M. Rawson, M. Gilchrist*

OS126 **13:30 – 15:30** **Hall 8**

2-hour Oral Session

CLN DX PHEI

Emerging viruses, diverse threats

Chairs *Luisa Barzon (Padua, Italy)*
Karin Stiasny (Vienna, Austria)

O0910	13:30	**Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study** *I. Brosius* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijck, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni*
O0911	13:42	**Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023** *G. Romano* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti*
O0912	13:54	**Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024.** *M. Torres Portillo* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan*
O0913	14:06	**Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023** *L. Mueller* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. Johne, V.M. Corman*
O0914	14:18	**Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein** *A. Hirvonen* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop*
O0915	14:30	**Health-economic impacts of chikungunya vaccination in 34 countries** *J. Zhou* (Oxford, United Kingdom), N. Salant, D. Smith, S. Radoykova, J. Lord, K. French, D. Hollingsworth, K. Pouwels*
O0916	14:42	**Clinical importance of a new tick-borne *flaviviridae* virus, Alongshan Virus: retrospective serologic and molecular study in Switzerland** *F. Tagini* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub*
O0917	14:54	**From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach** *S. Ahmad* (Tampere, Finland)*
O0918	15:06	**Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection** *A. Mancon* (Milan, Italy), G. Gagliardi, D. Mileto, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci*
O0919	15:18	**Substantial viral diversity in bats and rodents from East Africa: insights into conservation, recombination, and co-circulation** *J. Li* (Shenzhen, China), D. Wang, L. Junhua*

SY170 **13:30 – 15:30** **Hall 13**

2-hour Symposium

TRN

Novel strategies for eliminating the 'worst films ever'

Chairs *Elisa Borghi (Milan, Italy)*
Markus Zeitlinger (Vienna, Austria)

S0465	13:30	**What answers can biofilm PK/PD modelling provide?** *Coen Van Hasselt (Leiden, The Netherlands)*
S0466	14:00	**subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant?** *Francoise Van Bambeke (Brussels, Belgium)*
S0467	14:30	**PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm models** *Maria Dolores Macia Romero (Palma De Mallorca, Spain)*
S0468	15:00	**Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategies** *Claus Moser (Copenhagen, Denmark)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee

SY171 **13:30 – 15:30** **Hall 14**

2-hour Symposium

DX

Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing

Chairs *Mauricio Farfan (Santiago, Chile)*
Chiara Minotti (Basel, Switzerland)

S0469	13:30	**Congenital cytomegalovirus detection by pool testing in saliva** *Giannina Izquierdo (Santiago, Chile)*
S0470	14:00	**Detection of blood-corne pathogens in asymptomatic blood donors by pool testing** *Patricia Alvarez (Rio De Janeiro, Brazil)*
S0471	14:30	**Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis** *Melissa Sander (Bamenda, Cameroon)*
S0472	15:00	**Approach to measuring efficiency of pooled molecular tests** *Denise O'sullivan (Teddington, United Kingdom)*

SY168 **13:30 – 15:30** **Hall 2**

2-hour Symposium

TRN

Staphylococcus aureus: its expansion dynamics and interactions with its pals

Chairs *Barbara C. Kahl (Münster, Germany)*
Marc Stegger (Copenhagen, Denmark)

S0457	13:30	***S. aureus*** **and its special relationship to *S. epidermidis*** *Andreas Peschel (Tübingen, Germany)*
S0458	14:00	**Computational and in *vitro* evaluation of probiotic treatments for nasal *S. aureus* decolonisation** *Silvio Daniel Brugger (Zurich, Switzerland)*
S0459	14:30	**Clonal population expansion of *S. aureus* occurs due to escape from a finite number of intraphagocyte niches** *Simon Foster (Sheffield, United Kingdom)*
S0460	15:00	**How bacteriophages and pathogenicity islands drive the evolution of *S. aureus*** *John Chen (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY169 **13:30 – 15:30** **Hall 4**

2-hour Symposium

AMR CLN

Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria

Chairs *Agnes Maria Sonnevend (Pécs, Hungary)*
Kyriaki Xanthopoulou (Cologne, Germany)

S0461	13:30	**Globally emerging resistance patterns of Enterobacterales** *Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)*
S0462	14:00	**Non-fermenters still important globally: a review of spread and resistance** *Anupa Thampy (Vellore, India)*
S0464	14:30	**Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approaches** *Juan P. Horcajada (Barcelona, Spain)*
S0463	15:00	**Innovative rapid diagnostic methodologies for Gram-negative pathogens** *Laurent Dortet (Le Kremlin-Bicêtre, France)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW174 **13:30 – 15:30** **Hall 11**

Educational Session

CLN IPC

Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia

Chairs *Fusun Can (Istanbul, Türkiye)*
Jeroen Schouten (Nijmegen, The Netherlands)

W0481	13:30	**Artificial intelligence to predict VAP** *Miia Jansson (Oulu, Finland)*
W0482	13:50	**Metagenomic approach to VAP diagnosis** *Jacques Schrenzel (Geneva, Switzerland)*
W0483	14:10	**Viruses in VAP and HAP: should we worry about them?** *Catia Cilloniz (Barcelona, Spain)*
W0484	14:30	**Optimising antibiotic therapy in VAP** *Pinyo Rattanaumpawan (Bangkok, Thailand)*

EW172 **13:30 – 15:30** **Hall 3**

Educational Session

CLN VAX

Beyond the gift of life: viral infection during pregnancy

Chairs *Gülsen Özkaya Sahin (Lund, Sweden)*
Simona Ruta (Bucharest, Romania)

W0474	13:30	**RSV and influenza during pregnancy: management and outcome** *Monika Redlberger-Fritz (Vienna, Austria)*
W0475	13:50	**Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline** *Marianne Leruez-Ville (Paris, France)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

EW173 **13:30 – 15:30** **Hall 5**

Educational Session

CLN

Tropical dermatology: a case-based approach

Chairs *Pedro Legua (Lima, Peru)*
Bobbi Pritt (Rochester, United States)

W0477	13:30	**Parasitic diseases: dermatological manifestations in the tropics** *Kirti Sabnis (Mumbai, India)*
W0478	13:50	**Madura foot and other implantation mycoses** *M Ramam (New Delhi, India)*
W0479	14:10	**Mycobacteria** *Francisco Bravo (Lima, Peru)*
W0480	14:30	**Approach to rash in the returning traveller** *Frank O. D. Pettersen (Oslo, Norway)*

EF131 **13:30 – 14:30** **Arena 1**

ePoster Flash Session

AMR

The current landscape of carbapenem resistance: from genotype to phenotype and virulence determinants

Chair *Amy Mathers (Charlottesville, United States)*

E0940	13:30	**Molecular Insights into the Growing Threat Carbapenem-Resistant Hypervirulent *Klebsiella pneumoniae* and the Rising Challenge of Ceftazidime-Avibactam Resistance** *C. Vatansever* (Istanbul, Türkiye), A. Akpinar, J. Boral, S. Belge, N. Kardan, B. Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö. Ergönül, F. Can*
E0941	13:36	**Global large-scale genomic snapshot on the diversity of carbapenem-resistant and hypervirulent *Klebsiella pneumoniae* strains** *R. Elias* (Lisboa, Portugal), T. Clark, I. Portugal, J. Perdigao*
E0942	13:42	**Carbapenem-resistant *Enterobacter cloacae* complex: genetic determinants of resistance and molecular epidemiology** *D. Pinheiro De Sousa Santos* (Lisbon, Portugal), D. Santos, A. Bruschy-Fonseca, E. Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C. Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo-Cristino, C. Caneiras*
E0943	13:48	**Molecular epidemiology of carbapenemase-producing *Escherichia coli* in Hungary** *A. Hanczvikkel* (Budapest, Hungary), D. Göbhardter, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K. Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G. Jakab, Á. Sonnevend, Á. Tóth*
E0944	13:54	**Genomic multicentre surveillance of VIM-producing *Enterobacterales* shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021** *A. Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter*
E0945	14:00	**Three distinct routes of virulence-resistance convergence in ST-395 *K. pneumoniae* from Eastern Europe over the last decade.** *A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton*
E0946	14:06	**Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria** *N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok, A. Anders, S. Gatermann*
E0947	14:12	**Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022** *V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakki, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng*

EF132 **13:30 – 14:30** **Arena 2**

CLN ePoster Flash Session

Difficult-to-treat cases in the immunocompromised

Chair *Nicolas Mueller (Zurich, Switzerland)*

E0949 **13:30** **A case of IRIS nocardiosis***S.K. Dlamini* (Cape Town, South Africa), P. Arnab, P. Namale*

E0951 **13:36** **Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing long-term glucocorticoid therapy for autoimmune thrombocytopenia: A case report***N. Zhang* (Bengbu, China)*

E0952 **13:42** **Subcutaneous paeohyphomycosis due to *Alternaria infectoria* in an immunosuppressed renal transplant recipient: successful multidisciplinary management***M. Arias* (London, United Kingdom), E. Vetsiou, E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli*

E0953 **13:48** **Lung nodules in a patient with breast cancer history... Not everything is cancer.***E. Muñoa Hernández* (Tuxtla Gutierrez, Mexico), E. Muñoa*

E0954 **13:54** **Treatment of fulminant *Clostridioides difficile* infection using bacteria-free stool supernatant in adult hematological patients during chemotherapy-induced aplasia***B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko*

E0955 **14:00** **Eradication of multidrug resistant Pseudomonas aeruginosa pneumonia in acute lymphoblastic leukemia patient with broad host-range phage***P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola*

E0956 **14:06** **An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by *Chondrostereum purpureum****P. Kitjacharoenchai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan*

E0957 **14:12** **Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico***E. Sienra Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J. Corredor Nassar, A.P. Rodriguez Zulueta*

EF133 **13:30 – 14:30** **Arena 3**

CLN PHEI VAX ePoster Flash Session

Viral infections in special populations

Chair *Federico Garcia (Granada, Spain)*

E0958 **13:30** **ORCHESTRA Delphi Consensus: Therapeutic and Diagnostic Management of SARS-CoV-2 Infection in Rheumatological Patients***M.G. Caponcello* (Seville, Spain), P. Olivares Navarro, C. Bonazzetti, C. Campoli, A. Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L. Otero-Varela, I. Castrejón, E. Tacconelli, J. Rodríguez Baño, Z.R. Palacios Baena*

E0959 **13:36** **Immunogenicity, reactogenicity and safety of booster vaccinations with BNT162b2 or full-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report***J. Stemler* (Cologne, Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K. Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E. Romero Rodriguez, J. Moltó, I. Vergara Mitxeltorena, T. Welte, B. Zablockienė, M. Akova, U. Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L. Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J. Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhann, R. Sprute, J. Frías-Iniesta, R. Negi, C. Gaillard, G. Saini, A. García León, P.W.G. Mallon, C. Lammens, A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H. Goossens, S. Kumar-Singh, F. König, M. Posch, P. Koehler, O.A. Cornely*

E0960 **13:42** **Effectiveness of adjuvanted recombinant zoster vaccine in adults aged ≥50 years in the United States***L. Qian* (Pasadena, United States), H.F. Tseng, L.S. Sy, B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng, J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A. Cohen, H. Yun, D. Oraichi, H. Seifert*

E0961 **13:48** **Differential SARS-CoV-2 RNAemia features and humoral immune response analysis of acute COVID-19 in solid organ transplant recipients and patients with hematological malignancies.***A. Ruiz-Molina* (Seville, Spain), J. Martín-Escolano, C. Infante-Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F. Martín-Dominguez, G. Bernal-Blanco, B. Villacorta-Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D. Rangel-Sousa, C. Rodríguez-Urbistondo, B. Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N. Maldonado, S. Salto-Alejandre, B. Gallego, L. Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A. Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes*

E0962 **13:54** **Prevalence of and risk factors for persisting COVID-19 in patients with B-cell malignancies***A. Toschi* (Bologna, Italy), Z. Pasquini, A. Amicucci, N. Caroccia, M. Di Chiara, F. Simone, B. Casadei, C. Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M. Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E. Nicastri, M. Krampera, P.L. Zinzani, J. Rodriguez Baño, E. Tacconelli, M. Giannella*

E0963 **14:00** **Clinical characteristics and predictors of severe outcome among older adults hospitalized with respiratory syncytial virus (RSV) infection– a retrospective study from Israel***M. Jurkowicz* (Tel Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper, I. Royzman, S. Uppal, C. Liang, E. Begier, I. Ganiel, M. Mandelboim, D. Yahav*

E0964 **14:06** **RSV and bronchiolitis associated primary care and emergency department visit rates in children under 5 years: Estimates for Europe and other high-income countries.***F.F. Stelma* (Utrecht, The Netherlands), S. Heemskerk, L. Van Heuvel, P. Spreeuwenberg, L. Bont, J. Van Summeren*

E0966 **14:18** **Insights from a single center's experience in hepatitis C treatment across four prisons in Slovakia***I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, M. Novotný, Z. Paraličová, P. Kristian*

EF134 **13:30 – 14:30** **Arena 4**

AMR DX IPC ePoster Flash Session

Infection controller's daily

Chair *Cansu Cimen (Oldenburg, Germany)*

E0967 **13:30** **Mortality and length of stay associated with antimicrobial-susceptible and resistant hospital-onset bloodstream infections at a tertiary referral hospital in Melbourne, Australia***A. Stewardson* (Melbourne, Victoria, Australia), S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg*

E0968 **13:36** **MRSA on the rise in neonatal care departments***E. Herkes* (Amsterdam, The Netherlands), A. Schoffelen, R. Zwittink, J. Kluytmans, D. Notermans*

E0969 **13:42** **Risk factors for OXA-carbapenemase-producing *Enterobacteriaceae* acquisition in Israel: a retrospective case control study***M. Amar* (Haifa, Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked-Mishan, O. Barnett-Griness*

E0970 **13:48** **Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UK***L.B. Snell* (London, United Kingdom), M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter, A. Alcolea-Medina*

E0971 **13:54** **Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-*Escherichia coli* Enterobacterales***J. Männer* (St.Gallen, Switzerland), V. Steinacher, T. Dörr, M. Schlegel, P. Kohler*

E0972 **14:00** **A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant**

		Enterococcus faecium from bloodstream infections at three tertiary care hospitals in Bavaria, Germany*A. Rath* (Regensburg, Germany), B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider-Brachert*
E0973	**14:06**	**Molecular epidemiology and transmission dynamics of vancomycin-resistant *Enterococcus faecium* in Belgian hospitals (2022-2023)***S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheeussen*
E0974	**14:12**	**Increasing Prevalence of Linezolid-resistant Enterococci: Outbreak or Overuse?***R. Traynor* (Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey*
E0975	**14:18**	**Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPA-filtered/positive pressure rooms***M.H. Nguyen* (Pittsburgh, United States), Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham, C. Clancy*